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 ABSTRACT 
 
Hyperoxaluria is a pathologic condition due to genetic and non-genetic causes that 
leads to the deposition of calcium oxalate (CaOx) crystals at first in the urinary 
system and, in the most severe forms, in the whole body. The disease can be due to 
either an increased endogenous oxalate production (primary hyperoxaluria or PH) 
or an increased intestinal oxalate absorption (secondary hyperoxaluria or SH). 
Three forms of PH are known. They are inherited disorders caused by the deficit of 
enzymes involved in liver glyoxylate metabolism. The most common and most 
severe form is PH1. Two curative therapies are currently available for the treatment 
of PH1: pyridoxine administration (PN) and liver transplantation. However, The 
first is only effective in 10-30% of the patients, while the second is a very invasive 
and risky procedure. Thus, the development of new therapeutic strategies represents 
an urgent need. 
In this regard, we hypothesized that a possible approach could be the use of an 
oxalate-degrading enzyme, which would reduce plasma oxalate concentration thus 
counteracting the formation of CaOx. Oxalate Decarboxylase (OxDC) from B. 
subtilis is an hexameric Mn-dependent enzyme belonging to the bicupin family that 
catalyses the cleavage of the oxalate C-C bond to give carbon dioxide and formate. 
A mutated form of the enzyme, called OxDC-DSSN, shows a reduced 
decarboxylase specific activity, but is endowed with the ability to catalyse an 
oxalate oxidation reaction. It should be underlined that OxDC displays an optimum 
pH around 4 and a deep characterization of the enzyme at neutral pH is still lacking.  
Based on these considerations, the aim of my PhD was the study of the biochemical 
features of OxDC at neutral pH and their possible improvement by protein 
engineering techniques. Moreover, since the direct administration of a non-human 
protein would elicit a remarkable immune reaction, we thought to encapsulate 
OxDC in red blood cells (RBCs) and use loaded RBCs as oxalate-degrading 
bioreactors.  
The data obtained indicate that: 
1) OxDC and OxDC-DSSN (i) display optimal activity at pH 4.2 but retain a 
detectable residual activity at pH 7.2, the intracellular pH of RBCs, (ii) do 
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not undergo major structural changes at neutral pH, (iii) are able to detoxify 
oxalate endogenously produced in a cellular model of PH1. 
2) OxDC can be efficiently encapsulated in human and murine RBCs and does 
not loose catalytic activity during the encapsulation process. 
3) by using directed evolution approaches, a mutated form of OxDC could be 
engineered that is more resistant to thermal stress and aggregation under 
physiological conditions as compared with wild-type OxDC.  
 
Overall these data provide the proof-of-principle for the feasibility of a therapy for 
PH based on the administration of RBCs-loaded with an oxalate-degrading enzyme. 
Future studies will be focused on the testing of the ability of wild-type and 
engineered OxDC to detoxify oxalate in a mouse model of PH1. 
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SOMMARIO 
 
L’iperossaluria è una condizione patologica caratterizzata da un aumento 
dell’escrezione urinaria di ossalato. A seconda delle cause questa malattia può avere 
due espressioni cliniche differenti: l’iperossaluria primaria (PH) è dovuta a deficit 
enzimatici che causano l’aumento della produzione endogena di ossalato, mentre 
l’iperossaluria secondaria (SH) è causata da un aumento di ossalato esogeno (ad 
esempio in seguito ad un aumentato apporto con la dieta). 
L’ossalato è un acido dicarbossilico che deriva dall’ossidazione epatica del 
gliossilato, un intermedio di alcune reazioni metaboliche. Poiché nell’uomo non 
può essere metabolizzato, va incontro ad escrezione mediante le urine. Nei casi di 
PH, l’aumento nei livelli di ossalato sintetizzati ed escreti provoca la deposizione 
di cristalli insolubili di ossalato di calcio (CaOx) dapprima nei reni e nel tratto 
urinario. Il conseguente danno renale determina l’aumento della concentrazione di 
ossalato anche a livello plasmatico, e la deposizione di CaOx in tutto il corpo. 
Quest’ultima condizione, detta ossalosi sistemica, porta in molti casi alla morte del 
paziente. Oltre alle terapie volte a migliorare la funzione renale, le quali non curano 
la malattia perché sono indirizzate più ai sintomi che non alle cause della patologia, 
le uniche cure disponibili sono la terapia con piridossina e il trapianto di fegato. 
Tuttavia, la terapia con piridossina è efficace solo per il 10-30% dei pazienti affetti 
dalla forma più comune di PH e il trapianto di fegato è un intervento molto invasivo 
e problematico. Pertanto, sarebbe auspicabile la ricerca di strategie idonee per lo 
sviluppo di terapie innovative.  
E’ noto che alcuni microrganismi sono in grado di produrre enzimi che degradano 
l’ossalato, fra i quali il più studiato è l’ossalato decarbossilasi da Bacillus subtilis 
(OxDC). OxDC converte l’ossalato in formiato e CO2. È nota una forma mutata 
dell’enzima, chiamata OxDC-DSSN, la quale presenta una ridotta attività 
decarbossilasica, ma possiede attività ossalato ossidasica. Tuttavia, non è possibile 
somministrare direttamente OxDC ai pazienti affetti da PH, in quanto si 
svilupperebbe una significativa risposta immunitaria. Inoltre, è importante 
sottolineare che l’OxDC ha un optimum di pH attorno a 4 e molti studi si sono 
limitati a valutarne le proprietà a pH acido, tralasciando la caratterizzazione 
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dell’enzima a pH neutro. Tale aspetto non rappresenta solo un’importante premessa 
per il suo utilizzo all’interno degli eritrociti, ma può anche fornire informazioni 
importanti per gli impieghi dell’enzima a livello industriale. 
Lo scopo principale del mio progetto di dottorato è stato quello di studiare le 
proprietà di OxDC a pH neutro e di porre le basi per lo sviluppo di un approccio 
terapeutico basato sull’incapsulamento dell’enzima all’interno degli eritrociti, i 
quali funzionerebbero da bioreattori proteggendolo dalla degradazione e 
impedendo la risposta immunitaria del paziente. 
I dati ottenuti indicano che: 
(1) OxDC e OxDC-DSSN (i) mostrano un’attività ottimale a pH 4.2 ma 
conservano un’attività misurabile anche al pH 7.2 presente all’interno degli 
eritrociti, (ii) a pH neutro non vanno incontro a cambiamenti strutturali 
rispetto a pH 4.2 e (iii) sono in grado di detossificare l’ossalato endogeno 
prodotto in un modello cellulare di PH1. 
(2) OxDC può essere efficientemente incapsulata sia negli eritrociti umani che 
murini e durante il processo di loading non perde attività catalitica. 
(3) mediante approcci di evoluzione diretta è possibile ottenere una forma 
mutante di OxDC che presenta una aumentata termostabilità e una minore 
tendenza all’aggregazione rispetto all’enzima wild-type. 
 
In conclusione, questi dati confermano l’applicabilità di una terapia basata sulla 
somministrazione di enzimi che degradano l’ossalato incapsulati in eritrociti come 
possibile cura per l’iperossaluria. A tal proposito, in futuro verrà testata la capacità 
di degradare l’ossalato in un modello murino di malattia da parte dell’enzima wild-
type e della forma ingegnerizzata di OxDC. 
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1.1 The etiology of Hyperoxaluria 
 
Hyperoxaluria is a pathologic condition characterized by an increased urinary 
excretion of oxalate (Bhasin et al. 2015). Oxalate, in the form of its calcium salt 
(CaOx), is a highly insoluble end product of metabolism in humans (Cochat et al. 
2013) and it is excreted by urine. The excretion of more than 40-45 mg/24 hours of 
urinary CaOx is considered pathological (Bhasin et al. 2015). Primary 
hyperoxaluria (PH) and secondary hyperoxaluria (SH) are two different clinical 
expressions of the disease. PH comprises a group of rare inborn errors of glyoxylate 
metabolism that result in high endogenous oxalate production mainly by the liver 
(Marengo et al., 2008; Danpure et al., 2004; Harambas et al., 2011). In contrast, 
SH is caused by an increased intestinal oxalate absorption, as a consequence of 
various factors such as (i) high oxalate diet, (ii) fat malabsorption, (iii) alterations 
of the intestinal oxalate-degrading microorganisms, or (iv) genetic variations of the 
intestinal oxalate transporters (Robijn et al. 2011). The clinical phenotype of the 
two disease forms is qualitatively similar, and mainly related to the high urinary 
oxalate concentration leading to the production of CaOx stones, and to the 
consequent formation of diffuse renal calcifications (nephrocalcinosis) and stones 
(nephrolithiasis) (Robijn et al. 2011). However, PHs are usually characterized by 
an early-onset and are associated with more serious consequences for human health. 
In fact, the continuous CaOx deposition that occurs in the kidneys of PH patients 
frequently leads to remarkable kidney damage and to the consequent End Stage 
Renal Disease (ESRD). In ESRD, the progressive deterioration of the urinary tract 
finally causes renal failure and accumulation of CaOx crystals in other 
compartments like blood vessel, bones, retina, heart and the central nervous system 
(Osswald et al., 1979; Beck et al., 2013). These events generate a potentially fatal 
condition named systemic oxalosis (Beck et al., 2013, Hoppe 2012), whose main 
manifestations are reported in Table 1. 
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Table 1. Symptoms of systemic oxalosis in PH1. 
 
 
 
 
1.2 Primary Hyperoxaluria 
 
Three genetic defects are currently known to cause PH. The corresponding disease 
forms are named primary hyperoxaluria Type I (PH1), Type II (PH2) and Type III 
(PH3). All of them are inherited recessive disorders caused by the deficit of a 
hepatic enzyme involved in the metabolism of glyoxylate, which results in 
glyoxylate accumulation and oxidation to oxalate (Salido et al., 2012). (Fig 1).  
 
 
Figure 1. Molecular mechanisms of PH1, PH2 and PH3. HOGA: 4-hydroxy-2-
oxoglutarate aldolase; GRHPR: glyoxylate reductase/hydroxypyruvate reductase; AGT: 
alanine:glyoxylate aminotransferase; GO: glycolate oxidase; LDH: lactate dehydrogenase 
(Oppici et al., 2017). 
 
TISSUE CLINICAL SYMPTOMS 
Kidney and urinary tract Urolithiasis, nephrocalcinosis, renal 
failure 
Bone Bone pain, multiple fractures and 
osteosclerosis 
Eye Retinopathy and optic atrophy 
Heart Heart block, myocarditis and 
cardioembolic stroke 
Nerves Peripheral neuropathy 
Deep vasculature Vasospasm 
 10 
 
(i) PH1 is the most common and most severe form of PH (70-80% of 
the patients). It has an estimated prevalence ranging from 1 to 3 per 
million population and an estimated incidence rate of 1:120,000 live 
births per year in Europe and North America (Cochat et al., 2013, 
Kopp et al., 1995). However, the incidence is usually higher in 
geographically isolated countries such as Canary Islands and in 
populations where consanguineous marriages are common. The 
disease accounts for less than 1% of paediatric patients showing 
ESRD in Europe, but this percentage increases to more than 10% in 
Kuwait and Tunisia (Coulter-Mackie et al., 2003).  
PH1 is caused by mutations on the AGXT gene that encodes 
alanine:glyoxylate aminotransferase (AGT), a liver enzyme 
responsible for glyoxylate detoxification inside peroxisomes 
(Danpure et al., 2005). AGT is a pyridoxal 5'- phosphate (PLP)-
dependent enzyme that catalyses a transamination reaction in which 
the amino group of L-alanine is transferred to glyoxylate, leading to 
the formation of pyruvate and glycine. In the absence of functional 
AGT, a build-up of glyoxylate in peroxisomes occurs, followed by 
its translocation to the cytosol where it is oxidized to oxalate by 
lactate dehydrogenase (LDH) (Figure 1). The production of huge 
amounts of oxalate leads to a fast and conspicuous generation of 
CaOx stones at first in renal tissues and then, when supersaturation 
of CaOx in plasma occurs, to CaOx deposition in many other organs 
and tissues with consequent systemic clinical effects. 
The clinical manifestations of PH1 can be various. First symptoms 
can appear from early infancy to the sixth decade (median age: 4-6 
years) and mainly consist in nephrolithiasis, although some patients 
can present with ESRD in the first five years of life, thus underlying 
the severity of the disease. In adulthood PH1 presents with a mild-
to-moderate reduction of kidney function and with recurrent renal 
stones. Moreover, 20-50% of individuals receiving a diagnosis of 
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PH1 present the late stages of chronic kidney disease or ERSD 
(Milliner et al., 2002). 
 
Overall, more than 150 mutations on the AGXT gene have been 
identified and associated with PH1 (Williams et al., 2009, Mandrile 
2014). Besides deletion and insertions, which represent about 25% 
of all known mutations, the vast majority are point mutations that 
lead to single amino acid substitutions of residues spread over the 
entire protein structure. As already found for many other inherited 
diseases, missense mutations often map highly conserved residues 
that are supposed to be crucial for the preservation of the enzyme 
structure and function (Montioli et al., 2014). 
 
(ii) PH2, which accounts for approximately 10% of PH cases (Hoppe et 
al., 2015), is caused by the deficit of glyoxylate reductase-
hydroxypyruvate reductase (GRHPR). GRHPR is the enzyme that 
converts glyoxylate into glycolate and hydroxypyruvate to D-
glycerate (Figure 1). GRHPR is ubiquitous, but the majority is 
intrahepatic (Creegen et al., 2003), where it localizes in the cytosol 
of hepatocytes and partly inside mitochondria. The protein is also 
expressed in other tissues, including renal tubules where it likely 
contributes significantly to the kidney damage occurring in PH2 
(Giafi et al., 1998). The absence of hepatic GRHPR in PH2 patients 
leads to increased glyoxylate and hydroxypyruvate accumulation, 
two products that are converted by LDH to oxalate and L-glycerate, 
respectively. In fact, glyceric aciduria is one of the distinctive 
features of PH2 (Salido et al., 2012). PH2 patients normally suffer 
from less severe symptoms with respect to those affected by PH1 
and rarely progress to ESRD (Marangella et al., 1994). 
 
(iii) PH3 accounts for 10% of PH cases and it is caused by the deficit of 
4-hydroxy-2-oxoglutarate aldolase (HOGA1), encoded by the 
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HOGA1 gene (Figure 1). HOGA1 is located in the mitochondrial 
matrix and is responsible of the last step of the hydroxyproline 
degradation pathway, the cleavage of 4-hydroxy-2-oxoglutarate into 
pyruvate and glyoxylate (Phang et al., 2001). Since this reaction 
produces glyoxylate, it is difficult to understand how HOGA1 
dysfunction could lead to glyoxylate accumulation. It has been 
reported that the absence of HOGA1 results in increased 
concentration of 4-hydroxy-2-oxoglutarate, which could be 
transformed into glyoxylate by an unidentified cytosolic aldolase 
(Monico et al., 2005). Although the enzyme is abundant in 
hepatocytes, the finding that it is also expressed at renal level has 
raised the possibility that it could contribute to the mechanism of 
renal damage in PH3. Nevertheless, a clear explanation of PH3 
pathogenesis has not been provided until now (Salido et al., 2012).  
PH3 patients show a mild phenotype with recurrent urolithiasis and 
nephrocalcinosis during the first decade of life, occasionally leading 
to reduce kidney function starting from childhood or adolescence. 
Moreover, systemic oxalosis has never been reported in PH3 patients 
(Cochat and Rumsby, 2013).  
 
 
1.3 Secondary Hyperoxaluria 
 
SH results from an increased intestinal absorption of exogenous oxalate (Bhasin et 
al., 2015). It is usually associated with a milder phenotype with respect to PH. 
Despite the fact that ESRD has been reported as a possible clinical manifestation, 
systemic oxalosis is less common and may only occur in severe cases of 
inflammatory bowel disease or short bowel syndrome (Bhasin et al., 2015). The 
molecular bases of SH can be various and span from environmental to genetic 
factors, including in particular: 
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(i) Excessive intake of oxalate precursors. Dietary intake contributes to about 
50% of the excreted urinary oxalate, thus proving that diet could be an 
important determinant in total oxalate excretion (Holmes et al., 2001). 
Spinach and rhubarb are the main source of dietary oxalate whose daily 
intake must not exceed 1000 mg. However, it must be mentioned that the 
amount of oxalate effectively absorbed by the intestine could vary 
depending on the amounts of oxalate-binding cations present in the 
intestinal tract. In fact, ingested calcium or magnesium ions can complex 
oxalate producing insoluble salts and thus reducing the amount absorbed by 
the intestine.  
 
(ii) Fat malabsorption (enteric hyperoxaluria). An altered capacity to absorb fat-
containing food increases the intestinal absorption of oxalate as a result of 
two different mechanisms: (i) dihydroxy bile acids and fatty acids increase 
the permeability of the intestinal mucosa to oxalate, and (ii) fatty acids 
complex with luminal calcium, thus increasing the amount of soluble 
oxalate available for intestinal absorption (Worcester et al., 2012). This 
form of hyperoxaluria is often a consequence of partial gastrectomy, 
bariatric surgery or the use of gastrointestinal lipase inhibitors (Bhasin et 
al., 2015, Karaolanis et al., 2014). 
 
(iii) Alteration in intestinal microflora. One of the microorganisms that colonize 
the intestinal tract is Oxalobacter formigenes, an aerobic gram negative 
bacterium that uses oxalate as its energy source, thus decreasing intestinal 
absorption (Mittal et al., 2004, Hatch et al., 2006). Oxalate enters the 
bacterium through an oxalate-formate antiporter on the cell membrane, and 
it is then metabolized to formate and CO2 (Mittal et al., 2004, Robijin et al., 
2011). Environmental influences, such as frequent antibiotic treatment, 
gastrointestinal disorders, or bariatric operations, often lead to a loss of 
intestinal colonization, and to a consequent increased absorption of free 
oxalate in the intestinal lumen (Hoppe et al., 2005). In this regard, the 
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restoration of O. formigenes colonization has been proposed as an effective 
approach for the treatment of hyperoxaluria (see below). 
 
1.4 Biochemical properties of AGT 
 
PH1, the most recurrent and severe form of PH, is due to inherited mutations in the 
gene encoding AGT. AGT is a liver-specific enzyme present inside peroxisomes. It 
is a homodimer and each subunit is composed by 392 amino acids. According to its 
crystal structure (Zhang et al., 2003), AGT belongs to the Fold Type I class of PLP-
dependent enzymes (Figure 2). Each subunit comprises: a N-terminal extension 
composed by residues 1-21 wrapping over the surface of the neighbouring subunit, 
a large domain (residues 22-282) containing the dimerization interface and most of 
the active site and a C-terminal domain (residues 283-392) containing the 
peroxisomal targeting information. 
 
 
Figure 2. Representation of the AGT dimeric structure (PDB 3R9A). One subunit is 
colored grey; on the other subunit the N-terminal extension, the large domain and the C-
terminal domain are shown in blue, orange and red, respectively. PLP is shown as green 
sticks. Oxygen, nitrogen and phosphorous atoms are shown in red, blue and purple, 
respectively. 
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As in all PLP-enzymes, the coenzyme is covalently bound to the amino group of a 
lysine residue (Lys209 in AGT) by means of a Schiff base linkage, forming a 
complex called internal aldimine (Amadasi et al., 2007). Other weak interactions at 
the active site stabilize the AGT-PLP complex including: (i) a salt bridge between 
the pyridine nitrogen of PLP and Asp183, (ii) a base stacking interaction between 
Trp108 and the pyridine ring of PLP and (iii) hydrogen bonds between the hydroxyl 
group of PLP and Ser158 as well as between the phosphate group of PLP and 
Gly82, His83, Tyr260 and Thr263 (Figure 3) (Zhang et al., 2003).  
 
 
 
 
 
Figure 3. AGT active site. Particular of the AGT active site (PDB: 3R9A). PLP is shown 
as green sticks. Residues interacting with the coenzyme are shown as grey sticks (if belong 
to the same subunit of the coenzyme) or orange sticks (if belong to the neighboring 
subunit). Oxygen, nitrogen and phosphorous atoms are colored red, blue and fuchsia, 
respectively.  
 
 
The active site is located in a cleft at the monomer-monomer interface and it is 
formed by residues belonging to both subunits, thus suggesting that the catalytic 
activity is strictly related to the folded dimeric structure. In this regard, it has been 
recently reported that the mutation of the interface residues Arg118, Phe238 and 
Phe240 produces a form of the enzyme stable in solution as monomer. Monomeric 
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AGT is devoid of catalytic activity but is able to bind PLP, which strongly promotes 
dimer formation (Dindo et al., 2016).  
A peculiar structural feature of AGT can be observed by looking to the surface of 
the protein, where it can be noticed an asymmetric distribution of charged residues, 
i.e. the presence of negative and positive patches. The latter condition can promote 
self-association processes mediated by electrostatic forces (Dindo et al., 2017).  
AGT catalyses the reversible transamination of L-alanine and glyoxylate to 
pyruvate and glycine, respectively, by a classical ping-pong mechanism (Figure 4). 
In the first half-reaction, after the binding of the substrate to the catalytic site of the 
enzyme in the internal aldimine form (AGT-PLP) and the formation of the 
Michaelis complex, the ε-amino group of Lys209 is replaced by the α-amino group 
of L-alanine, generating the external aldimine. The extraction of the Cα -proton 
from the external aldimine yields a quinonoid intermediate, which is then 
reprotonated at the C4’ of the coenzyme to give the ketimine intermediate. The 
latter form is then hydrolyzed to pyridoxamine 5’-phosphate (PMP) and pyruvate. 
In the second half transamination, following the same steps of the first half-reaction 
but in reverse order, glyoxylate reacts with the AGT-PMP complex and is converted 
to glycine, thus regenerating AGT-PLP (Cellini et al., 2017).  
 
 
 
 
Figure 4. Mechanism of the transaminase reaction catalyzed by AGT.  
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AGT kinetic studies confirm that the enzyme is highly specific for the glyoxylate 
to glycine conversion, in agreement with the proposed physiological role of the 
enzyme in glyoxylate detoxification (Cellini et al., 2017). In fact, the equilibrium 
constant of the overall transamination is about 9400 and the kcat for the 
transamination reaction of the alanine/glyoxylate pair is about 150-fold higher with 
respect to that of the glycine/pyruvate pair (Cellini et al., 2017). Moreover, it has 
been demonstrated that the enzyme possesses a higher affinity for PMP than for 
PLP, and the coenzymatic form PMP remains tightly bound to the apoprotein 
during the catalytic cycle, producing an enzyme more reactive toward oxoacids 
(Cellini et al., 2017). The spectral changes occurring in AGT during the two half-
transamination reactions have indicated that some conformational changes at the 
active site occurs. Through computational studies, it has been suggested that slight 
rearrangements of aromatic residues at the active site and a tilting of the coenzyme 
could take place and these structural re-orientations could be responsible for the 
tight PMP binding during catalysis (Cellini et al., 2017).  
 
 
1.4.1 The major and minor allelic form of AGT 
 
AGT is encoded by the AGXT gene which is located on chromosome 2q37.3. This 
gene is present in human population as two polymorphic variants, named the “major 
allele” and the less common “minor allele”. The frequency of the minor allele varies 
from 2% in Japanese population, to 20% of Europeans and North Americans, to 
28% in the Saami population (Purdue et al., 1990, Purdue et al., 1991). The minor 
allele differs from the major one for a 74-bp duplication in intron 1 and two point 
mutations (32C à T and 1020A à G) which cause the Pro11Leu and Ile340Met 
amino acid substitutions (Purdue et al., 1991). The presence of the minor allele 
polymorphism is not pathogenic per se, but it could promote an increased 
susceptibility of AGT to the effect of several missense mutations, which are 
predicted to be non-pathogenic when associated with the major allele. For this 
reason, many investigations have been carried out to understand the differences 
between the two allelic forms of AGT at cellular and molecular level. Studies 
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performed in human hepatocytes suggest that the protein encoded by the minor 
allele (AGT-Mi) has a specific activity of about 70% as compared with that encoded 
by the major allele (AGT-Ma) (Purdue et al., 1991, Lumb et al., 2000). Moreover, 
while AGT-Ma is entirely located in peroxisomes, AGT-Mi shows a localization of 
about 95% peroxisomal and 5% mitochondrial (Purdue et al., 1991). In cellular 
models it has been demonstrated that the partial mitochondrial localization of AGT-
Mi is due to the presence of the P11L mutation, which creates a weak putative 
mitochondrial targeting sequence (MTS) at the N- terminus of the protein. Despite 
the presence of a putative MTS, a large part of AGT-Mi is not imported into 
mitochondria, probably because the protein quickly folds and dimerizes, thus 
avoiding the interaction with the mitochondrial import machinery that only acts on 
unfolded or partly-unfolded monomeric species (Lumb et al., 1999).  
Biochemical studies on the purified form of AGT-Ma and AGT-Mi (Cellini et al., 
2010, Salido et al., 2012) have indicated that the P11L/I340M mutations do not 
affect either the UV-visible absorbance, dichroic and fluorescence features of AGT 
or the equilibrium dissociation constant for PLP (KD(PLP)) value. This suggests the 
absence of gross conformational changes between the two allelic forms that share 
a similar active site architecture (Cellini B et al., 2010). Nevertheless, AGT-Mi 
shows an approximately 30% decreased kcat value for the overall transamination of 
the L-alanine/glyoxylate pair, in agreement with the reduced specific activity 
observed in human hepatocytes. Furthermore, yeast complementation assays 
(Hopper et al., 2008) along with pulse-chase and cross-linking experiments 
performed on cell-free transcription/translation products (Coulter-Mackie et al., 
2006) have shown that AGT-Mi is less stable in vivo and is more susceptible to 
proteolytic degradation and aggregation in comparison to AGT-Ma (Cellini et al., 
2012).  
Thermal and chemical unfolding experiments have provided evidence for a less 
stable dimeric structure and a decreased overall stability of both holo- and apoAGT-
Mi as compared with the corresponding forms of AGT-Ma. The structural 
destabilization of AGT-Mi has been exclusively attributed to the P11L mutation 
(Cellini et al., 2012). In silico analyses predict that its replacement by a leucine 
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residue could increase the flexibility of the N- terminal arm of AGT, possibly 
promoting its dissociation from the neighboring subunit (Dindo et al., 2017).  
Moreover, the perturbation of the N- terminal arm could also be transmitted to the 
AGT active site through a loop (residues 24-32), which contributes to the PLP 
binding site. Overall, the analyses on the differences between AGT-Ma and AGT-
Mi, have allowed not only to better understand the structural features of AGT, but 
have also represented an important starting point to investigate the effect of 
pathogenic mutations associated with the major or the minor allele. 
 
1.4.2 The role of misfolding and aggregation in PH1 
 
In the last ten years, protein misfolding induced by missense mutations was 
demonstrated to be the molecular mechanism in a constantly growing number of 
inborn errors of metabolism. To attain functionality, proteins must fold into their 
three-dimensional native state structure during or following translation at the 
ribosomes (Sala et al., 2017).  To maintain proteostasis a cell must assume a correct 
balance between protein synthesis, folding and degradation. However, this balance 
is constantly altered by either mutations or environmental stress factors.  
The vast majority of PH1-causing mutations are missense and they involve residues 
spread over the entire AGT sequence. Although this would suggest that a great 
variety of mechanisms could lead to AGT deficit, studies at molecular level 
strongly agree upon the finding that the main consequence of pathogenic mutations 
is protein misfolding. AGT misfolding can lead to various downstream effects, as 
outlined in Figure 6 (Oppici et al., 2015, Pey et al., 2013). 
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Figure 6. Tentative scheme describing the AGT folding pathway and the effects of 
mutations leading to folding defects. Most pathogenic mutations associated with PH1 
cause folding defects that then lead to a variety of downstream effects including increased 
degradation or aggregation, destabilization or mistargeting. 
 
It should be also underlined that most missense mutations are pathogenic only when 
present on the minor polymorphic form of the enzyme, while in other cases the 
same mutation can lead to different effects if present on the background of the major 
or the minor allele. 
Pathogenic mutations altering AGT folding in PH1 can have the following 
consequences: 
(i) Destabilization of the dimeric structure. The mutations involved are 
residues located at monomer-monomer interface, as demonstrated for the 
G41R, G41V and G47R variants in the purified form (Cellini et al., 2009, 
Cellini et al., 2010a, Cellini et al., 2010b) and in cellular systems (Fargue 
et al., 2013, Montioli et al., 2015). In some cases, substitutions of amino 
acid distant from the interface could give rise to indirect destabilizing effect 
on the quaternary structure, as proved for the F152I and G170R mutations 
which co-segregate with the minor allele polymorphism (Cellini et al., 
2009, Cellini et al., 2010a). 
(ii) Reduction of intracellular stability. This point is related to proteolytic 
phenomena because in the presence of exposed flexible regions the 
proteolysis increase meaning the presence of a folding defect (Fontana et 
al., 2014). Some pathogenic variants of AGT associated with the minor 
allele, such as G41R, A112D and I244T, and with the major allele, such as 
Unfolded
protein
Misfolded
protein
Fully folded
protein
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G41R and A112D, show a high susceptibility to proteolytic degradation 
resulting in a reduced intracellular half-life (Cellini et al., 2010b, Fargue et 
al., 2013, Montioli et al., 2015). 
(iii) Increased aggregation propensity. Two different mechanisms related to the 
aggregation process of AGT have been reported. Some variants, like F152I-
Mi, undergo hydrophobic aggregation deriving from a destabilization of the 
dimeric structure which causes the population of monomeric intermediates 
exposing apolar surfaces (Cellini et al., 2009, Fargue et al., 2013, Montioli 
et al., 2015). In other cases, variants undergo electrostatic aggregation in 
which interaction between patches of opposite charge create a native-like 
aggregation prone protein (Cellini et al., 2010b, Oppici et al., 2013b). AGT 
aggregates can deposit both in peroxisomes or in the cytosol, probably 
depending on the competition between the kinetics of aggregation and that 
of peroxisomal import (Fargue et al., 2013, Oppici et al., 2013b, Santana et 
al., 2003). In fact, if the aggregation rate is higher with respect to the import 
rate, cytosolic aggregates are unable to reach the peroxisomal compartment 
as demonstrated for the Gly161 variant (Oppici et al., 2013b). 
 
 
1.5 Current and future strategies for the treatment of Hyperoxaluria 
 
Hyperoxalurias are difficult-to-treat diseases. An early diagnosis and a focused 
therapy are crucial to avoid renal damage in patients. Classical treatments are 
addressed at preventing kidney failure or at restoring kidney function (Cochat et 
al., 2012, Cochat et al., 2013, Ben-Shalom et al., 2015, Cellini 2017, Cochat et al., 
2013). In this regard, all patients affected by hyperoxaluria must assume a large 
daily intake of fluids (>31 per 1.73 m2) to avoid CaOx concentration and prevent 
stones formation (Robijn et al., 2011). Since in infants the assumption of fluids can 
be difficult, combination of haemodialysis and peritoneal dialysis may be used to 
further enhance oxalate elimination. The timing of haemodialysis and peritoneal 
dialysis should be coordinated as the latter may be more efficient in removing 
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oxalate in the later phases of the interdialytic period when rebound is much higher 
than in the earlier interdialytic phase (Bhasin et al., 2015). 
Other classical therapies are aimed at: 
(i) Decreasing the intake of oxalate by dietary restriction. This approach 
was not regarded as being very helpful, because dietary oxalate is 
supposed to contribute only marginally to the pathogenesis of the most 
severe forms of hyperoxaluria, where the highest amount of 
accumulating oxalate is of endogenous origin (Archer et al., 1957; 
Zarembski et al., 1969; Marshall et al., 1972; Chadwick et al., 1973). 
However, more recent studies have shown that diet contribution could 
be more significant than previously known (Holmes et al., 2001). 
(ii) Preventing CaOx crystallization, by the administration of crystallization 
inhibitors (i.e. magnesium and potassium citrate) to decrease the amount 
of calcium oxalate available for precipitation (Bhasin et al., 2015) or by 
hyper-hydration of the patient as mentioned above (Harambat et al., 
2011, Hoppe 2012). 
(iii) Removing CaOx stones by lithotripsy (Carasco et al., 2015). 
(iv) Under more severe conditions, treating renal failure and associated 
uremia by dialysis or kidney transplantation (Carasco et al., 2015). 
However, all the problems related to transplantation are well-known 
(Danpure et al., 2005). 
All these approaches address the symptoms of the disease rather than the causes 
and thus they do not represent a real cure and only slow down disease progression. 
Unfortunately, no true curative strategies are available for most disease forms, 
except for PH1.  
In the case of PH1, two therapeutic approaches addressing the causes of the disease 
are currently in use: the administration of pharmacological doses of pyridoxine 
(PN), a B6 vitamer, and liver transplantation (Cellini et al., 2014). In responsive 
patients, the administration of 10 mg/kg body weight of PN can enhance AGT 
expression and enzymatic activity (Cellini et al., 2014). It is well-known that PN 
can be converted to PLP, the essential cofactor of AGT. PLP plays not only a 
prosthetic role for the protein, but also a chaperone role, because the binding of the 
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cofactor to the apo-form induces a strong stabilization that can be observed both at 
protein and at cellular level (Cellini et al., 2014). In particular, recent papers have 
demonstrated that the coenzyme is able to induce dimer formation as well as to 
stabilize the dimer once folded (Oppici et al., 2015a, Dindo et al., 2017, Dindo et 
al., 2018). This explains why PN-responsive patients usually bear mutations that 
compromise the correct folding of AGT by allowing the population of monomeric 
intermediates and/or by promoting intracellular aggregation (Oppici et al., 2013, 
Fargue et al., 2013a, Mesa-Torres et al., 2013, Montioli et al., 2015). Unfortunately, 
although very safe, PN administration is effective for only a minority (25-35%) of 
PH1 patients (Cochat et al., 2012). The only alternative for unresponsive ones is 
liver transplantation. Liver transplantation is considered a form of enzyme 
replacement because it allows to substitute the entire pool of AGT thus restoring 
glyoxylate detoxification ability of the patients. However, it represents a very 
invasive intervention that comes with several side-effects (Cochat et al., 2010). 
While this approach has been usually limited to PH1, recently it has been also 
employed with success in a PH2 patient (Dhondup et al., 2018). 
In the last years, an increased knowledge of the molecular bases of PH and SH has 
allowed to make big progresses in the development of new treatment strategies. The 
rationale of the approaches currently under development is outlined below, but most 
of them aim at either improving liver glyoxylate detoxification, or at preventing 
endogenous oxalate synthesis, based on the estimate that about 40% of oxalate 
production derives from the glycine/glyoxylate metabolism. Another category of 
therapies under development include those aimed at reducing the amount of 
exogenous oxalate absorbed at intestinal level.  
The approaches currently under investigation include: 
(i) Gene therapy. It consists in the recovery of a defective enzymatic 
function by replacing a mutated gene with a normal copy. Being single-
gene diseases, all three forms of PH could be cured by a gene therapy 
approach. The first attempts started on PH1 using liver-directed viral 
vectors to recover AGT expression in mice disease models. One 
employed two adeno-associated virus serotypes (AAV5 and AAV8) 
(Salido et al., 2011), while the other employed helper-dependent 
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adenoviral vectors (Castello et al., 2016). In both cases a reduction of 
urinary oxalate excretion was observed. However, the high dosage 
required reduces the safety of this approach and prompt for the 
searching of new viral vectors endowed with a better specificity and 
safety profile.  
(ii) Substrate reduction therapy (SRT). The principle of this strategy is the 
reduction of an accumulating substrate using small molecules that 
inhibit the enzymes working upstream of the mutated one in the same 
metabolic pathway (Guerard et al., 2018, Shemesh et al., 2015, Smid et 
al., 2016).  In the three forms of PH, various SRT strategies have been 
designed to reduce the amount of glyoxylate endogenously produced, 
with the direct consequence of preventing oxalate formation. They are 
based on the use of either small-molecule or RNA interference (RNAi) 
therapeutics directed against two different targets: (i) glycolate oxidase 
(GO), which is a flavin-dependent enzyme belonging to the hydroxyacid 
oxidases family that catalyses the conversion of (S)-2-hydroxy acids and 
molecular oxygen to 2-oxo acids and hydrogen peroxide. The protein is 
considered a suitable target for SRT in PH, because it is the enzyme 
mainly involved in glyoxylate production in human hepatocytes (Booth 
et al., 2006, Mdluli et al., 2005). (ii) LDH, which catalyses the 
conversion of lactate to pyruvate and back, with the concomitant 
conversion of NAD+ to NADH. LDH is the enzyme directly involved in 
glyoxylate-to-oxalate conversion in the cytosol of liver hepatocytes. In 
2016, Higueras et al. identified a compound named 4-carboxy-5[(4-
chlorophenyl) sulfanyl]-1,2,3-thiadiaziole (CCPST) which is able to 
inhibit GO in primary cultures of hepatocytes deriving from mice 
knock-out for the AGXT gene. Upon in vivo oral administration to AGXT 
knock-out mice, it reduces urinary oxalate excretion by 30-50%. 
Notwithstanding this very promising result, a more detailed 
investigation of toxicity is necessary to test the biosafety of this 
compound. Very recently, Moya-Garzon et al. have studied the effect of 
salicylic acid derivatives on the inhibition of GO. Most of the identified 
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compounds are able to reduce the production of oxalate in hyperoxaluric 
hepatocytes by acting as GO inhibitors. However, more detailed studies 
are ongoing in order to design molecules with an improved affinity and 
specificity for the enzyme (Moya-Garzon et al., 2018). 
In the last years, very promising SRT strategies for the treatment of PH 
have been designed taking advantage of the RNAi technologies. RNAi 
is based on the use of 19-21 bp RNA molecules which bind and degrade 
a specific mRNA, thus preventing the expression of the corresponding 
protein (Alagia et al., 2016). The first attempt in this direction was made 
by Dutta et al. in 2016 using a Dicer-substrate RNAi produced by 
Dicerna Therapeutics, which is delivered by nanoparticles and targets 
the HAO1 gene encoding GO. Preclinical studies have highlighted a 
remarkable suppression of GO expression and activity, associated with 
a decreased urinary oxalate excretion in mice and monkey models of 
hyperoxaluria. A subsequent study has been performed in 2016 by 
Liebow et al., who tested a RNAi named ALN-GO1 produced by 
Alnylam Therapeutics and administered by subcutaneous injection. 
ALN-GO1 exerted a potent silencing of HAO1 gene and reduced urinary 
oxalate in mice, rats and non-human primates (Liebow et al., 2016). 
Based on these data the company developed Lumasiran, a drug based on 
ALN-GO1 conjugated to N-acetylgalactosamine, for an efficient 
delivery to hepatocytes. Lumasiran is currently tested in a phase 1/2 
clinical trial in patients affected by PH1. 
Very recently, the possibility to target LDH by RNAi has been evaluated 
by Lai et al. (Lai et al., 2018). This approach could be mentioned as SRT 
because the reduction of hepatic LDH would block glyoxylate-to-
oxalate convertion, thus achieving efficient oxalate reduction. In this 
work the authors hypothesized that the reduced expression of hepatic 
LDH, which converts glyoxylate into oxalate, could avoid the 
accumulation of oxalate in PH patients. They found that targeting LDHA 
gene by RNAi actually decreases oxalate production and prevents CaOx 
crystals precipitation in mouse and primate disease models. Nowadays, 
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this RNAi developed by Dicerna Pharmaceuticals is in phase 1 clinical 
trial. However, a deep investigation about biosafety is needed. 
 
(iii) Pharmacological chaperones. One of the approaches under development 
in the last decades for the treatment of protein misfolding diseases is the 
use of chemical or pharmacological chaperones (PCs) which are small 
molecules able to improve the folding and restore the activity of 
misfolded proteins (Powers et al., 2009). The term chemical chaperones 
usually refers to low molecular weight molecules that non-specifically 
stabilize a misfolded protein without directly interacting with it. Some 
research groups have analysed the action of chemical chaperones in 
PH1. Phenylbutyric acid (PBA), betaine, glycerol and trimethylamine 
N-oxide (TMAO) have been tested. However, only glycerol and betaine 
were found to exert a stabilizing effect of the pathogenic variants F152I-
Mi, G170R-Mi, and I244T-Mi (Coulter-Mackie et al., 2006, Coulter-
Mackie et al., 2008). On the other hand, PCs usually exert a specific 
binding and stabilize misfolded proteins against denaturation and 
proteolytic degradation (Ringe et al., 2009). When a disease is due to an 
enzymatic deficit, compounds acting as PCs are either (i) vitamin 
derivatives functioning as coenzymes, or (ii) competitive inhibitors of 
the enzyme involved. Both classes of molecules are usually endowed 
with a high binding affinity and specificity, two features that allow them 
to be effective at very low concentrations (Ringe et al., 2009). The use 
of PCs as therapy has been successful for the treatment of various inborn 
disorders such as lysosomal storage diseases and phenylketonuria 
(Powers et al., 2009). Based on the finding that in some AGT variants 
the folding defect only or mainly affects the apo-form, and that this is 
also true for mutations responsive to Vitamin B6 at clinical level (Cellini 
et al., 2011, Monico et al., 2005, Hoyer-Kuhn et al., 2014), the possible 
chaperone role of the coenzyme has been evaluated. Studies carried out 
on purified proteins and in a cellular model of PH1 have revealed that 
PLP not only shifts the equilibrium from the less stable apo-form to the 
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more stable holo-form of AGT, but also binds apomonomeric and 
apodimeric folding intermediates promoting the acquirement and the 
maintenance of the dimeric structure that is crucial for functionality 
(Cellini et al., 2009, Cellini et al., 2010a, Cellini et al., 2012, Mesa-
Torres et al., 2013, Mesa-Torres et al., 2014, Pey et al., 2011). As a 
confirmation of the chaperone role of PLP, it has been recently reported 
that mutations located at the AGT monomer-monomer interface that 
cause structural alterations on the apo-form but not on the holo-form, 
are responsive to PN administration in vitro. Interestingly, the 
responsiveness seems to inversely correlate with the degree of 
conformational alteration of each variant, thus implying that a kind of 
threshold could exist, above which the coenzyme is not able to rescue 
for the folding defect of a variant (Dindo et al., 2018). Another 
parameter that could influence B6 responsiveness is the type of vitamer. 
In fact, even though PN is the only vitamer used in clinics, also 
pyridoxal (PL) and pyridoxamine (PM), can be internalized by cells 
(Ueland et al., 2015). The comparison of the effectiveness of the three 
B6 vitamers in a cellular model of PH1 has revealed that PN and PM are 
more effective than PN in the rescue of folding-defective variants of 
AGT (Oppici et al., 2015). The reason underlying this difference is that 
PM and PL administration, differently from PN, avoids the intracellular 
accumulation of pyridoxine phosphate (PNP) that competes with PLP 
for AGT binding and inhibits catalytic activity. Considering the safety 
of vitamins administration, and the fact that PM is already in the market 
for the treatment of diabetes Type II, these data hold promise for a 
possible future improvement of the therapy with Vitamin B6, which 
could completely or at least partly relief disease symptoms, provided 
that responsive mutations are identified and that the more effective 
vitamer is administered. 
The possibility to use substrate analogs acting as competitive inhibitors 
has been also evaluated in PH1. In particular, aminooxyacetic acid 
(AOA) has been analysed because it is a well-known ligand of the 
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protein. AOA binds the AGT active site by mimicking the position of 
the substrate L-alanine (Andy et al., 1995) and is supposed to form an 
oxime with the carbonylic group of PLP, similarly to what happens in 
other PLP-dependent enzymes. AOA behaves as a tight-binding 
inhibitor, but when administered to cells expressing AGT misfolded 
variants it plays a chaperone role for the most common mutations 
leading to PH1 such as F152I, G170R and I244T, due to its ability to 
specifically bind the enzyme and to dissociate from it in the presence of 
the physiological substrate. However, it lacks of specificity because it 
interacts with many PLP enzymes as well as with free PLP, thanks to its 
highly reactive aminic group (Andy et al., 1995). To overcome the low 
specificity of AOA, which makes it unsuitable for clinical use, a 
preliminary structure activity relationship analysis has been performed. 
This study allowed to identify a number of AOA derivatives among 
which 2-aminooxy-3-phenylpropionic acid was found to work as PC 
(Oppici et al., 2015).  
 
(iv) Intestinal oxalate degradation. A class of approaches under development 
aiming at reducing the burden of oxalate includes treatments directed to 
the consumption of intestinal oxalate. It has been mentioned that the 
intestine exerts a double function by (i) contributing to the absorption of 
dietary oxalate, and (ii) working as alternative pathway for the 
elimination of oxalate. It is well known how Oxalobacter formigenes 
plays a fundamental role in degrading intestinal oxalate, thus promoting 
a reduction in oxalate absorption which in turn reduces urinary oxalate 
excretion (Hatch et al., 2008, Hatch et al., 2013, Hoppe et al., 2011). 
Clinical studies have underlined a correlation between the lack or 
decreased activity of O. formigenes and the development of recurrent 
oxalate stone disease. Since the elimination of intestinal oxalate could 
induce a concentration-dependent transport into the intestinal lumen, the 
possibility that intestine colonization with O. formigenes could 
represent a treatment option in PH1 has been tested. In animal models, 
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the oral administration of O. formigenes leads to a net reduction of the 
levels of oxalate in urine and plasma, due to the complete colonization 
of the intestinal tract that effectively induces a progressive excretion of 
endogenous oxalate. Studies based on this approach are presented since 
2002, when Duncan et al., demonstrated that O. formigenes 
administration was able to reduce urinary oxalate in four human subject. 
More recently Hoppe et al., reported very encouraging results producing 
an oral formulations of O. formigenes with a good safety profile and 
leading to the reduction in urinary oxalate levels, as shown in a Phase 1 
trial in PH patients (Hoppe et al., 2006). In 2011, Hoppe et al. have also 
reported the effectiveness of the same treatment in two patients affected 
by infantile oxalosis (Hoppe et al., 2011).  
Moreover, a company named OxThera developed a lyophilized form of 
O. formigenes named Oxabact. Unfortunately, phase I/II clinical trials 
have not completely confirmed the results obtained in animal models. In 
fact, no significant differences were seen between control and treated 
group, probably due to a high heterogeneity in urinary oxalate excretion 
among patients. 
 
Following the idea that any approach able to decrease oxalate levels could reduce 
CaOx supersaturation and remarkably counteract stone formation in all forms of 
hyperoxaluria, it has been proposed that oxalate degrading-enzymes could be 
suitable candidates to carry out oxalate degradation in hyperoxaluric patients 
(Grujic et al., 2009). Among oxalate-degrading enzymes, oxalate decarboxylase 
(OxDC) is the most studied as new curative approach for PH1 patients. We will 
better explain this aspect in the chapter 4. 
 
1.6 Oxalate degrading-enzymes 
 
Oxalate is an end-product of metabolism in humans and other vertebrates (Smith et 
al., 1978). On the other hand, some bacteria, fungi and plants produce enzymes able 
to catabolize oxalate. In bacteria, oxalate-degrading enzymes are mainly involved 
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in the adaptation to pH stress conditions (Tanner et al., 2000), while in fungi and 
plants they take part of defence mechanisms in response to infection by pathogens 
(Wojtaszek et al., 1997; Dumas et al., 1995; Zhang et al., 1995). The three major 
pathways of oxalate catabolism are (i) oxidation, (ii) decarboxylation in form of 
oxalyl-CoA, and (iii) direct decarboxylation. Oxalate oxidases, also known as 
germins, cleave oxalic acid to two molecules of carbon dioxide (CO2) with the 
concomitant generation of hydrogen peroxide (H2O2). Oxalyl-CoA decarboxylase 
is a bacterial enzyme that converts oxalyl-CoA to formyl-CoA and CO2 employing 
thiamine pyrophosphate as cofactor. Finally, OxDC catalyzes the direct 
decarboxylation of oxalate to formate and CO2 (Just et al., 2004).  
 
1.6.1 Oxalate decarboxylase from B. subtilis 
 
Among oxalate-degrading enzymes, OxDC from B. subtilis is the most extensively 
characterized from a biochemical point of view. It is a metalloenzyme that requires 
manganese (II) and O2 to catalyse the conversion of oxalate to formate and CO2 
(Zhu et al., 2016). The resolution of the enzyme crystal structure (Anand et al., 
2002; Just et al., 2004) has revealed that OxDC is a 264 kDa homohexameric 
protein made up of two trimeric units (Figure 7A). The cupin domain I is made up 
of a continuous stretch of amino acid residues (56-233), while the cupin domain II 
is formed by residues 234-379 and 8-55 that contribute to one β-strand of the second 
cupin barrel and by two short helices (Figure 7B and C). A Mn(II) ion is located in 
the centre of each cupin domain and has an octahedral geometry in which four 
interactions are contributed by highly conserved amino acid side chains (His95, 
His97, His140, and Glu101 for the cupin domain I and His273, His275, His319, 
and Glu280 for the cupin domain II). The OxDC trimer is stabilized by interlocking 
claw-like α-helical protrusions of adjacent monomers. In the hexameric structure 
two trimeric layers are packed face to face and a large solvent channel extends 
entirely through the hexamer. 
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Figure 7. Structural representation of OxDC from B. subtilis. (A) Crystal structure of 
the OxDC hexamer. Each bicupin monomer is differently coloured. Grey spheres represent 
Mn (II) ions. (B) Crystal structure of the OxDC monomer. The cupin domain I and cupin 
domain II are coloured green and purple, respectively. The yellow spheres show the 
position of the two Mn(II) centers (PDB: 1J58). (C) Topology diagram of OxDC. The six-
stranded β-sheets that form the front of the cupin barrel are blue, the five-stranded α-sheets 
that form the back are red, α-helices are green. The first and last residue numbers of each 
secondary structural element are shown (Anand et al., 2002). 
 
 
The proposed catalytic mechanism of OxDC has been extensively studied and is 
illustrated in Figure 8. The enzyme requires oxygen for catalysis, although the 
reaction does not involve any direct oxidation (Reinhardt et al., 2003). In the first 
step of reaction, oxalate in the monoprotonated forms binds both Mn (II) and the 
side chain guanidinic group of an Arg residue at the active site. Then, dioxygen 
oxidizes the catalytically important Mn (II) ion to Mn(III), which can then oxidize 
the bound substrate to the appropriate radical intermediate. Oxidation reaction is 
thought to take place with the concomitant formation of a Mn-bound superoxide. 
Then, an active site glutamate residue probably mediates a proton-coupled electron 
transfer in the initial complex to give a Mn(II)-bound oxalate radical anion, which 
undergoes heterolytic bond cleavage to release CO2. After decarboxylation, a 
Mn(II)-bound radical anion of formate is produced, which can then be protonated 
by the active site glutamate, again with electron transfer from the metal, to yield 
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Mn(III)-bound formate (Svedružić et al., 2007; Zhu et al., 2016). It is well known 
that OxDC has an optimum pH of 4.2 and a Km for oxalate of 5 mM (Burrel et al., 
2007). 
The identity of the catalytically active Mn containing site is still highly debated 
(Just et al., 2007). Recently, it has been postulated that the cupin domain I is the 
one responsible for the decarboxylase activity, while the cupin domain II 
exclusively plays a structural role. This hypothesis is supported by numerous 
structural and kinetic evidences as well as by site-directed mutagenesis studies. In 
particular, the presence in the crystal structure of a formate molecule bound to the 
active site and the identification of a suitable proton donor (Glu162) have been only 
detected in the cupin domain I (Anand et al., 2002; Just et al., 2004). Moreover, 
mutation of residues in the putative active site of the cupin domain I completely 
abolishes the OxDC catalytic activity (Just et al., 2004). 
Recently, it has been discovered that, besides the involvement of Glu162, also the 
oxidation state of the bound metal ion plays a crucial role during catalysis of the 
OxDC reaction. For many years it has been suggested that the enzyme used 
dioxygen to generate Mn ions in the oxidation state Mn(III) or Mn(IV). Zhu et al., 
(Zhu et al., 2016) have demonstrated using paramagnetic resonance spectroscopy 
that under acidic condition and in the presence of oxalate and dioxygen the 
oxidation state of manganese is Mn(III). So, the new vision of the catalytic 
mechanism of OxDC is based on a removal of electrons from the substrate by the 
cofactor Mn(III). This process then generates a radical intermediate in which the 
barrier to the C-C bond cleavage is significantly decreases, followed by the other 
reaction steps cited above (Figure 8). 
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Figure 8. Proposed catalytic mechanism for the oxalate decarboxylase reaction. 
 
Crystallography studies have identified in cupin domain I the presence of a channel 
for oxalate diffusion that can exist in an ‘‘open’’ or ‘‘closed’’ form as a result of 
the conformational rearrangement of a lid structure formed by residues 161–165. 
The open-closed conformational change seems to be important to (i) allow access 
of the substrate to the active site, (ii) move Glu162 in an optimal position to 
protonate the formyl radical intermediate, and (iii) release the products (Just et al., 
2007). 
In addition to the decarboxylase reaction, wild type OxDC is also able to catalyse 
the oxygen-dependent oxidation of oxalate to carbon dioxide in a reaction that is 
coupled with the formation of hydrogen peroxide (H2O2). However, the turnover 
number for the oxidase activity is 0.2% that of the decarboxylase activity (Tanner 
et al., 2001). It has been demonstrated that the substitution of the four amino acids 
in the OxDC lid from Ser161, Glu162, Asn163, Ser164 to Asp, Ser, Ser, Asn 
respectively (161-164 SENSàDSSN) (Burrel et al., 2007), gives rise to an OxDC 
variant named OxDC-DSSN, characterized by an undetectable decarboxylase 
activity and a 116-fold increased oxidase activity (Table 2) as compared with wild-
type OxDC. Burrel and co-workers solved the OxDC SENS161-4DSSN crystal 
structure and they did not find significant differences with respect to wild type 
OxDC (Burrel et al., 2007). Moreover, the mutant still had full occupancy of 
manganese ions. The only significant structural difference was the conformation of 
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the lid itself, which is intermediate between those of the open and closed forms of 
the wild-type enzyme. While the loss of decarboxylase activity was expected, 
considering the absence of Glu162 that acts as proton donor, further studies will be 
necessary in order to completely understand the structural reasons explaining the 
improved oxidase activity.  
 
Table 2. Kinetics parameters of wild type OxDC and OxDC-DSSN. 
 
 
 
 
 
 
 
 
 
 
                                a: expressed as formate production; 
                                b: expressed as hydrogen peroxide production; Data from Burrel M. R. et al., 2007; 
 n.d.: not determined. 
 
 
1.6.2 Use of OxDC in the treatment of hyperoxaluria 
 
As described above, the symptoms of the various forms of hyperoxalurias arise 
from oxalate accumulation and the consequent formation of CaOx stones. (Cochat 
and Groothoff, 2013; Canales et al., 2014; Hoppe et al., 2003). Thus, any approach 
able to decrease oxalate levels could in principle reduce CaOx supersaturation and 
remarkably counteract stone formation (Salido et al., 2006; Salido et al., 2012). On 
these bases, the possibility that OxDC could be a suitable candidate to carry out 
oxalate degradation in hyperoxaluric patients has come out (Hoppe et al., 2005). 
The idea is that the degradation of intestinal oxalate should reduce the absorption 
from exogenous sources and possibly promote the clearance of the endogenous pool 
(Grujic et al., 2009, Cowley et al., 2017, Langman et al., 2016). In agreement with 
Oxalate decarboxylase activity 
Enzyme Vmax 
(U mg-1) 
Km 
(mM) 
Wild-type 27.6 ± 1.8 8.1 ± 0.8 
OxDC-DSSN 0.04 n.d. 
Oxalate oxidase activity 
Wild-type 0.038 ± 0.03 0.27 ± 0.11 
OxDC-DSSN 4.4 ± 0.1 3.2 ± 0.2 
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this hypothesis, studies performed in mice demonstrated that an efficient enteric 
secretion was able to reduce renal oxalate burden (Hatch et al., 2011). On these 
bases, a crystalline cross-linked formulation of OxDC, called OxDC-CLEC, has 
been proposed as oral drug for the treatment of hyperoxaluria. It has been found to 
have a detectable residual activity at neutral pH, corresponding to about 2% that 
observed at its optimum pH of 4.2 (Grujic et al., 2009). The oral administration of 
OxDC-CLEC is able to significantly reduce both urinary (44%) and fecal oxalate 
(72%) in AGT knockout mice (AGT1KO), a model of PH1, as well as in mice 
challenged with ethylene glycol (EG), which represent a general model of 
hyperoxaluria because EG is readily absorbed throughout the intestine and 
metabolized in the liver to oxalate (Grujic et al., 2009; Salido et al., 2006). 
Interestingly, in 2016 Langman et al., have implemented the use of OxDC in 
humans by using ALLN-177A, a crystal form of the enzyme filled into capsules 
(1,500 units/capsule). In a double-blind, placebo controlled, phase-I study of 
ALLN-177 in healthy volunteers with diet-induced hyperoxaluria, they 
demonstrated that ALLN-177 significantly reduced urinary oxalate excretion by 
efficiently degrading dietary oxalate in the gastrointestinal tract thereby reducing 
its absorption. Thus, ALLN-177 has been proposed as a new approach for the 
treatment of secondary hyperoxalurias. Sasikumar and co-workers have designed 
another approach to reduce intestinal oxalate absorption by using a genetically 
engineered strain of L. plantarum that constitutively expresses and secretes OxDC 
from B. subtilis (Sasikumar et al., 2014). The in vivo oxalate degradation ability of 
this strain has been demonstrated in rats which, upon treatment, showed significant 
reduction of urinary oxalate, calcium, uric acid, creatinine and serum uric acid as 
compared with untreated controls. Moreover, no CaOx crystals where detected in 
the kidneys of treated animals.  
The approach based on the use of OxDC could be useful for the treatment of both 
primary and secondary hyperoxalurias. Very recently, the Allena Pharmaceuticals 
has completed the clinical trial concerning the ALLN-177A and it has developed 
the drug Reloxaliase (see https://clinicaltrials.gov; Government trial Identifiers: 
NCT03847090), an orally-administred recombinant oxalate-degrading enzyme 
formed by 142 mg of OxDC (equivalent to 3,750 units of enzyme activity). 
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Reloxaliase is being evaluated in the ongoing pitoval Phase 3 URIROX-1 for 
patients with enteric and/or secondary hyperoxaluria. Moreover, for the first time, 
this drug has been proposed and it has been granted separate orphan drug 
designations by FDA fot the treatment of primary hyperoxaluria and for the 
treatment of pediatric hyperoxaluria. However, the administration of oxalate-
degrading enzyme would be unsuitable in case of systemic oxalosis, where an 
increased plasmatic oxalate concentration is observed in PH1 patients, leading to a 
very serious and often fatal condition (Osswald et al., 1979). In this regard, it should 
be pointed out that oxalate-degrading enzymes cannot be directly administered in 
humans, because they would elicit a remarkable immune response. 
 
1.7 Drug delivery by red blood cells 
 
Erythrocytes or red blood cells (RBCs) drug delivery is one of the most promising 
therapeutic approaches for the administration of selected drugs in order to improve 
their therapeutic action and reducing their toxicity. RBCs constitute the largest 
population of blood cells and are the main carriers of oxygen to the body’s cells and 
tissues. RBCs constitute potential biocompatible vectors for different bioactive 
substances, including drugs and proteins (Barker et al., 2001). Loading procedures 
exploit the capacity of RBCs placed in hypotonic solutions to form pores large 
enough to enable the entrance of particles with a molecular weight up to 50000 Da 
(Gutierrez et al., 2004).   
Initial attempts for the encapsulation of drugs in RBCs were undertaken in the 
1970s, subsequently extended to the encapsulation of enzymes and peptides with 
therapeutic activity (Gutierrez et al., 2004, Magnani et al., 2002, Zocchi et al., 
1989, Noel-Hocquet et al., 1992). The use of RBCs as carriers has several 
advantages. RBCs are highly biocompatible, easy to handle, provide an 
encapsulated drug with a systemic clearance similar to their normal life (120 ± 20 
days) (Magnani et al., 1988, Guyton et al., 1996) and protect the encapsulated drug 
from premature degradation by the immune system.  
From a therapeutic perspective, RBCs may be employed for three main purposes: 
(i) to act as a reservoir for the drug, providing the sustained release of the same into 
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the body, (ii) to selectively direct the drugs to the reticulo-endothelial system (RES) 
of the liver, spleen and bone marrow, and (iii) to act as bioreactors in which an 
enzyme is encapsulated and is able to metabolize its physiological substrate without 
leaving the cell. The applications of this carrier system are currently very numerous, 
even though more clinical studies are required to confirm its pharmacokinetic and 
pharmacodynamic advantages (Biagiotti et al., 2011). Beside the numerous 
advantages, the use of RBCs as carrier also presents some disadvantages (Jain et 
al., 1997; Moss et al., 2000; Valbonesi et al., 2001; Sugai et al., 2001; Lvarez et 
al., 2005). The major problem encountered in the use of biodegradable materials or 
natural cells as drug carriers is that they are removed in vivo by the RES. This 
seriously limits their half-life and in some cases may also pose toxicological 
problems. Moreover, due to their biological origin, RBCs may present greater 
variability and are more liable to contamination as compared with other carrier 
systems. Finally, encapsulated drugs may alter the physiology of the erythrocyte 
and/or induce a rapid leakage from the RBC.  
Notwithstanding the possible shortcomings, RBC loading techniques were recently 
used in the treatment of phenylketonuria. Phenylketonuria (PKU) is an autosomal 
recessive genetic disease caused by the deficit of phenylalanine hydroxylase, the 
enzyme that converts L-phenylalanine to L-tyrosine (Scriver et al., 2001). PKU 
patients accumulate high levels of phenylalanine in the bloodstream, with 
pathologic consequences mainly consisting in mental retardation. One of the 
available therapies for PKU is the administration of phenylalanine ammonia lyase 
(PAL), a cyanobacteria-derived enzyme able to degrade phenylalanine into 
metabolically harmless products (trans-cinnamic acid and trace amounts of 
ammonia) (Hoskins et al., 1982). PAL is usually administered in complex with 
polyethylene glycol, to increase stability and limit immunogenicity (see 
www.ClinicalTrials.gov; Government trial Identifiers: phase I NCT00634660; 
phase II NCT00925054, NCT01560286, NCT00924703 and NCT01212744; phase 
III NCT01819727 and NCT01889862). Recently, Rossi L. and co-workers (Rossi 
et al., 2014) developed erythrocytes loaded with recombinant PAL from Anabaena 
variabilis, as bioreactors able to overcome the accumulation of phenylalanine in the 
bloodstream in a murine model of PKU. They demonstrated that PAL-loaded RBCs 
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are able to decrease blood Phe levels and do not induce the generation of antibodies 
as the recombinant enzyme. These results have opened new perspectives for the use 
of RBCs as carrier in enzyme administration therapies for other disorders due to 
enzyme deficiencies.  
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Hyperoxaluria is a pathologic condition characterized by the deposition of calcium 
oxalate crystals at first in the urinary system and, in the most severe forms, in the 
whole body. Primary hyperoxalurias (PHs) are rare inborn errors of glyoxylate 
metabolism leading to an increased production of endogenous oxalate. Secondary 
hyperoxalurias (SHs) result from an increased intestinal absorption or an increased 
intake of exogenous oxalate. 
Among PHs, Primary Hyperoxaluria Type I (PH1) is a rare disease caused by 
mutations in the gene encoding alanine:glyoxylate aminotransferase (AGT), an 
enzyme that utilizes pyridoxal 5’-phosphate (PLP) as coenzyme to catalyse the 
transamination of L-alanine and glyoxylate to pyruvate and glycine. AGT 
deficiency allows glyoxylate accumulation and its oxidation to the metabolic end-
product oxalate. 
Hyperoxaluria is a difficult-to-treat disease. The therapeutic strategies currently 
available are either poorly effective or very invasive. Thus, many efforts have been 
dedicated in the last years to the development of innovative and non-invasive 
treatment strategies. In this regard, we focused our attention on the possible use of 
oxalate-degrading enzymes, and in particular on oxalate decarboxylase (OxDC) 
from B. subtilis. OxDC is a 264 kDa homohexamer belonging to the cupin-like 
family, that converts oxalate to formate and CO2. The mutation of the sequence of 
the loop (161-164) from Ser-Glu-Asn-Ser to Asp-Ser-Ser-Asn, abolishes the 
decarboxylase activity, but enhances a secondary oxalate oxidase activity of the 
enzyme, thus converting OxDC into OxDC-DSSN, which metabolizes oxalate to 
carbon dioxide and hydrogen peroxide. Both enzymes could be effective in 
preventing oxalate accumulation, but their biochemical properties under 
physiological conditions have not been investigated. Moreover, the therapeutic use 
of OxDC requires its activity at neutral pH, but the enzyme displays an optimal pH 
of activity around 4. Finally, the administration of non-human enzymes would elicit 
a remarkable immune response, we thought to the possibility of encapsulating the 
enzyme inside red blood cells (RBCs) to generate bioreactors able to metabolize 
plasmatic oxalate and reduce its urinary excretion.  
Based on these considerations, my research activity during the PhD program has 
been focused on: 
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(i) The biochemical characterization of OxDC and OxDC-DSSN at their 
optimum pH (4.2) and at the intracellular pH of RBCs (7.2);  
(ii) The analysis of the ability of both enzymes to metabolize oxalate in a 
cellular model of PH1; 
(iii) The setup of a protocol for OxDC loading in human and murine RBCs.  
(iv) The application of protein engineering techniques to select mutant forms 
of OxDC endowed with a higher activity or stability at physiological pH  
 
In parallel with my main PhD project, I have also focused my attention on the study 
of the molecular mechanisms underlying the tendency of AGT to aggregation and 
the effect of polymorphic and pathogenic mutations associated with PH1.  
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3 
MATERIALS AND METHODS 
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3.1 Materials  
 
Potassium oxalate, formate, formate dehydrogenase (FDH) from Candida boidinii, 
bovine plasma thrombin, glycolate, Bradford reagent, nicotinammide adenine 
dinucleotide oxidate form (NAD+), lysozyme, leupeptine, pepstatin, imidazole, 
isopropyl β-D-1 thiogalactopyranoside (IPTG), pyridoxal 5-phosphate (PLP), L-
alanine, sodium glyoxylate, rabbit muscle L-lactic dehydrogenase (LDH) and 
EDTA were purchased from SIGMA-Aldrich. 2,2’-azinobis-3- 
ethylbenzothiazoline-6-sulphonic acid (ABTS) and the EDTA free protease 
inhibitor cocktail were purchased from Roche. The rabbit anti-His (C-Term)-HRP 
antibody was purchased from Invitrogen, the Enhanced ChemiLuminescence® 
(ECL) reactive was purchased from Millipore. The XfectTM Protein Transfection 
kit was purchased from Clontech Laboratories. Zeocin, geneticin (G418), PBS 
(phosphate-buffered saline), modified Ham's F12 Glutamax medium and trypsin 
were purchased from Life TechnologiesTM. All other chemicals were of the highest 
purity available.  
 
3.2 Expression vectors and site-directed mutagenesis 
 
The cDNA of B. subtilis OxDC with a thrombine cleavage site and a 6-Histidine 
(6xHis) tag at the C-terminus cloned in a pET24a(+) vector (pET24a-OxDC) was 
purchased from GeneScript. This vector allows the expression of the recombinant 
protein in E. coli under the control of the lactose operon upon isopropyl β-D-1 
thiogalactopyranoside (IPTG) addition to the culture medium.  
The expression vector for OxDC-DSSN (pET24a-OxDC-DSSN) was obtained by 
introducing the S161D, E162S, N163S, and S164N mutations by site-directed 
mutagenesis on the pET24a-OxDC vector using the QuikChange II site-directed 
mutagenesis kit (Stratagene). The primers used were 5ʹ-CTG CTG GTT TTT GAC 
GAT GGC AGC TTC AGC GAG AAC AGC ACC TTT CAA CTG ACC GAC 
TGG CTG GC-3’and its complement. Underlined codons indicate mutated amino 
acids.  
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The expression vectors for OxDC E162H, E162K and E162Q (pET24a-OxDC-
E162H, pET24a-OxDC-E162K and pET24a-OxDC-E162Q) by site-directed 
mutagenesis on the pET24a-OxDC vector using the QuikChange II site-directed 
mutagenesis kit (Stratagene) in order to produce site-saturation mutagenesis of 
Glu162. The primers used were 5’-GAC GAT GGC AGC TTC AGC CAT AAC 
AGC ACC TTT CAA CTG-3’ for E162H, 5’-GAC GAT GGC AGC TTC AGC 
AAA AAC AGC ACC TTT CAA CTG-3’ for E162K and 5’-GAC GAT GGC AGC 
TTC AGC CAT AAC AGC ACC TTT CAA CTG-3’ for E162Q. Underlined 
codons indicate mutated amino acids. 
The primers used to produce the mixture of primers used in chapter 6.1 for the 
substitution of residues in the proximity of the active site were designed as shown 
below. The expression vectors for OxDC E60H, E60K, E60R, E99H, E99K, E99R, 
E198H, E198K and E198R (pET24a-OxDC-E60H, pET24a-OxDC-E60K and 
pET24a-OxDC-E60R, pET24a-OxDC-E99H, pET24a-OxDC-E99K, pET24a-
OxDC-E99R, pET24a-OxDC-E198H, pET24a-OxDC-E198K) were obtained 
using the primers 5’-C CCA CAA CCG TCT CAT AAG GGT GGC TAC GC -3’ 
for E60H, 5’- C CCA CAA CCG TCT AAA AAG GGT GGC TAC GC -3’ for 
E60K, C CCA CAA CCG TCT AGA AAG GGT GGC TAC GC -3’ for E60R,  5’-
CGT GAG CTG CAC TGG CAC AAA CAT GCG GAA TGG GC-3’ for E99H,  
5’-CGT GAG CTG CAC TGG CAC AAA AAA GCG GAA TGG GC-3’ for E99K, 
5’-CGT GAG CTG CAC TGG CAC AAA AGA GCG GAA TGG GC-3’ for E99R, 
5’-C AGC AAC CTG CCG GGC AAA CAT AAG TAC ATT TTT GAG AAC C-
3’ for E198H, 5’-C AGC AAC CTG CCG GGC AAA AAA AAG TAC ATT TTT 
GAG AAC C-3’ for E198K and 5’-C AGC AAC CTG CCG GGC AAA AGA AAG 
TAC ATT TTT GAG AAC C-3’ for E198R. Underlined codons indicate mutated 
amino acids. 
The pAGT-His construct and the expression vectors for AGT-Ma, AGT-Mi, and 
the P11L, I360M, F152I, G170R and I244T AGT-Mi mutants were already 
available (Cellini et al., 2010) 
All mutations were confirmed by DNA sequencing. 
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3.3 OxDC, OxDC DSSN and G2 clone expression and purification  
 
E. coli BL21 (DE3) Codon plus cells transformed with the constructs pET24a-
OxDC or pET24a-OxDC-DSSN were grown in Luria Broth (LB) in a total volume 
of 4.5 litres at 37 °C. Cells were grown with vigorous shaking to an OD of 0.3-0.4 
at 600 nm and then heat-shocked at 42°C for 20 minutes. 5 mM MnCl2 was added 
to the culture and protein expression was induced with 0.5 mM IPTG for 16 hours 
at 30°C. Cells were then harvested by centrifugation and resuspended in lysis buffer 
(50 mM Tris-HCl pH 8 containing 0.5 M NaCl, 20 mM imidazole and EDTA-free 
protease inhibitor cocktail). Lysozyme was added to a final concentration of 0.2 
μg/mL and the culture was incubated for 20 minutes at room temperature. After a 
freeze-thaw cycle, leupetin (0.5 μg/mL) and pepstatin (0.7 μg/mL) were added and 
cell debris were removed by centrifugation (16000 x g for 30 minutes at 4°C). The 
lysate was loaded on a HiTrapTM TALON® crude column equilibrated with 50 mM 
Tris-HCl pH 8 containing 500 mM NaCl and 20 mM imidazole. A linear gradient 
(0-100% in 100 ml) was then applied with the same buffer containing 500 mM 
imidazole. OxDC-His and OxDC DSSN-His eluted approximately at 200 mM 
imidazole. Upon forced dialysis by Amicon ultra 10 devices (10000 kDa) and wash 
with storage buffer (50 mM Tris-HCl pH 8, 500 mM NaCl and 5 mM DTT), OxDC-
His and OxDC-DSSN-His can be conserved at -80°C where they are stable for 
several months. The purification efficiency was evaluated by SDS-PAGE: 1 μg of 
OxDC or OxDC-DSSN were loaded per lane on 10% polyacrilmide gel along with 
the Precision plus protein KaleidoscopeTM (Bio-Rad) molecular mass markers. To 
remove the histidine tag, OxDC-His and OxDC-DSSN-His were incubated with 4U 
of thrombin per mg of protein in 50 mM Tris-HCl pH 8, 500 mM NaCl, 5 mM DTT 
buffer at 4°C for 16 hours with gentle mixing. The cleaved protein was then 
separated from thrombin excess by a Sephacryl S-300 column equilibrated and run 
in 50 mM Tris-HCl pH 8 containing 500 mM NaCl. Eluted proteins were 
concentrated to about 8 mg/ml using Amicon Ultra concentrators and stored at -
80°C for at least 6 months. 
Incorporation of Mg2+, Cd2+ and Co2+ in OxDC active site was carried out during 
the production of protein. The bivalent ions were added at 5 mM concentration in 
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the colture before the induction with IPTG. The proteins containing the new ions 
were purified exploit the His-tag tail as for wild-type enzyme. Trought SDS-PAGE 
and WB analysis with anti-His antibodies we have monitored the incorporation of 
ions. The FDH assay (see chapter 3.7 in Materials and Methods) was carried out in 
order to evaluate the shift of optimum pH. 
 
3.4 AGT expression and purification 
 
AGT-Ma, AGT-Mi and mutant enzymes in their histidine-tagged form were 
expressed in E. coli and purified by the procedure already described (Cellini et al., 
2008). The apo form of each variant was prepared as previously described (Cellini 
et al., 2007). AGT can be stored at 20 °C without loss of activity for more than 6 
months. Protein concentration was determined by using the apparent molar 
absorption coefficient of 95400 M-1 cm-1 at 280 nm (Pace et al., 1995). The PLP 
content was determined by releasing the coenzyme in 0.1 M NaOH and by using 
the apparent molar absorption coefficient of 6600 M-1 cm-1 at 388 nm.  
 
3.5 OxDC and OxDC-DSSN decarboxylase activity assay 
 
The oxalate decarboxylase activity was determined by a coupled 
spectrophotometric assay that determines formate production by using FDH, which 
catalyses the oxidation of formate to carbon dioxide, with the concomitant 
reduction of a molecule of NAD+ to NADH. Since NADH, differently from NAD+, 
absorbs the light at 340 nm, the conversion of formate to CO2 causes the increase 
of the absorbance at 340 nm. The assay was carried out according to Magro et al. 
with minor modifications. The reaction was started by adding 1 μg of OxDC to a 
solution containing 63 mM potassium oxalate in 50 mM sodium acetate (NaAc). 
The reaction mixture was incubated at 25°C for 4 minutes and stopped by the 
addition of 10 μl of 1 N NaOH. For the coupled reaction the protocol of Magro et 
al., (Magro et al., 1988) was modified in order to optimize the assay for a 96-well 
plate reader. Brefly, 15 μl of the assay mixture were transferred in a 96-well plate 
and incubated over night with NAD+ (9 mM) and FDH (0.7 U) in 50 mM potassium 
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phosphate pH 7.8 to a final volume of 200 μl. The absorbance at 340 nm was 
measured after an incubation at 25 °C, by using a micro plate reader (Tecan 
Infinity). A formate calibration curve (0-400 μM) and a blank were freshly 
performed for each experiment. The decarboxylase specific activity (U/mg) of was 
calculated by the equation:  
!" = $%&'()*	 µM ∗ 200	µl15µl ∗ (0.11µl)min∗':	%$	*;<='* 			(2) 
 
where one unit was defined as the amount of enzyme that produces 1 μmol of 
formate/min. The kinetic parameters of the decarboxylase reaction were determined 
by varying oxalate concentration from 0.1 mM to 250 mM. Data of initial velocity 
(v) as a function of substrate concentration were fitted to the Michaelis-Menten 
equation: >Et = ABCD	["]GH + ["]		(3) 
 
where Et is the total enzyme concentration, S is substrate concentration, kcat is the 
turnover number, and Km is the Michaelis-Menten constant. 
 
3.6 OxDC and OxDC-DSSN oxidase activity assay 
 
Oxalate oxidase activity was determined spectrophotometrically using a continuous 
assay in which the production of hydrogen peroxide was coupled to the oxidation 
of ABTS by horseradish peroxidase (HRP) (Requena et al., 1999). The oxidation 
of ABTS gives rise to a green and soluble end-product with an absorbance 
maximum at 420 nm (ε = 3.6 × 104 M–1 cm–1). The reaction was started by adding 
50 mM potassium oxalate to a mixture containing 5 μg of enzyme, 1 U of HRP, and 
0.5 mM ABTS in 50 mM NaAc pH 4.2, to a final volume of 250 μl. The absorbance 
at 420 nm was continuously recorded by using a Jasco V-550 spectrophotometer 
with a temperature controlled cell-holder set at 25 °C. Blank sample, containing all 
components except the enzyme, were taken immediately prior to the measurements 
of samples containing protein.  
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The oxidase specific activity (U/mg) was calculated by the equation:  !" = Δ!LM	 'N;OP ∗ 	10Q R	'N;OP ∗ 0.00025	LTUVWX	(MOP	cmOP) ∗ ':	%$	*;<='* 			(4) 
One unit of enzyme was defined as the amount consuming or producing 1 µmol of 
substrate or product, respectively/min.  
The kinetic parameters of the oxidase reaction were determined by measuring the 
oxidase activity at various oxalate concentrations from 10 mM to 200 mM. Data of 
initial velocity (v) as a function of substrate concentration were fitted to the 
Michaelis-Menten equation (3). 
 
3.7 Measurement of oxalate decarboxylase and oxidase activity as a function 
of pH 
 
For pH-dependence studies, decarboxylase and oxidase activity assays were carried 
out in the buffers reported in the Table 3 by using the previously reported 
procedures. In order to perform all the assays at physiological ionic strength (154 
mM), we kept the NaCl concentration (140 mM) constant and we modulated buffer 
concentration according to its ionic strength contribution. 
 
Table 3. Buffers used during pH-dependence experiments. 
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3.8 Determination of the AGT transaminase activity 
 
The catalytic activity for the overall transamination of the alanine/glyoxylate pair 
was determined by a coupled spectrophotometric assay, as previously described 
(Cellini et al., 2007). The kinetic parameters of the P11L and I340M variants (0.1 
μM) were determined in the presence of saturating PLP concentrations by varying 
the substrate concentration at a fixed saturating co-substrate concentration. At 
different times, the reactions were stopped by adding TCA 10% (v/v). The residual 
activity of pathogenic and polymorphic variants as well as of AGT-Ma and AGT-
Mi after aggregation was measured in presence of saturating PLP, substrate and co-
substrate concentration at 0.1 µM enzyme concentration, at 25°C in KP 0.1 M pH 
7.4. After 10 minutes, the reactions were stopped by adding TCA 10% (v/v). The 
produced pyruvate was measured by a spectrophotometric assay using the coupled 
lactate dehydrogenase system (Cellini et al., 2008). 
 
3.9 Spectroscopic techniques 
 
OxDC, OxDC-DSSN and AGT absorption measurements were made by a Jasco V-
550 spectrophotometer at a scan speed of 50 nm/min and a bandwidth of 2 nm, by 
using 1 cm path length cuvettes. 
Spectra of blanks, i.e. of samples containing all components except the enzyme, 
were taken immediately before the measurements of samples containing protein.  
Intrinsic fluorescence emission spectra of OxDC and OxDC-DSSN were registered 
by a Jasco FP750 spectro-fluorometer equipped with a thermostatically controlled 
cell holder by using 1 cm path length quartz cuvettes. Protein spectra were 
registered from 300 to 550 nm (excitation at 280 nm) by using 5 nm bandwidths at 
a protein concentration of 0.5 mg/ml both at pH 7.2 and pH 4.2. Blank spectra were 
taken immediately prior to the measurements of samples containing protein.  
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Circular dichroism (CD) spectra were recorded on a Jasco J-710 spectropolarimeter 
equipped with a thermostatically controlled cell compartment at 25 °C at a OxDC 
and OxDC-DSSN concentration of 0.5 mg/ml or AGT concentration from was 1 to 
15 µM. Routinely, three spectra were recorded at a scan speed of 50 nm/min-1 with 
a bandwidth of 2 nm and averaged automatically, except where indicated. The 
cuvette path length was 1 cm.  
All spectroscopic measurements were carried out both in 52 mM sodium acetate 
pH 4.2 containing 140 mM sodium chloride and in 16 mM Tris-HCl pH 7.2 
containing 140 mM sodium chloride for OxDC and OxDC-DSSN whereas for AGT 
the buffer was 0.1 M KP pH 7.4.  
Thermal stability studies on purified OxDC, OxDC-DSSN and AGT were 
performed by CD-monitored thermal unfolding. The CD signal at 222 nm of OxDC 
and OxDC-DSSN (0.5 mg/ml) at physiological ionic strength was registered at pH 
4.2 and 7.2 at increasing temperature from 25 to 90 °C at a heating rate of 1.5 
°C/min. For AGT the concentration was 10 µM in 0.1 M KP pH 7.4. The melting 
temperatures (Tm) was obtained by fitting the data to either a two- or a three-state 
unfolding model using the Origin Pro7 software according to the method of Pace 
(Pace et al., 1989).  
 
3.10 Aggregation studies  
 
Dynamic Light Scattering (DLS) measurements were performed on a Zetasizer 
Nano S device (Malvern Instruments) equipped with a Peltier temperature 
controller by using disposable 12.5 × 45-mm cells with stopper. The aggregation 
kinetics of OxDC and OxDC-DSSN (0.5 mg/ml) were measured at 25 °C in buffers 
at physiological ionic strength at pH 4.2 or 7.2. Furthermore, the aggregation 
propensity of OxDC (0.1 mg/ml) in RBC loading buffer (10 mM NaHCO3, 10 mM 
NaH2PO4, 20 mM glucose, pH 7.4, with additional 2 mM ATP, 1.5 mM GSH) was 
analyzed. The aggregation kinetics of AGT-Ma, AGT-Mi, P11L and I340M was 
determined at an enzyme concentration of 10 µM in KP at different pHs and ionic 
strengths, at 37°C. All the buffers were filtered immediately before measurement 
in order to eliminate any impurities. 
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The aggregation kinetics of OxDC and OxDC-DSSN (0.5 mg/ml) were also 
monitored by turbidimetry experiments measuring the change in the absorbance at 
600 nm as a function of time at 25 °C. In the case of OxDOx, the process was 
monitored in the absence or presence of sodium glyoxylate (50 mM). All the 
aggregation studies were performed both in 16 mM Tris-HCl pH 7.2 and 140 mM 
sodium chloride and in 52 mM sodium acetate pH 4.2and 140 mM NaCl buffers.  
 
3.11 Aggregation kinetics: the minimalistic/”Ockham’s razor” Finke-Watzky 
two-step model 
 
The minimalistic/ ‘‘Ockham’s razor’’ Finke–Watzky (F–W) two-step model was 
routinely used to analyze protein aggregation kinetic data. This model is 
characterized by nucleation and autocatalytic growth, yielding quantitative 
(average) rate constants for nucleation (k1) and growth (k2), respectively. It is 
described by the following scheme: 
   ! [\ ] 
  ! + ] [^ 2] 
 
where A is the monomeric protein and B is the polymeric protein i.e. in oligomers 
that are past the nucleation stages. The F–W two-step model is an oversimplified, 
phenomenological kinetic model that consists of hundreds, if not thousands, of 
steps in most cases. The resultant k1 and k2 values are therefore averages of the true 
underlying steps. The classic F–W two-step mechanism assumes an initial zero 
concentration of aggregate, and so the rate equation becomes 
 −` U`D = 	AP ! + Aa[!][]]                      (5) 
 
By mass balance, [!]b = [!]D + []]D                                   (6) 
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Combining these equations (5) and (6), integrating and solving for [A]t gives: 
 [!]D = c\c^d	[U]ePd	 c\c^[f]e ghi [\d	[^[U]e D         (7) 
 
where [A]0 represents the initial monomeric concentrations and [A]t represents the 
loss of [A] with time. Assuming that the initial [Bt] is null, all data were fit using 
the integrated analytical equation (8) corresponding to the F-W two-step model: []]D = [!]b − c\c^d	[U]ePd	 c\c^[f]e ghi [\d	[^[U]e D   (8) 
where [B]t represents the concentration of aggregated protein at time t, [A]0 
represents the initial protein concentrations and k1 and k2 are the rate constants of 
nucleation and growth, respectively. 
 
The pKspec was calculated by the following equation: 
 j = 	 klO	kmPd	Pbnopnqrstl + ju        (9)  
 
where YH and YL are the limit values of the rate constants k1 and k2 at high and low 
pH, respectively. 
 
 
3.12 Size-exclusion chromatography 
 
SEC analyses were performed on a Superdex 200 10/300 GL column at room 
temperature by an Akta FPLC system (GE Healthcare) using the Unicorn 5.01 (GE 
Healthcare) software. The injection volume was 100 μL with detection at 280 nm, 
and the flow rate was 0.5 ml/min. The experiments were carried out at concentration 
of 0.5 mg/ml OxDC and OxDC-DSSN and ionic strength 154 mM in Tris-HCl pH 
7.2. 
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3.13 Cross-linking  
 
Cross-linking was performed with glutaraldehyde, a reagent used in a variety of 
applications. OxDC or OXDC-DSSN (monomer concentration 9 μM) were cross-
linked in 52 mM sodium acetate pH 4.2 and 140 mM NaCl buffer with 1% 
glutaraldehyde and quenched by 1 M Tris–HCl pH 8 after 2 min. 7 µg of sample 
were analysed by SDS-PAGE (7.5%). 
 
3.14 Cell culture  
 
The PH1 cellular model used for the experiments reported in this thesis is made up 
of chinese hamster ovary (CHO) cells. In particular, we used two subtypes of this 
cell line: 1) CHO-GO cells, which stably expresses glycolate oxidase (GO) due to 
the transfection with the pCDNA3.1(-)Zeo-GO vector, and 2) CHO-GO-AGT cells, 
which stably express GO and wild type AGT thanks to the presence of the 
pcDNA3.1(+)Neo-AGT vector. Both cell clones were provided by Prof. C.J. 
Danpure of the University College London.  
The medium used for the growth of CHO-GO cells was the Ham's F12 Glutamax 
medium, supplemented with fetal bovine serum (10%, v/v), penicillin (100 
units/ml) and streptomycin (100 μg/ml). 400 μg/ml zeocin was used as selective 
agent for CHO-GO cells. 400 μg/ml zeocin and 1 mg/ml geneticin were used as 
selective agents for CHO-GO-AGT cells. Cells were cultured at 37°C under O2/CO2 
(19:1) atmosphere. Cell passaging was performed by treating with trypsin (0.01%) 
for 5 minutes at 37 °C. Cell counting was carried out by the CountesseTM apparatus.  
 
3.15 Xfect protein transfection 
 
The Xfect Protein Transfection Kit uses a cell-penetrating peptide, developed by 
Clontech, able to bind and transport active proteins directly into a wide variety of 
mammalian cell types.   
For protein transfection experiments, CHO-GO cells were seeded in two 6 cm 
dishes at 0.3x106 cells/dish and grown until they reached 80% confluence. 
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Transfection was then performed by following manufacturer instructions. Briefly, 
15 µl of the 1X Xfect Protein Transfection Reagent Stock were diluted in 85 µl of 
deionized H2O; in a second tube, 5 µg of OxDC-His or OxDC-DSSN-His were 
mixed with the Xfect Protein buffer in a total volume of 100 µl. Then the content 
of the second tube was added to the first one, gently vortexed and incubated at room 
temperature for 30 minutes. During the incubation step, the medium in the dish was 
aspirated and cells were washed once with PBS. Upon PBS removal, 1 ml of 
modified Ham's F12 Glutamax medium and 200 µl of the transfection 
reagent/protein mixture were added. Cells were then incubated at 37°C and 5% CO2 
for different times (1 hour, 6 hours and 24 hours). After incubation cell were 
harvested and assayed for the presence of the protein or used for subsequent 
experiments.   
 
3.16 Western Blot 
 
20 µg of cell lysate or 0.1 µg of purified proteins were loaded per lane on a 10% or 
7.5% polyacrylamide gel along with the Precision plus protein KaleidoscopeTM 
(Bio-Rad) molecular mass markers. The gel was run for 60 minutes at 150 V and 
25 mA. Proteins were then transferred from the gel to a nitrocellulose membrane 
using the iBlot device (Invitrogen) and blocked by incubation with 5% BSA (w/v) 
at 37° C for one hour. For OxDC-His and OxDC-DSSN-His detection, the 
membrane was incubated with an anti-His (C-Term)-HRP conjugate antibody 
(Invitrogen, dilution 1:5000) for 1hour at RT and the excess of antibody was then 
eliminated by washing the membrane for three times in TBST (50 mM Tris–HCl 
pH 7.5, 150 mM NaCl, 0.1% Tween 20) for 10 minutes. Band detection was 
performed by using the enhanced chemiluminescence (ECL) substrate reagent 
containing luminol and a peroxide solution. The horseradish peroxidase (HRP), 
conjugated with the primary antibody, in the presence of peroxide produces a 
radical of its substrate, the luminol. This makes a further reactions leading to the 
formation of a dianion in an excited electronically state that emits light when returns 
to the ground state. The light emission signal was acquired by the system Chemidoc 
(Biorad).  
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3.17 Viability assay 
 
In order to assess the capacity of OxDC and OxDC-DSSN to detoxify oxalate in a 
cellular model of PH1, cells were seeded into a 96-well plate at 8.000 cells/well 
density. After 6 hours, OxDC or OxDC-DSSN transfection was performed as 
previously described and cells were incubated over night at 37°C and 5% CO2. The 
subsequent day, glyoxylate production was induced by adding Hepes buffered 
glycolate pH 7.0 to a final concentration of 0.8 mM. Un-transfected CHO-GO and 
CHO-GO-AGT were used as negative and positive control, respectively. Cell 
viability was evaluated after further 24 hours incubation using a crystal violet assay. 
Briefly, cells were rinsed with PBS and incubated at room temperature for 5 min 
with a fixing and staining solution containing 4% formaldehyde and 0.5% Crystal 
Violet. Cells were then extensively washed with distilled water to remove the 
excess of dye and lysed with 1% SDS in PBS to allow crystal violet solubilization. 
The absorbance at 595 nm, which is proportional to the number of viable cells, was 
measured with a TECAN plate reader. Six replicates were performed for each assay 
condition. 
 
3.18 RBC loading 
 
Human blood was obtained from the Blood Transfusion Center of the Hospital “S. 
Maria della Misericordia”, Urbino (PU) Italy or “Policlinico G.B. Rossi”, Verona, 
Italy; blood was provided by healthly adult volunteers who signed an informed 
consent form before donation and samples were collected anonymously in 
heparinized tubes.  
The use of human blood in the present study was approved by the research ethics 
committee of the University of Urbino (PU), Italy. OxDC was loaded into human 
RBCs by means of hypotonic dialysis, isotonic resealing and “reannealing”, 
essentially according to Magnani et al., 1988 with these modifications: RBCs were 
pre-dyalyzed in human RBCs buffer containing 10 mM NaHCO3, 10 mM NaH2PO4, 
20 mM glucose, pH 7.4, 2 mM ATP without GSH. After that RBCs were loaded 
with 36.4 IU of OxDC with RBCs at 70% hematocrit (Ht). 1 ml final volume was 
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dialyzed at + 4 °C in a cellulose tube (14 kDa cut-off) vs 50 ml of hypotonic solution 
(using the same buffer used for pre-dyalisis) 60 mOsm measured by Osmometer 
Fiske Associates Model 210, Norwood, MA, USA. After dialysis the cells were 
approx. 90 mOsm. The GSH at 1.5 mM concentration was added during the 
resealing passage of loading. Unloaded (UL) RBCs (i.e. cells submitted to the same 
procedure without the addition of the enzyme) were used as controls. The amount 
of entrapped OxDC was quantified essentially by a kinetic assay as previously 
described (Magro et al., 1988). Hematological parameters were measured by an 
automatic Coulter AcT 5 Diff Hematology Analyzer (Beckmann, Miami, FL). 
Percent RBC recovery was calculated from the number of RBCs submitted to the 
dialysis step and those recovered at the end of the loading procedure. 
 
3.19 Combinatorial Incorporation of Synthetic Oligonucleotides During Gene 
Shuffling (ISOR) 
 
The ISOR procedure was carried out based on the protocol developed by Rockah-
Shmuel et al. 2014. The main steps are the following: 
A) DNA preparation:  
(i) Amplification of OxDC gene using external primers in order to obtain 
about 25 µg of starting DNA. 
(ii) Treatment of the DNA with 20 units of DpnI per 50 µl of PCR for 1 h 
at 37°C in order to remove the residual template plasmid DNA. 
(iii) Purification and concentration of the DNA to a final concentration ≥ 200 
ng/µl. 
B) Gene fragmentation 
(i) Preparation of a reaction solution mixing 20-25 µg DNA with 100 mM 
Tris-HCl pH 7.5 and 10 mM MnCl2 to generate a 200 µl solution 
(ii) Preparation of the stop solution in a 200 µl final volume containing 25 
µl of 500 mM EDTA pH 8.2 equilibrated to 85°C in a heating block. 
(iii) Addition of DNase I to a final concentration of 0.015 u/µg of DNA and 
incubation of all samples at 37°C 
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(iv) Stop of the reaction by removal of 50 µl aliquots every 0.5 min and mix 
with an aliquot of the EDTA stop solution kept at 85 °C. Incubation of 
each aliquot at 85°C for 15 min. 
(v) Loading of the samples on a 2% (w/v) agarose-TAE gel with a DNA 
ladder comprised of 50 or 100 bp bands. Each time point sample is run 
in a different well to see the DNA fragments which change in size range 
as a function of the DNase I digestion time. Excision of the part of gel 
which contains the fragments comprised from 50 to 250 bp and DNA 
extraction. 
(vi) Gel extraction and purification of the desired fragments using the 
GeneElute Plasmid miniprepr Kit (Sigma) 
C) Incorporation of Oligonucleotides by assembly PCR 
(i) Reassembly of the gene by PCR. 100 ng of the purified fragments were 
mixed in the presence of 1-10 nM of library nucleotides, dNTP mix and 
high-fidelity polimerase in 50 µl final volume. The program used for 
PCR analysis was: one denaturation step at 95°C for 2 min; 40 cycles 
composed by a denaturation step at 94°C (30 s); 13 hybridization steps 
separated by 2°C each, from 65°C to 41°C for 1.5 min each; an 
elongation step of 1 min/kb gene at 72°C and then a final 7 min 
elongation step at 72°C to allow full elongation of all assembled genes. 
(ii) Amplification of the assembly product by “nested” PCR using the 
external primer 5’ TCCCCATCGGTGATGTCGGCAT 3’ and its 
complement in 50 µl final volume. Purification of the product of nested 
PCR. 
(iii) Treatment of the purified DNA using EcoRI and NdeI and ligation to 
pET21a to create the plasmid library. Transformation in DH5a E.coli 
cells. 
 
3.20 Screening of libraries  
 
To screen the library of the OxDC each single colony was picked up and added in 
a well of a sterile, clear, flat-bottomed lidded microtiter plate that contained 200 μl 
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of LB medium supplemented with kanamicine. The 96-well plates were incubated 
at 37 °C overnight at 200 rpm agitation. 100 μl of each well were transferred in a 
new well with fresh 1 ml of LB and induced and lysed as described for the wild 
type enzyme (see chapter 3.3 of Materials and Methods). To normalize the data of 
specific activity, protein concentration was determined by Bradford assay. Specific 
activity was determined at either pH 5.5 and 6.5 by FDH assay reported in chapter 
3.8 of this section and compared with the wild-type clone.  
Each clone resulted positive was screened in triplicate in order to confirm the 
increase of activity respect to wild-type. 
 
3.21 Molecular modelling and hydrophobic patches analysis 
 
Molecular modelling analyses were performed by the software Molecular 
Operating Environment (MOE 2015.1001 and MOE 2016.08) developed by the 
Chemical Computing Group, starting from the available crystal structure of human 
AGT in complex with the tetratricopeptide repeat domain of human Pex5p (PDB: 
3R9A) (Fodor et al., 2001). We performed in silico mutagenesis on both AGT 
monomers by using the Protein builder and rotamer explorer tool of MOE 2016.08, 
which explores the conformational space of amino acid side chains within a protein 
in the presence of surrounding amino acids, ligands and solvent. The potential side 
chain conformations were visually inspected and calculated as the sum of the side 
chain strain energy, the van der Waals interaction energy with the environment, and 
the hydrogen bond interaction energy. The rotamer with the lowest values of energy 
were selected and analyzed. Upon modification of residues by the tool Protein 
builder, we performed an energetic minimization of the microenvironment around 
the mutation site. The side chain atoms of the mutated residue and of neighboring 
residues (within a distance of 6 Å) were minimized. All other atoms and all 
backbone atoms were kept fixed. 
The analysis of the hydrophobic patches was performed by using the Patch analyzer 
tool of MOE 2015.1001 by setting the size and energy cut-offs of the hydrophobic 
patches at 100 Å2 and 0.25 kcal/mol, respectively. Salt-bridge interactions and 
hydrophobic interactions between residues were scored as positive if they fell 
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within 5 Å of each other in the structure. Hydrogen bonds were scored as present if 
the distance between the electronegative atoms (N & O) within O-H-N or O-H-O 
groups were ≈2.9 Å apart.  
 
3.22 Calculation of electrostatic potential maps and predicted pKa 
 
The electrostatic potential maps of AGT-Ma and mutants were calculated by the 
Adaptive Poisson-Boltzmann Solver 1.3 tool (Baker et al., 2001), using the non-
linear Poisson-Boltzmann equation and modulating the ionic strength (setting ions 
charge, molar concentration and radius in Å of potassium phosphate buffer, to 
mimic the experimental conditions) and temperature.  The graphic interface of the 
tool is integrated in UCSF Chimera version 1.1 (Petterson et al., 2004). The 
calculations were performed on the Opal web server (Ren et al., 2010). Structure 
preparation and analysis of the protonation state of residues at different pH values 
were carried out by the PDB2PQR (Dolinsky et al., 2004) (using CHARMM as 
forcefield) and PROPKA 3.0 (Olsson et al., 2010) tools respectively, on the Opal 
web service. 2Dmaps were calculated by the tool Patch Analyzer of MOE 2016.08. 
For 2D views, structure preparation and protonation were performed directly by 
MOE 2016.08. Calculation of the predicted pKa of AGT residues was obtained by 
the tool Residue pKa of MOE 2016.08.   
 
 
3.23 Determination of the consensus sequence 
 
The Bacillus subtilis OxDC sequence was retrieved from GeneScript. We 
performed both a multiple sequence alignment (MSA) and a structure based 
sequence alignment (STRAP). The MSA was obtained by aligning the OxDC 
sequence with 200 homologous sequences with a % of identity between 35 and 95 
(using the protein database Uniref90) using the MUSCLE and T-COFFEE 
programs and analyzed with the ConSurf Server (http://consurf.tau.ac.il/2016/). 
The STRAP alignment was obtained using EXPRESSO and PROMALS 3D 
softwares based on the MSA obtained previously to generate the conservation score 
 60 
from structural information. The two outputs were combined using the Jalview 
program.  
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Background Information 
 
The administration of oxalate-degrading enzymes is considered one of the new 
avenues in the therapeutic approaches directed to the treatment of hyperoxaluria. 
The rationale behind this strategy is to metabolize the excess of oxalate 
accumulating at intestinal and/or plasma level, so that to reduce the amount excreted 
by urine. Among oxalate-degrading enzymes, the best characterized is oxalate 
decarboxylase (OxDC) from B. subtilis. OxDC catalyses the conversion of oxalate 
into formate and carbon dioxide (Begley et al., 2004; Svedružić et al., 2005). As 
for other oxalate degrading-enzymes the optimum of catalytic activity is shown at 
acidic pH (Tanner et al., 2000). The initial use of OxDC was focused on industrial 
and biotechnology applications, i.e. to prevent the formation of oxalate salt deposits 
in industrial processes such as papermaking (Sjöde et al., 2008; Cassland et al., 
2010) and beer production (Hiatt et al., 1987). Very recently, the potential of OxDC 
as medical application has been advanced. In fact, at diagnostic level, OxDC is used 
for the determination of oxalic acid concentration in food and complex biological 
samples such as blood and urine (Parkinson et al., 1985; Allen et al., 1989; 
Langman et al., 1998). Finally, the enzyme has been proposed as a possible 
biological drug in the treatment of hyperoxaluria. The use of OxDC in 
hyperoxaluric patients is currently focused on its oral administration and the ability 
to degrade oxalate in the intestine, and thus is suitable for secondary hyperoxalurias 
(Grujic et al., 2009). However, its use in primary hyperoxalurias has been also 
proposed, based on the possibility that consuming exogenous oxalate could 
promote the intestinal excretion of the endogenous pool (Hatch et al., 2006).  
Although the medical applications of OxDC exploit its ability to degrade oxalate 
under physiological conditions (Grujic et al., 2009; Cowley et al., 2010; Langman 
et al., 2016), a deep characterization of OxDC at neutral pH is lacking. Moreover, 
it has been reported that a mutant form of OxDC, called OxDC-DSSN and 
characterized by the four mutations S161D-E162S-N163S-S164N, is endowed with 
an oxalate oxidase activity while the decarboxylase activity is completely 
abolished. If OxDC-DSSN displays any activity at neutral pH is unknown. 
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To fill these gaps, in the first part of my PhD, we performed a deep characterization 
of OxDC wild-type and OxDC DSSN at neutral pH in order to verify if the two 
proteins maintain their stability and functionality.  
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RESULTS AND DISCUSSION 
 
4.1 Kinetic and structural properties of OxDC and OxDC-DSSN 
 
Using a two-step purification process (see Materials and Methods) we obtained 
untagged OxDC and OxDC-DSSN with a yield of 20 mg of pure protein per litre 
of bacterial culture (Figure 9).  
 
Figure 9. Purification of OxDC and OxDC-DSSN. (A) SDS-PAGE analysis of the 
various steps of OxDC-His and OxDC-DSSN-His purification. Lanes are coded as follows: 
1 molecular weight markers; 2 and 5 soluble fraction of the cell lysate; 3 and 6 flow-
through; 4 and 7 eluted OxDC-His and OxDC-DSSN-His, respectively. (B) 
Chromatographic profile of cleaved OxDC and OxDC-DSSN on a Sephacryl S-200 
column. The buffer was 50 mM Tris- HCl pH 8 containing 500 mM NaCl. (C) SDS-PAGE 
analysis of OxDC-His (lane1), OxDC (lane 2), OxDC-DSSN-His (lane 3) and OxDC-
DSSN (lane 4).  
 
 
At pH 4.2 in the presence of o-phenilenediamine (o-PDA), purified OxDC 
displayed an oxalate decarboxylase specific activity of 83 U/mg in line with 
previous reports (Tanner et al., 2001), thus suggesting that our purification strategy 
did not alter protein functionality and/or Mn2+ binding. Although o-PDA is a known 
OxDC activator (Emiliani et al., 1964), it is highly toxic and not suitable for 
biomedical applications (o-PDA CAS No. 95-54-5). Thus, we also determined 
OxDC activity at pH 4.2 in the absence of o-PDA in the assay mixture and we found 
that it displayed a significantly lower decarboxylase specific activity (28 U/mg) and 
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a Km for oxalate of 8 mM. As expected, the mutation of lid residues Ser161Asp, 
Glu162Ser, Asn163Ser, Ser164Asn in OxDC-DSSN completely abolished the 
decarboxylase activity, but gave rise to an enzyme displaying a detectable oxalate 
oxidase activity, in the same range of that already reported (Table 3) (Burrel et al., 
2007). 
We measured the decarboxylase and oxidase activity of OxDC and OxDC-DSSN, 
respectively, in the pH range 4.2-7.2. The upper limit of the analysis was chosen 
taking into account the functional test of the two enzymes in a cellular model of 
PH1 (see below) because it represents the pH value of the cell cytosol (Martinez-
Zaguilan et al., 1991). Appropriate controls were performed to validate each assay 
in the whole pH range, as well as to evaluate possible buffer effects. The buffer 
used are reported in detail in the Material and Methods section. We found that the 
activity of both enzymes significantly decreases at increasing pH (Figure 10A and 
10B), in line with previous reports (Reinhardt et al., 2003; Twahir et al., 2016). 
However, at pH 7.2 the two proteins retain 7% and 15% activity, respectively. It 
should be observed that the OxDC activity values do not significantly change in the 
range of pH 6-7.2. Considering that (i) assay calibration curves obtained at various 
pH values allow to exclude any influence of the coupled assay, and that (ii) in the 
pH range 6-7.2 the coefficient of variation inter-assay is below 15%, we cannot 
exclude that the observed differences could have a biological meaning possibly 
related to the biochemical mechanism of action of OxDC in the neutral range. 
Unfortunately, we could not increase the signal by increasing protein concentration 
or incubation time, because of the strong tendency of the protein to aggregation (see 
below). 
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Figure 10. Effect of pH on OxDC and OxDC-DSSN activity. A and B: histograms 
representing specific activity values of OxDC decarboxylase activity (A) and OxDC-DSSN 
oxidase activity (B) at different pHs. Protein concentration was 10 µg/ml. Data are 
representative of two independent experiments. Bar graphs represent the mean ± SEM. The 
buffers used and the technical details are reported in Materials and Methods. C and D: 
Michaelis-Menten curves of the kinetic parameters of OxDC at pH 4.2 (C) and 7.2 (D). 
Enzyme activity was measured as described in Materials and Methods. The amount of 
enzyme used in each assay mixture was 1 µg and 5 µg for experiments carried out at pH 
4.2 and 7.2, respectively. Each point represents the average of five replicates. One unit of 
OxDC is defined as 1 nmol of fomate formed per hour at 25°C. 
 
Nevertheless, we determined the kinetic parameters for the decarboxylation or 
oxidation reaction at pH 7.2. As shown in Figure 10 C and 10D  and  Table 4, OxDC 
shows a 13-fold reduction in the Vmax of the decarboxylation reaction, without 
significant alterations of the Km value for oxalate as compared to pH 4.2. On the 
other hand, OxDC-DSSN shows a 7-fold reduced Vmax for the oxidation reaction 
and a remarkably increased Km for oxalate as compared to pH 4.2.  
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Table 4. Kinetic parameters for the oxalate decarboxylase and oxidase activity of 
OxDC and OxDC-DSSN, respectively, at pH 4.2 and 7.2.  
 
  
 
These findings are in contrast with previous results (Reinhardt et al., 2003; Twahir 
et al., 2016; Tanner et al., 2000; Svedružić et al., 2007) which reported that OxDC 
activity is undetectable at neutral pH due to the fact that only monoprotonated 
oxalate is a productive substrate. However, an in-depth analysis of the OxDC 
kinetic properties at neutral pH has never been performed. Moreover, a recent report 
suggests that the pH-dependence of catalytic activity could be also governed by 
small changes in the active site of the protein that could stabilize the +3 oxidation 
state of the Mn ion (Twahir et al., 2016). In addition, Moomaw et al. reported that 
the change in oxalate oxidase activity as a function of pH is influenced by the 
protonation state of an active site Asp residue at position 241. All these 
considerations could possibly explain why the measured activity of OxDC and 
OxDC-DSSN at pH 7.2 does not correspond to that expected based on the amount 
of monoprotonated oxalate present in solution. In this regard, recent experimental 
evidences indicate that (i) OxDC activity is detectable in E. coli cells grown at pH 
7 (Lee et al., 2014) and (ii) an oral formulation of recombinant OxDC in its 
crystalline form shows 2% residual activity under physiological conditions and is 
able to metabolize intestinal oxalate in a mouse model of hyperoxaluria (Grujic et 
al., 2009), and (iii) OxDC is able to degrade the oxalate contained in spinach leaves 
under conditions mimicking the intestinal environment (Mufarrij et al., 2013). 
Finally, Albert et al., demonstrated that HEK293 cells transfected with a construct 
encoding OxDC (HEK293-OxDC) exhibit a higher viability as compared to 
untransfected HEK293 cells when exposed to oxalate stress. Moreover, HEK293-
	
																Decarboxylase	activity	 																	Oxidase	activity	
	 Vmax 
(U mg-1) 
Km 
(mM) 
k cat 
(s-1) 
 Vmax 
(U mg-1) 
Km 
(mM) 
k cat 
(s-1) 
OxDC	
pH	4.2	
28.0 ± 2.0 8.0 ± 0.8 20.0 ± 1.8 OxDC-
DSSN  
pH 4.2 
2.0 ± 0.1 0.30 ± 0.07 1.4 ± 0.2 
OxDC	
pH	7.2	
2.0 ± 0.4 2.0 ± 1.0 1.45 ± 0.15 OxDC-
DSSN  
pH 7.2 
0.35 ± 0.04 70.0 ± 20.0 0.85 ± 0.07 
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OxDC, but not HEK293 cells, are able to metabolize oxalate added to the medium, 
thus suggesting that OxDC is biologically active in the cytoplasm (Albert et al., 
2017). These results provide indirect evidence for the presence of residual 
enzymatic activity at neutral pH. 
To investigate if any structural change could occur in OxDC and OxDC-DSSN at 
physiological pH, we compared their spectroscopic properties at acidic and neutral 
pH maintaining a physiological ionic strength. At pH 4.2, the two proteins exhibited 
almost identical far-UV (data not shown) and near-UV CD spectra (Figure 11A). 
No significant alterations were noticed at pH 7.2. Upon excitation at 280 nm (Figure 
11B), both OxDC and OxDC-DSSN exhibited an intrinsic fluorescence emission 
spectrum with maximum at 329 nm, indicating a folded structure. However, the 
emission intensity of OxDC-DSSN was about 1.5-fold lower than that of OxDC, 
probably as a consequence of the fact that the mutation of lid residues could affect 
the orientation of some buried aromatic residues. 
 
Figure 11. Spectroscopic features of OxDC and OxDC-DSSN (A) Near-UV CD spectra 
and (B) intrinsic fluorescence emission spectra (λexc 280 nm) of OxDC at pH 4.2 (⎯) or 
pH 7.2 (• •) and of OxDC-DSSN at pH 4.2 (---) or pH 7.2 (− • −). Spectra were registered 
at 0.5 mg/ml enzyme concentration in 52 mM sodium acetate pH 4.2, 140 mM NaCl or 16 
mM Tris-HCl pH 7.2, 140 mM NaCl. 
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DLS analyses revealed that at both acidic and neutral pH OxDC and OxDC-DSSN 
display a peak with a diameter of 12 ± 1 nm, corresponding to an hexamer, and a 
second peak at approximately 200 nm, corresponding to aggregates (Figure 12A). 
Considering that the scattering intensity is proportional to the sixth power of a 
particle diameter (Plakoutsi et al., 2004) the hexamer represents by far the most 
abundant species in solution, thus suggesting that neither the mutation of residues 
of the lid, nor the change of the pH, affects the quaternary structure of the enzyme. 
We confirmed these data by SEC experiments, which were only performed at pH 
7.2 due to the technical limitations of the Superdex 200 10/300 GL column. In line 
with previous data, OxDC eluted from the column with a main peak at 10.8 ml, 
corresponding to the elution volume of a hexamer, along with a shoulder at 9.3 ml, 
corresponding to an aggregated form (Svedružić et al., 2007). We found a similar 
elution profile for OxDC-DSSN, although the area of the hexamer is 1.5-fold lower 
with respect to that of OxDC (Figure 12B). Since no other peaks were present in 
the elution profile of OxDC-DSSN, and considering that the two proteins have a 
similar molar extinction coefficient at 280 nm, the reduced peak area is probably a 
consequence of the formation of high-molecular weight aggregates that do not enter 
the column bed (see below), as previously reported for other proteins (Cellini et al., 
2006; Bertoldi et al., 2005). Since the technical features of the SEC column did not 
allow to carry out runs at pH 4.2, we could only perform cross-linking experiments 
that confirmed the presence of the hexamer for both proteins, along with tetrameric, 
dimeric and monomeric species deriving from the limited efficiency of the cross-
linking reactions (data not shown).  
Overall, spectroscopic data indicate that OxDC and OxDC-DSSN do not undergo 
gross changes of their secondary, tertiary and quaternary structure at neutral pH 
with respect to acidic pH. Although this is not surprising considering that the 
available crystal structures have been solved at neutral or alkaline pH (Anand et al., 
2002; Just et al., 2004), the results confirm that the reduced catalytic activity 
observed at increasing pH does not depend on a significant conformational change 
of the protein. Rather, it is merely a catalytic problem related to the protonation 
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state of the substrate and/or of active site groups as discussed above (Svedružić et 
al., 2005; Reinhardt et al., 2003; Moomaw et al., 2013).  
 
 
Figure 12. Analysis of the OxDC and OxDC-DSSN quaternary structure. (A) DLS 
analysis of the size distribution of 0.5 mg/ml OxDC and OxDC-DSSN at pH 4.2  (52 mM 
sodium acetate pH 4.2, 140 mM NaCl) and pH 7.2 (16 mM Tris-HCl pH 7.2, 140 mM 
NaCl). (B) Elution profile of OxDC (…) and OxDC-DSSN (.-.-) at 0.5 mg/ml concentration 
loaded on a Superdex 200 10/300 GL column (GE Healthcare) equilibrated and run in 16 
mM Tris-HCl pH 7.2 containing 140 mM NaCl. Detection was set at 280 nm.  
 
 
4.2 Stability and aggregation propensity of OxDC and OxDC-DSSN at pH 4.2 
and 7.2 
 
Considering the possible use of OxDC and/or OxDC-DSSN as biological drugs, we 
compared their thermal stability at pH 4.2 and 7.2 and physiological ionic strength 
by monitoring the decrease of dichroic signal at 222 nm indicative of the secondary 
structure content. At pH 4.2 OxDC maintains its secondary structure up to 60°C 
and shows a transition with mid-point at 69°C to a conformation characterized by 
a higher signal, followed by a second transition with mid-point at 85 °C leading to 
the almost complete loss of secondary structure content (Figure 13A). This 
behaviour, which is frequently observed during acid protein unfolding (Uversky et 
al., 2001) suggests a two-step process consisting in the first formation of a partly-
folded intermediate characterized by a pre-molten globule like structure and its 
subsequent conversion to the fully-unfolded state. On the other hand, OxDC-DSSN 
undergoes a progressive loss of secondary structure from 36°C to 64°C, with a mid-
point around 47°C, followed by an apparent recovery of secondary structure with 
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mid-point at 85°C and by the subsequent almost complete loss of the dichroic signal 
(Figure 13A). At pH 7.2, both OxDC and OxDC-DSSN show a classical two-state 
unfolding process with mid-point transitions at 38°C and 36°C, respectively.  
Thus, although OxDC and OxDC-DSSN do not seem to undergo major structural 
changes at neutral pH, they are less resistant to thermal stress with respect to acidic 
pH. This finding is not easy to explain at structural level, but it can be speculated 
that the protonation state of key protein residues, whose identity is presently 
unknown, could be crucial for the maintenance of the native structure although it 
does not affect the overall conformation of the protein. In addition, it is worth 
nothing that OxDC-DSSN displays a lower resistance with respect to OxDC, thus 
suggesting that one or more of the mutations altering the reaction specificity could 
also induce some local conformational change that could promote unfolding.  
Similar conclusions were also drawn by looking to the aggregation propensity of 
OxDC and OxDC-DSSN at pH 4.2 and 7.2, physiological ionic strength. 
Turbidimetry experiments (Figure 13B) did not reveal aggregation of both enzymes 
up to 60 min at pH 4.2, as well as for OxDC at pH 7.2. Accordingly, we did not 
notice the formation of significant amounts of aggregates in DLS analyses, as 
shown by the presence of the signal corresponding to the dimer throughout the 
analysis. On the other hand, for OxDC-DSSN at pH 7.2 we detected a time-
dependent increase in the absorbance at 600 nm, indicative of an ongoing 
aggregation process. By fitting the signal changes at 600 nm vs time we estimated 
a t1/2 of aggregation equal to 28.4 ± 0.3 min. Under the same experimental 
conditions, a rapid increase in DLS count rate occurred after a 6 min lag phase, 
followed by a decrease of the signal probably due to the precipitation of insoluble 
high molecular weight aggregates (Figure 13D). Accordingly, the signal of the 
OxDC-DSSN hexamer disappeared after 9 min and high molecular weight 
aggregates (200-1200 nm) appeared (Figure 13C). Finally, the increase of the count 
rate in DLS is paralleled by a progressive decrease of the CD signal at 222 nm, thus 
suggesting that aggregation is associated with an unfolding process (Figure 13E). 
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Figure 13. Thermal stability and aggregation propensity of OxDC and OxDC-DSSN 
at pH 4.2 and 7.2. (A) Change in the CD signal at 222 nm at increasing temperature from 
25° to 90°C (heating rate 1.5°C/min). (B) Absorbance changes at 600 nm as a function of 
time, (C) time-dependent change of species (measured as nm) of OxDC-DSSN at pH 7.2, 
the hexamer and aggregates are represented by cyan and black dots, respectively (D) 
change in the total count rate (measured as kilo counts per second) and (E) CD signal at 
222 nm as a function of time. All measurements were performed at 0.5 mg/ml enzyme 
concentration, in 16 mM Tris-HCl pH 7.2, 140 mM NaCl or 52 mM sodium acetate pH 
4.2, 140 mM NaCl, at 25°C. The colour code is the following: red, OxDC pH 4.2; blue, 
OxDC pH 7.2; black, OxDC-DSSN pH 4.2; green, OxDC-DSSN pH 7.2. 
 
 
Overall these results agree with thermal stability studies and confirm an enhanced 
propensity of OxDC-DSSN to unfold and aggregate at neutral pH with respect to 
OxDC. Crystallographic analyses did not reveal major structural differences 
between the two proteins (Burrel et al., 2007). However, in OxDC-DSSN the lid 
remains in an intermediate form between the open and close position, as shown in 
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Figure 14, thus causing the exposure of residues located in the channel connecting 
the protein surface with the active site (Burrel et al., 2007).  
 
 
 
Figure 14. Superimposition of OxDC and OxDC-DSSN active sites. The OxDC 
strucuture (PDB code 1J58) is depicted in magenta whereas that of the OxDC-DSSN 
mutant (PDB code 1UW8) is coloured cyan. The main chain backbone of the lid regions 
(residues 161-164) are shown as sticks. Mn2+ ion is represented as red sphere. The figure 
was generated using PyMOL. 
 
Based on these considerations, we hypothesized that the use of a substrate analogue, 
such as sodium glyoxylate (NaGlyox), could induce at least a partial closure of the 
active site channel and consequently prevent aggregation. Thus, in order to better 
understand the mechanism leading to OxDC-DSSN aggregation, we monitored the 
change in turbidity at pH 7.2 and physiological ionic strength upon addition of 
OxDC-DSSN to the buffer in the absence or presence of 50 mM NaGlyox (Figure 
15). We found that NaGlyox prevents aggregation and, if added to the mixture 
during aggregation, it is able to stop the process, as shown by the progressive 
stabilization of the 600 nm absorbance signal to a value lower than that observed in 
the absence of ligand. The latter effect cannot be ascribed to dilution, since the 
addition of NaGlyox led to a less than 20% change in the overall volume of the 
mixture. Thus, we can conclude that the ligand at the active site is able to partly 
rescue for the conformational changes induced by amino acid substitutions in 
OxDC-DSSN. It should be mentioned that the addition of NaGlyox is not suitable 
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for the biotechnological application of the enzyme, since it would affect the 
enzymatic activity. Nevertheless, these findings confirm the hypothesis that OxDC-
DSSN aggregation comes from the increased flexibility of the lid and could be 
instrumental for a possible future engineering of the protein. 
 
 
 
Figure 15. Time-dependent aggregation of OxDC-DSSN at pH 7.2 in absence or 
presence of sodium glyoxylate. Absorbance changes at 600 nm as a function of time of 
OxDC-DSSN at 0.5 mg/ml concentration in the absence (light blue) or presence (orange) 
of 50 mM sodium glyoxylate. The black line shows the absorbance changes occurring upon 
addition of sodium glyoxylate during aggregation (at the time indicated by the arrow). The 
buffer was 16 mM Tris-HCl pH 7.2, 140 mM NaCl, at 25°C. 
 
 
 
4.3 Oxalate detoxification ability of OxDC and OxDC-DSSN in a PH1 cellular 
model 
 
 
Considering the potential use of an oxalate-degrading enzyme for the treatment of 
hyperoxaluria, we wonder if at neutral pH the residual decarboxylase or oxidase 
activity of OxDC and OxDC-DSSN, respectively, endowed the two proteins with 
the ability of metabolizing oxalate in a cellular environment. To test this hypothesis, 
we employed a PH1 cellular model made up of CHO-GO cells (Benham et al., 
2006). CHO-GO cells overexpress glycolate oxidase (GO), an enzyme that converts 
glycolate into glyoxylate inside peroxisomes (Benham et al., 2006). Thus, in the 
presence of glycolate in the culture medium, cells generate glyoxylate inside 
peroxisomes. Glyoxylate accumulates and is oxidized to oxalate in the cytosol, thus 
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promoting cell death (Figure 16). It follows that the highest is the ability to detoxify 
glyoxylate or oxalate, the highest is the cell survival in the presence of glycolate. 
In other words, cell viability in the presence of glycolate represents an indirect 
measure of the amount of oxalate or glyoxylate detoxification ability of the cells 
(Fargue et al., 2018). 
 
 
 
Figure 16. Schematic representation of oxalate detoxification in CHO-GO cells. (A) 
Negative control: CHO-GO cells (B) Positive control: CHO-GO-AGT cells; (C) CHO-GO 
cells after OxDC or OxDC-DSSN transfection. GO: glycolate oxidase; LDH: lactate 
dehydrogenase AGT: alanine:glyoxylate aminotransferase; CO2: carbon dioxide; H2O2: 
hydrogen peroxide. 
 
We transfected recombinant purified OxDC or OxDC-DSSN in CHO-GO cells by 
using the Xfect Protein Transfection Reagent. A preliminary experiment using 
OxDC-His (Figure 17A), revealed that the protein is detectable inside the cell 
starting from 1 hour incubation and reaches its maximum level after 24 hours. Thus, 
we evaluated the oxalate degradation ability of CHO-GO-OxDC cells and CHO-
GO-OxDC-DSSN cells 24 h after protein transfection. As negative control we used 
non-transfected CHO-GO cells, which lack any detoxifying enzyme. As positive 
control, we used CHO-GO cells stably expressing AGT. AGT catalyzes the 
conversion of glyoxylate into glycine. Thus, it prevents oxalate formation and 
preserves cell viability (Figure 16).  
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As shown in Figure 17B, as compared with that of CHO-GO, the culture medium 
of CHO-GO-OxDC and CHO-GO-OxDC-DSSN cells treated with glycolate 
contains a lower amount of oxalate, in line with that present in the medium of CHO-
GO-AGT cells. This would imply that transfected cells are able to detoxify the 
oxalate produced inside the cell. In particular, the residual activity at pH 7.2 of 
OxDC and OxDC-DSSN encapsulated inside CHO-GO cells (equal to 7 and 15%, 
respectively, as compared with the value at pH 4.2) was sufficient to reduce the 
concentration of oxalate released in the culture medium from 678 to 298 and 291 
µM, respectively, over 24-h incubation at 37°C. To confirm these data, we 
determined the viability upon treatment with glycolate of each cell clone. 
Although we verified that the protein transfection process did not affect cell 
viability per se, in order to exclude any possible bias for each cell clone we obtained 
the viability value from the ratio between each glycolate-treated sample and its 
untreated control. As expected, after treatment with glycolate CHO-GO cells and 
CHO-GO-AGT cells showed a viability of 18% and 80%, respectively (Figure 17C) 
(Oppici et al., 2015). Interestingly, CHO-GO-OxDC cells and CHO-GO-OxDC-
DSSN cells showed a significant increase in viability of about 1.8 and 1.6-fold 
respectively, as compared with CHO-GO cells. It should be noted that cells viability 
does not seem to correlate with the reduction in oxalate content. However, it should 
be taken into account that there is no direct proportionality between the 
glyoxylate/oxalate content and cell viability. Thus, a threshold value probably 
exists below which viability is preserved, thus explaining our data.  
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Figure 17. Indirect glycolate toxicity assay. (A) CHO-GO cells were transfected with 
OxDC-His. At different times cells were harvested and lysed. 20 µg of lysate were 
subjected to SDS-PAGE and immunoblotted with anti-His (C-term) antibody (1:5000). 
GAPDH (indicated as CNT in the figure) was used as loading control. Lanes are coded as 
follows: CNT: non transfected CHO-GO cells; 1 h: cells harvested 1 hour after transfection; 
6 h: cells harvested 6 hour after transfection; 24 h: cells harvested 24 hour after transfection. 
(B) Amount of oxalate present in the culture medium of the indicated cell clones upon 24 
h treatment with 0.8 mM glycolate, expressed as percentage with respect to the negative 
control. Three replicates have been measured for each sample. Bars represent mean ± SEM. 
* P < 0.05. (C) Histogram representative of cell viability after 24 hours of treatment with 
0.8 mM glycolate expressed as percentage with respect to untreated control. Six replicates 
have been measured for each sample. Bars represent mean ± SEM; ** P < 0.01, **** P< 
0.0001.  
 
 
Overall, these data indicate that both OxDC and OxDC-DSSN, although with a 
different efficiency, are able to degrade oxalate formed in the cell cytosol, thus 
suggesting that they could be able to metabolize oxalate under conditions similar to 
those present in biological fluids. These results are in line with those recently 
obtained in HEK293 cells (Albert et al., 2017). 
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CONCLUSIONS 
 
The use of OxDC for industrial and therapeutic applications has greatly attracted 
the interest of the scientific community in the last years. One of the main concerns 
on the use of this enzyme is related to its extremely low optimum pH of activity. In 
an attempt to explore the potential of OxDC as biological drug, we deeply 
investigated its biochemical properties at neutral pH. Our main findings indicate 
that OxDC wild-type and a mutated form showing oxalate oxidase activity (OxDC-
DSSN) (i) retain detectable decarboxylase or oxidase activity, respectively, at 
neutral pH, (ii) do not undergo gross structural changes at neutral with respect to 
acidic pH, except for a reduced thermal stability associated in OxDC-DSSN to an 
enhanced propensity to unfolding and aggregation, and (iii) although with a 
different efficiency, are able to degrade oxalate in a cellular model of PH1. 
These data provide the proof of principle for the possible use of oxalate degrading 
enzymes as biological drugs for the treatment of primary and enteric 
hyperoxalurias, pathologic conditions caused by the accumulation of oxalate from 
endogenous or exogenous sources, respectively. 
In this regard, it should be mentioned that the direct administration of a bacterial 
enzyme is not feasible, because it would generate a remarkable immune response 
on the patients. Thus, as already done in other enzymatic deficits (Rossi et al., 2014, 
Sarkissian et al., 2008) appropriate delivery systems can be designed to profit from 
the metabolizing activity while being protected from the interaction with the 
immune system. In addition, the very low activity and stability of the enzyme at 
neutral pH implies that protein engineering techniques should be applied to select 
mutant forms endowed with improved fitness under physiological conditions. 
These two problems will be addressed in chapters 5 and 6 of this thesis. 
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Background Information 
 
 
The main hallmark of PH is the increased production of endogenous oxalate. In the 
most severe forms, the disease progresses to systemic oxalosis, a status where 
oxalate accumulates in plasma and deposits in various organs including heart, 
leading to serious and often fatal consequences (Beck et al., 2013; Hoppe 2012). 
Under the latter condition, any treatment able to degrade plasmatic oxalate could 
represent an effective cure. One of the possibilities to reduce the plasmatic oxalate 
burden is the administration of an oxalate-metabolizing enzyme such as OxDC. 
However, the direct intravenous administration of OxDC is not feasible, because it 
would elicit a significant immune response. In this regard, an intriguing approach 
to prevent immunogenicity of exogenous proteins is their encapsulation inside red 
blood cells (RBCs). Indeed, RBCs can encapsulate large particles thanks to the 
unique ability of their membranes to be opened, thus allowing the entrance of 
enzymes that remain entrapped within the cells after resealing (Gutierrez-Millan et 
al., 2004; Magnani et al., 1988; Magnani et al., 2002). Upon reinfusion, the enzyme 
is functional and able to perform his activity assuming that the substrate can enter 
RBCs. Since RBCs are able to internalize oxalate through the SLC4A1 ion channel 
(or band 3) transporter (Jennings and Adame, 1996), the possibility to apply this 
strategy to PH is attractive. In addition, the use of RBCs provides several 
advantages over alternative carriers, owing to their biocompatibility, the induction 
of little or no antigenic response, their long life-span in circulation, and their large 
internal capacity (Biagiotti et al., 2011). A similar approach has been recently 
applied to phenylketonuria (PKU). PKU patients accumulate high levels of 
phenylalanine in the bloodstream, with pathologic consequences mainly consisting 
in mental retardation. One of the available therapies for PKU is the administration 
of phenylalanine ammonia lyase (PAL), a cyanobacteria-derived enzyme able to 
degrade phenylalanine to ammonia and trans-cinnamic acid (Hoskins et al., 1982). 
It has been reported that RBCs loaded with recombinant PAL from Anabaena 
variabilis are able to avoid hyperphenylalaninemia in a murine model of PKU. 
Moreover, the therapy does not produce adverse immune reactions (Rossi et al., 
2014). 
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Based on these considerations, we thought that encapsulating OxDC inside RBCs 
and using them as bioreactors could allow to degrade plasmatic oxalate in the most 
severe forms of PH. The elimination of plasmatic oxalate would also reduce the 
amount of urinary oxalate and avoid the accumulation of insoluble calcium oxalate 
salt at kidney level, thus preventing stone formation. In order to use OxDC inserted 
in RBCs as a therapeutic bioreactor in PH, we setup loading conditions using the 
wild-type enzyme and human erythrocytes. This part of my PhD project was carried 
out in collaboration with the group of Prof. Magnani at the University of Urbino. 
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RESULTS AND DISCUSSION 
 
5.1 Stabilities studies of OxDC in human RBCs loading buffer 
 
The studies described in chapter 4 indicate that under conditions mimicking the 
RBCs cytoplasm OxDC maintains its functional and structural properties. 
However, since it is well-known in the literature that OxDC is sensible to changes 
in ionic strength (Tanner et al., 2001), as preliminary step we tested the behaviour 
of the enzyme under the experimental conditions used for the human RBC loading 
procedure. In particular, we investigated the aggregation propensity of the protein 
in loading buffer at 0.1 mg/ml protein concentration and 4°C for 90 minutes, which 
is the time necessary for encapsulation. DLS analyses revealed that the total count 
rate in complete buffer was very high and the signal of the hexamer was detectable 
for only few minutes (data not shown). This result suggests that one or more 
components of the buffer could promote OxDC aggregation. Therefore, we 
performed the same analysis by excluding one component at a time, while 
preserving the basal buffer components. As shown in Figure 18 we found that GSH 
is responsible for OxDC aggregation. In fact, in the presence of complete human 
RBCs buffer, containing 3 mM GSH, the total count rate increases rapidly, thus 
indicating an aggregation process. In contrast, upon the elimination of GSH from 
the buffer no increase in count rate is observed up to 90 min. In agreement with 
these data, OxDC rapidly aggregates in the same buffer used for the studies at 
physiological ionic strength (see Figure 18) upon addition of 3 mM GSH.  
An explanation of the effect of GSH at molecular level is not straightforward. 
Nevertheless, we noticed from the OxDC sequence that a Cys residue is present at 
the C-terminus (Cys383). Although Cys383 is not visible in the crystal structure we 
can speculate that, being the third to last residues, it should be exposed to the 
solvent. To understand if Cys383 was responsible for the aggregation of OxDC in 
the presence of GSH, we treated the protein with dinitrothiocyanobenzene (DNTB), 
which promotes the alkylation of cysteines with an exposed sulfhydryl group. We 
first confirmed that only one cysteine per monomer is titrated (data not shown), as 
expected. We then monitored the aggregation propensity of OxDC-DNTB, i.e. of 
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OxDC upon alkylation with DTNB. DLS analyses revealed that OxDC-DNTB is 
stable in complete human RBCs loading buffer up to 90 min (Fig 18B). This result 
agrees with the hypothesis that OxDC aggregation induced by GSH could involve 
Cys383. It can be speculated that GSH could directly bind Cys383 and cause a 
conformational change of the protein that makes it more susceptible to self-
association.  
 
 
Figure 18. DLS analysis of OxDC aggregation. (A) Time dependence of total count rate 
(measured as kilocounts per second) of 0.1 mg/ml OxDC in complete human RBCs buffer 
(10 mM NaHCO3, 10 mM NaH2PO4, 20 mM glucose, pH7.4, 2 mM ATP) in the presence 
(red), or absence (blue) of 3 mM GSH. (B) Time dependence of total count rate (measured 
as kilocounts per second) of OxDC alkylated with DNTB in human RBCs buffer (10 mM 
NaHCO3, 10 mM NaH2PO4, 20 mM glucose, pH7.4, 2 mM ATP and 1.5 mM GSH) at 4°C. 
The experiment was carried out in presence of 0.1 mg/ml enzyme and 0.1 mM DNTB. 
 
The finding that GSH promotes OxDC aggregation opened a big problem in view 
of RBCs loading, because GSH is very important to maintain erythrocytes integrity 
and its absence during the loading protocol could compromise the success and/or 
the efficiency of the procedure. For this reason, we decided to monitor OxDC 
aggregation in the presence of different concentrations of GSH, to look for a limit 
value to preserve OxDC stability. As shown in Figure 19, when GSH is reduced 
below 2 mM concentration, OxDC aggregation is prevented, as demonstrated by 
the low values of count rate and by the persistence of the signal of the hexamer up 
to 90 min. Based on these data, we decided to slightly modify the loading buffer 
using 1.5 mM GSH to prevent aggregation while possibly avoiding RBCs 
alterations. 
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Figure 19. Aggregation of OxDC in human RBCs loading buffer in presence of 
different concentration of GSH. Time dependence of total count rate (measured as 
kilocounts per second) of 0.1 mg/ml OxDC in human RBCs loading buffer (10 mM 
NaHCO3, 10 mM NaH2PO4, 20 mM glucose, pH7.4, 2 mM ATP) in the presence of GSH 
at 3 mM (red), 2 mM (black), 1.5 mM (orange), 1 mM (black), or 0.5 mM (blue), at 4°C. 
 
As final control, we performed a standard decarboxylase assay at pH 4.2 after 
incubation of OxDC for different times (10, 30, 60 and 90 minutes) in the chosen 
formulation of the human RBCs loading buffer, i.e. 10 mM NaHCO3, 10 mM 
NaH2PO4, 20 mM glucose, pH7.4, 2 mM ATP, 1.5 mM GSH. Results reported in 
Figure 20 reveal that after an initial decrease of about 15%, the catalytic activity 
remains stable up-to 90 minutes suggesting an almost unaltered functionality of 
OxDC. 
 
 
Figure 20. Specific activity of OxDC after incubation in RBCs loading buffer. 
Time-dependent loss of activity of OxDC measured by the FDH-coupled assay at pH 
4.2 after incubation of OxDC in RBCs loading buffer (10 mM NaHCO3, 10 mM 
NaH2PO4, 20 mM glucose, pH7.4, 2 mM ATP, 1.5 mM GSH) at 4°C. 
 
0 20 40 60 80 100
0
1000
2000
3000
4000
5000
Time (min)
M
ea
n 
co
un
t r
at
e 
pe
r s
ec
on
d 
(k
cp
s)
0 10 30 60 90
0
20000
40000
60000
Time (min)
Sp
ec
ifi
c 
A
ct
iv
ity
(n
m
ol
/m
in
/m
g)
 85 
5.2 OxDC loading in human RBCs 
 
 
We used a loading procedure setup by the group of Prof. Magnani (Magnani et al., 
1988), that involves the following three steps:  
1) hypotonic dialysis: upon exposure to a hypotonic solution a swelling of the 
erythrocyte membrane is observed, accompanied by an increased membrane 
permeability and by the formation of pores; 
2) isotonic resealing: erythrocytes are incubated in a isotonic solution in the 
presence of the particle to be encapsulated, and the reduced osmotic pressure 
favours encapsulation; 
3) “resealing”: erythrocytes are exposed to a hyperosmotic solution, which 
promotes the closure of the pores and the consequent encapsulation of the target 
particle. 
 
We introduced minor modifications to the protocol due to the interference of GSH 
with OxDC aggregation. First, before the hypotonic dialysis step we decided to pre-
dialyze RBCs to eliminate endogenous GSH. RBCs pre-dialysed were then dialysed 
in hypotonic solution in the presence of 36.4 IU of OxDC at 70% haematocrit. Then, 
since RBCs should not stay for long time in the absence of GSH, we added 1.5 mM 
GSH during the hyperosmotic resealing step.  
The percentage of recovery was 79% calculated from the number of RBCs 
submitted to the dialysis step and those recovered at the end of the loading 
procedure. We then estimated the yield of OxDC internalization by performing an 
OxDC activity assay on the hemolysate of loaded RBCs. Based on the specific 
activity value of the enzyme, we could estimate that the yield of entrapment of 
OxDC was 26%. This value is in line with those previously observed by Rossi et 
al., on the encapsulation of PAL (Rossi et al., 2014).  
In order to monitor the vitality and functionality of RBCs-loaded we determined 
the haematological parameters. The resulting corpuscular indices (MCV, MCH, 
MCHC) of loaded RBCs were in agreement with those of native cells (Rossi et al., 
2014) at 90% haematocrit.  
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5.3 OxDC loading in murine RBCs 
 
To provide the necessary information for preclinical investigations, we also 
determined the best experimental conditions to load OxDC in murine RBCs. We 
carried out the experiment using the same protocol of human RBCs. However, we 
obtained an entrapment yield of 18% and a recovery of 55%. These values are 
significantly lower than those obtained with human RBCs. The difference is due to 
the fact that murine RBCs are much more fragile than human erythrocytes (Rossi 
et al., 2014). Nevertheless, our result was very satisfying if compared with other 
encapsulation procedures (Rossi et al., 2014).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 87 
CONCLUSIONS 
 
 
In this chapter we have setup one of the first steps necessary for the preclinical 
investigation to use RBCs-loaded with OxDC as bioreactors to detoxify oxalate in 
PH. We demonstrated that OxDC can be efficiently encapsulated inside RBCs and 
it does not loose activity during the encapsulation process. Moreover, enzyme 
loading does not compromise RBC morphological parameters.  
Overall these data provide the proof-of-principle for the feasibility of a therapy for 
PH based on the administration of RBCs loaded with an oxalate-degrading enzyme. 
The next step to validate this approach are tests in a murine model of disease. In 
this regard, the success of the encapsulation in murine RBCs provide the necessary 
premise to proceed with in vivo experiments that are currently under way.  
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Background information 
 
The biochemical characterization of OxDC at neutral pH has revealed that the 
enzyme maintains its global structural properties but, as expected, displays a 
strongly reduced catalytic activity. Moreover, under conditions mimicking a 
physiological environment, the enzyme shows a reduced thermal stability, probably 
due to an influence of the different state of protonation of key amino acid residues. 
Therefore, although the administration of OxDC is considered as a promising 
strategy against the various forms of hyperoxaluria, the reduced activity and 
stability at neutral pH represents a major problem. In this regard, the acidic 
optimum pH of OxDC has been historically attributed to the protonation state of 
oxalate (Anand et al., 2002; Just et al., 2004), but some recent papers suggest that 
the pH-dependence of the catalytic activity could be also governed by small 
changes in the active site of the protein that could stabilize the +3 oxidation state of 
the Mn ion (Zhu et al., 2016). Based on these considerations, we reasoned that 
mutations of key protein residues could in principle shift the optimum pH toward 
the neutral range. Therefore, we decided to apply protein engineering techniques to 
generate mutant forms of OxDC possibly endowed with higher activity and/or 
higher stability at neutral pH. As described in early 90s by Gupta et al., protein 
engineering approaches are presented as “a highly promising techniques within the 
frame of biocatalyst engineering to improve enzyme stability and efficiency in low 
water systems” (Gupta et al., 1992). Nowadays, many strategies are available to 
“evolve” a protein with a desired function or property (Chen 2001). They can be 
classified in two main classes (Figure 21):  
 
(i) Rational design, for which the knowledge of the structure and function 
of the target protein represents an essential prerequisite. The term 
rational refers to the perfect control of the desired change to be 
introduced into the protein. A rational gene mutation is planned by using 
in silico analyses and by taking into account the information available 
on the biochemical properties of the protein. This is followed by 
designed changes in the gene of the protein cloned in a specific vector 
for heterologous expression, and into the purification of specific 
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mutants. The final step is a screening based on an assay reporting on the 
success of the change (Arnold 1993). 
 
One of the well-known successful application of rational design is the 
engineering of the enzyme subtilisin to avoid its inactivation by bleach 
(Bryan 2000). Subtilisin is a protease which is added to detergents to 
improve their efficiency, but is inactivated by bleach. Thanks to the 
knowledge of the catalytic mechanism and to the availability of the 
crystal structure, it has been found that the inactivation was due to the 
oxidation of the methionine at position 22. Using site-directed 
mutagenesis this residue has been changed to alanine, thus resulting in 
a mutant enzyme showing improved activity and stability in the presence 
of bleach (Stauffer and Etson, 1969). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Flow-chart illustrating the basic steps of rational and irrational 
protein design approaches. 
 
 
 
(ii) Irrational design, also called direct evolution. It is mainly applied when 
the structure of the target protein is not available. In this method, random 
changes (mutations) are inserted into the protein, the best mutants are 
selected based on a phenotypic assay, and the inserted mutations are 
finally analysed. Direct evolution mimics the process of natural 
Rational	Design
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selection. In fact, the target gene undergoes iterative rounds of 
mutagenesis that create libraries of variants which are selected for the 
desired function and expressed on a large scale.  
 
Direct evolution has been largely used to improve protein stability 
(Beadle and Shoichet, 2002; Tokuriki et al., 2008), substrate binding 
affinity (Dalby 2003; Park et al., 2005), substrate specificity 
(Paramesvran et al., 2009; Bougioukou et al., 2009) and optimum pH 
(Tomschy et al., 2002; van Tilbeurgh et al., 1992).  
The born of direct evolution strategies dates back to 1980s when George 
Smith pioneered phage-display technology for the engineering of 
proteins with desired binding specificities (Smith, 1985). In the 
following years, other irrational design techniques have been developed. 
Among them, error prone PCR is used to generate randomized genomic 
libraries. It allows the initiation of DNA amplification, starting with tiny 
amounts of the parent molecule, and produces a considerable number of 
mutated genes. The principle of this technique is based on the ability of 
Taq polymerase to anneal incompatible base-pairs to each other under 
conditions favouring an erroneous interaction. In this way, the 
polymerase makes mistakes in the newly synthetized complementary 
DNA resulting in a new gene with unknown mutations. 
Another direct evolution technique is DNA shuffling, which is used to 
rapidly increase the size of a library because it permits the 
recombination of homologous gene fragments. The target genes are 
randomly fragmented by DNaseI, and fragments of the desired size are 
purified from an agarose gel. These fragments are then reassembled 
using cycles of denaturation, annealing, and extension by a polymerase. 
Recombination occurs when fragments from different parents anneal in 
a region of high sequence identity. Following this reassembly reaction, 
PCR amplification with primers is used to generate full-length chimeras 
suitable for cloning into an expression vector. 
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In light of these considerations, is difficult to understand which one of 
these strategies is the more suitable to generate improved forms of a 
target protein because either the rational and the irrational design present 
some disadvantages. In the rational design technique, besides a lot of 
successful results, numerous attempts have failed, probably due to an 
incomplete understanding of mechanism required to enhance the 
enzymatic properties. Moreover, a unique substitution in a specific site 
could give an inactive enzyme without the desired properties due to an 
undesired conformational change. Finally, this approach could be 
tedious and expensive and might be impractical for multiple cycles of 
mutagenesis. In fact, at each mutation cycle, the inserted mutation must 
be confirmed by sequencing and the properties of the corresponding 
variant in the purified form must be defined before proceeding to other 
mutagenesis cycles. On the other hand, the irrational design does not 
need the previous knowledge of the protein structure, but the 
introduction of mutations in unknown sites can often result in 
deleterious effects such as deletions, insertions or duplications. 
Moreover, a detailed screening of the obtained libraries is required, to 
avoid the exclusion of clones with improved features. 
 
In our project, we decide to use both rational and irrational design 
techniques in order to develop mutant forms endowed with higher 
activity and stability at neutral pH.  
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RESULTS AND DISCUSSION 
 
 
6.1 Rational approach 
 
Based on the knowledge of sequence, crystal structure, biochemical features and 
catalytic mechanism of OxDC we decided to use three different strategies for the 
rational engineering of the protein: (i) change of metal specificity, (ii) site-
saturation mutagenesis of Glu162, (iii) substitution of residues in the proximity of 
the active site. 
 
(i) Change of metal specificity. It has been reported for many 
metalloenzymes that the change of the metal acting as cofactor could 
improve catalytic efficiency (van Tilbeurgh et al., 1992). This is 
possible only if the new metal is able to maintain the same distance 
between residues, usually histidines, implicated in the coordination of 
the natural cofactor. In the specific case of OxDC, we wonder if a metal 
change could change the pH-dependence and improve the activity at 
neutral pH. Since in OxDC the presence of Mn in a redox state II is 
fundamental for the correct start of reaction, we thought to substitute 
this metal with another one with a similar oxidation state (van 
Tilbeurgh et al., 1992). To incorporate different metals, we included 
them at millimolar concentration as supplement in the medium of the 
bacterial culture. As for other Mn-dependent enzymes (van Tilbeurgh 
et al., 1992) we decided to substitute Mn2+ with magnesium (Mg2+), 
zinc (Zn2+), cobalt (Co2+) or cadmium (Cd2+). Moreover, we used an 
expression protocol similar to that used for Mn incorporation (see 
Materials and Methods), to try to maintain the same yield of protein 
recovery and the same molar ratio of cofactor per monomer. 
Unfortunately, in the presence of Co2+ and Zn2+ the expression of 
OxDC was almost completely depleted, as shown in Figure 22. This is 
probably due to the toxic effect of these metal ions, which possibly 
influence the fitness of bacterial cells and/or decrease the efficiency of 
protein folding. 
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Figure 22. Western blot analyses of purified OxDC-His expressed in the 
presence of different metal ions. 0.1 ug of OxDC-His (lane 1), 8 ug of OxDC 
magnesium induced (lane 2), cobalt induced (lane 3), zinc induced (lane 4) and 
cadmium induced (lane 5). Upon SDS-PAGE, proteins transferred on 
nitrocellulose membrane were revealed using an anti-His-HRP antibody 
(1:5000). 
 
 
On the other hand, in the presence of Mg2+ and Cd2+ ions the expression 
of the protein was even higher than that obtained in the presence of Mn 
(Figure 22). In line with previous reports, Mg-complexed OxDC 
maintained a catalytic activity at pH 4.2 equal to 90% with respect to 
that of Mn-complexed OxDC (Anand et al., 2002). However, the 
activity at pH 7.2 was undetectable, probably due to the incapacity of 
the metal cofactor to reach the oxidation state suitable to carry on 
catalysis. In the case of the Cd2+-complexed enzyme, no activity was 
detected at both acidic and neutral pH, although the protein was 
correctly expressed and folded, thus suggesting that cadmium at the 
active site could negatively impact the OxDC catalytic mechanism.  
 
(ii) Site-saturation mutagenesis of Glu162. Site-saturation mutagenesis 
is usually included among irrational techniques. It consists in the 
change of a specific protein residue with all other possible amino acid 
residues. However, we exploited the principle of this technique to 
substitute Glu162, an OxDC active-site residue, with some other 
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residues chosen in a rational way. Glu162 is an acid-base catalyst 
involved in the protonation of the the formyl radical intermediate 
during the OxDC reaction. For this reason, we wonder if the 
substitution of Glu162 with amino acids positively charged at neutral 
pH such as histidine and lysine could promote oxalate decarboxylation. 
Moreover, we also tested the substitution with glutamine which shows 
a steric hindrance similar to that of glutamate, but could act as proton 
donor. We constructed, expressed and purified the mutants E162H, 
E162K and E162Q, which did not display any gross conformational 
alteration with respect to the wild-type enzyme. Unfortunately, when 
we tested their oxalate degrading ability at pH 4.2 and 7.2, we did not 
detect any catalytic activity, indicating that histidine, lysine and 
glutamine are not able to substitute glutamate as proton donors. These 
results are not completely unexpected, since it has been already 
reported that the mutation of E162Q caused a complete loss of activity 
at acidic pH (Svedružić et al., 2007).  
  
(iii) Substitution of residues in the proximity of the active site. Various 
protein engineering studies have shown that the kinetic power of an 
enzyme can be influenced by residues not directly involved in the 
catalytic pathway, but located in the proximity of the active site and 
possibly interacting with the substrate during its channelling. This idea 
is supported by a previous study where xylose isomerase, a 
metalloenzyme, has been engineered to increase its optimum pH by 
changing Glu186, an active site residue not directly involved in 
catalysis, to Gln. (Tomschy et al., 2002). 
Based on these premises, we elaborated the hypothesis that the presence 
of a proton donor at the entrance of the OxDC active site could improve 
the activity at neutral pH by inducing oxalate protonation. Therefore, 
we performed an initial bioinformatic analysis that allowed the 
identification of three glutamate residues (Glu60, Glu99 and Glu198) 
which are not directly involved in metal binding or in the catalytic 
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mechanism of OxDC. We replaced them by amino acids able to act as 
proton donors at neutral pH (Figure 23).  
 
 
 
 
Figure 23. OxDC active site architecture. Residues involved in the formation 
of the active site pocket are shown as red sticks, while glutamate residues 
located at the entrance of the active site are represented as green sticks. The 
Mn2+ ion is depicted as a blue sphere. 
 
Their substitution with charged amino acids such as lysine, arginine and 
histidine could create at neutral pH a positive channel where oxalate 
could be protonated before reaching the active site, thus becoming in a 
state suitable for catalysis.  
Although we started from a rational approach to choose glutamate 
residues to be subjected to site-directed mutagenesis, we performed a 
casual insertion of the selected mutations by using a mixture of primers 
in a single mutagenesis reaction to obtain all possible mutants: E60H, 
E60K, E60R, E99H, E99K, E99R, E198H, E198K, E198R. We used the 
vectors encoding each mutant to transform E. coli cells, and we measured 
the decarboxylase activity on the obtained lysates at pH 5.5 and 6.5. The 
latter choice was dictated by the necessity to detect even minimal 
increases of the optimum pH. The screening revealed the presence of two 
mutants, E60K and E198H, which showed a slight increase in catalytic 
activity. In particular, E60K presented an increased catalytic efficiency 
of  1.4-fold at both pHs, whereas E198H showed a   1.3-fold increase in 
activity only at pH 6.5. We decided to test the effect of the combination 
His95
Arg92
Glu162
His140 Glu99
Glu60
Tyr200
Phe160
Phe155
His97
Glu198
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of the two mutations, but the double mutant did not show any 
improvement of catalytic activity, as reported in Figure 24. 
 
Figure 24. Oxalate oxidase activity of mutants of the pool of colonies 
selected after transformation and induction of E.coli BL21 cells. Here is 
reported the decarboxylase activity in the lysate of cells expressing OxDC. The 
measurement of single clones has been repeated 12-fold at two different pHs. 
For assay condition see Materials and Methods. 
 
 
The E60K mutant, which showed the highest specific activity in the 
bacterial lysate, was also expressed and purified, and a complete 
analysis of activity as a function of pH was carried out (data not shown). 
Unfortunately, the purified protein did not show any difference with 
respect to wild-type OxDC, thus indicating that the small increase 
observed in the bacterial lysate could be related to an improved folding 
efficiency that increases the amount of protein present inside the cell. 
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From the analysis of the OxDC active site entrance, shown in Figure 25, 
we also noticed the presence of aromatic residues which are not in direct 
contact with residues of the active site, but could be involved in 
substrate channelling and possibly influence the pH-dependence of 
catalytic activity: Phe155, Phe160 and Tyr200. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. OxDC active site architecture. Residues involved in the 
formation of the active site pocket are shown as red sticks while aromatic 
residues located at the entrance of the active site are represented as green 
sticks. Mn ion is depicted as a blue sphere. 
 
 
In order to change as less as possible the active site architecture, we 
mutated the three amino acids to histidine and we produced both the 
single mutants (F155H, F160H and Y200H) and the combined double 
and triple mutants. The clones obtained and their decarboxylase specific 
activity at pH 5.5 and 6.5 are shown in Figure 26. Unfortunately, no 
significant improvements of catalytic activity were noticed. We also 
tried to combine the mutation of glutamate and aromatic residues, to 
investigate if the combination of mutations could generate a mutant with 
improved features, as shown in Figure 26, but the strategy was not 
successful. 
His95
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Figure 26. Oxalate oxidase activity of mutants of the pool of colonies selected 
after transformation and induction of E. coli BL21 cells. Here is reported the 
decarboxylase activity in the lysate of cells expressing OxDC. The measurement 
of single clones has been repeated 12-fold at two different pHs. For assay condition 
see Materials and Methods. 
 
 
In conclusions, we used three different strategies to engineer OxDC to change its 
optimum pH toward the neutral range. None of our attempts produced significant 
results. This is probably due to the complex catalytic mechanism of the enzyme. In 
fact, a monoprotonated substrate and/or a correct ionization state of the metal 
cofactor is necessary to produce the formyl radical. In this process Glu162 plays a 
key role and other residues are probably involved in maintaining the overall active 
site geometry suitable to promote catalysis. Therefore, it is possible to conclude that 
any alteration could negatively influence the catalytic mechanism. In a previous 
study, a pH-shift of a metalloenzyme, xylose isomerase, was obtained thanks to 
protein engineering approaches (van Tilbeurgh et al., 1992). This enzyme catalyses 
an aldoses/ketose isomerization and requires bivalent cations such as Mg2+, Mn2+ 
or Co2+. The active site of the enzyme contains two metal ions that are involved in 
substrate binding and participate to the hydride shift between the C1 and C2 atoms 
of the substrate. Similarly to OxDC, a glutamate residue is present at the active site 
but not in contact with the substrate nor with the metal cofactor. The authors of the 
study found a mutation, the E186Q, which preserved most of the activity, but 
drastically shifted the optimum pH from 7.5 to 6.5 (Tomschy et al., 2002).  
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In the case of OxDC, however, we did not find any active site residue that do not 
directly participates to catalysis. This could be the main reason underlying the lack 
of success of our rational design strategies and prompted us to attempt irrational 
approaches on residues distant from the active site. 
 
 
6.2 Irrational approach 
 
 
Based on the unsatisfactory results obtained by the different strategies employed in 
the rational approach to obtained an OxDC showing improved activity at neutral 
pH, we decided to focus our efforts on protein engineering methods based on 
irrational approaches. The latter strategy could in principle allow to find mutations 
of residues spread over the entire sequence that improve the functional parameters 
and/ or the thermodynamic stability of a protein.  
It is well-known that one of the main problems of protein directed evolution 
methods is the high rate of gene combinations and the consequent high number of 
produced variants, which imply a high number of screening procedures and a low 
global efficiency of the process (Rockah-Shmuel et al., 2014). In fact, the frequency 
of beneficial mutations in randomly mutated variants is very low (Lang and Murray, 
2008) and combinations of multiple beneficial mutations are often needed to obtain 
a significant improvement of a desired property (Chen, 2001). Considering all these 
shortcomings, we reasoned that a totally irrational approach could not be applied to 
efficiently select a good OxDC variant in our laboratory setting. One of the methods 
recently employed to reduce the dimension of screening libraries is to produce the 
so called “smart libraries”, (Lane and Seelig, 2014), i.e. libraries that are less 
complex but of high-quality and are endowed with a high potential of containing 
functional variants. To build those libraries, a targeted mutagenesis guided by 
structural or phylogenetic information, along with methods allowing an improved 
speed of selection, should be applied.  
Among the available methods, we utilized the consensus-mutants based approach 
(Porebski and Buckle, 2016). Consensus design, like ancestral sequence 
reconstruction, utilises evolutionary history. However, rather than inferring 
phylogenetic hierarchy, all sequences are aligned and the most frequently observed 
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amino acid identified at each position in the alignment are considered potentially 
beneficial. Moreover, in order to speed-up the selection, we took advantage of the 
epistatic effect of mutations. Usually, each mutation alone could have neutral or 
deleterious effects. However, when two or more mutations are combined in a 
sequence space, they can give rise to a structural improvement (higher 
thermostability or stress resistance, higher surface adaptability, etc) or to a 
functional change (altered Km or kcat, shift of optimum pH, substrate promiscuity). 
The technique that we employed to combine the selected mutations is named 
Incorporation of Synthetic Oligonucleotides During Gene Shuffling (ISOR) 
(Rockah-Shmuel et al., 2014). This technique, which is described in detail in the 
Materials and Methods section, permits to explore a large number of potentially 
beneficial mutations in a combinatorial manner such that individual library variants 
carry a limited number of mutations. The efficacy of this technique is demonstrated 
by the fact that its rate of success is comparable to that achieved by several rounds 
of evolution using random mutagenesis approaches (Rockah-Shmuel et al., 2014). 
In summary, the strategy that we used for the OxDC direct evolution involves (i) a 
consensus-based approach to select residues spread over the entire sequence and 
identify possibly beneficial mutations, followed by (ii) the combinatorial insertion 
of the selected mutations by the ISOR technique (Figure 27). As a read-out of our 
study, we tested both the stability and the activity of the enzyme at neutral pH. 
Figure 27. Overall strategies for the irrational design of OxDC 
 
 
 
6.2.1 Identification of target mutations by the consensus based-approach 
 
The consensus based-approach involves the following four steps: (i) identification 
of a domain of the protein to be targeted, (ii) acquisition and pre-processing of 
homologous sequences, (iii) iterative assessment of several multiple sequence 
alignments (MSA) and (iv) calculation of sequence conservation. To apply the 
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consensus-based approach to OxDC we selected 200 proteins displaying an 
homology sequence from 35 to 95% with OxDC from the UniProt database and we 
carried out a first multiple sequence alignment using the software MUSCLE on the 
Consurf server, and then analysed the consensus sequence generated by Jalview 
program. The output of this analysis allowed us to define the conservation score of 
each residue with respect to the other analysed sequences. In Figure 28 is reported 
a slice of the results where the intensity of the blue colour is related to the 
conservation grade of each residue. In order to confirm the results obtained, we also 
performed a conservation analysis based on a structural alignment using the MSA 
obtained previously. We obtained the consensus structural-based alignment, where 
the conservation score takes into account structural information. At this point, we 
decided to cross the two outputs (sequence and structure based alignment) and 
select only the consensus residues common to both predictions. As final step, we 
mapped the consensus residues identified in the OxDC crystal structure, and we 
chose the target mutations based on the position and the degree of conservation of 
each residue. 
  
 
 
Figure 28. Portion of the sequence alignment of OxDC. Results of sequence alignment 
of OxDC with 200 proteins with a homology sequence from 35 to 95% obtained using the 
software CONSURF. A darker colour indicates an higher conservation index of the residue. 
Yellow bars represent the degree of conservation of each residue. 
 
It should be mentioned that the most conserved residues of a protein are not good 
candidates for a directed evolution approach, because they usually play an essential 
role for the structure and/or the biologic activity (Mesa-Torres et al., 2014). Rather, 
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in order to uncover or evolve properties of a protein that are possibly hidden, one 
should look for residues with a low conservation score. This usually avoids gross 
structural/functional alterations. In the case of OxDC, we observed that most of the 
strongly conserved residues are located at the active site, such as the His involved 
in manganese binding. On the other hand, we noticed that other regions contain 
many residues characterized by a low degree of conservation. Among them, we 
looked for amino acids that are strongly conserved in all or most of the two-hundred 
proteins used as query for the alignment, but are not highly conserved in OxDC. 
We then choose to convert each of these residues to that present in the other 
sequences but absent in OxDC. The analysis gave us 38 mutations, which are listed 
in Table 5 and represent the starting point for in vitro analyses. 
 
Table 5: List of mutations obtained from bioinformatics analyses. Blue, green and red 
colour indicates mutations involving residues located on the protein surface, at the 
monomer-monomer interface, or at the entrance of active site, respectively. The black 
colour indicates mutations involving residues distributed on the other parts of the structure. 
 
 
 
 
 
 
 
 
 
 
 
We mapped each residue on the OxDC crystal structure (Figure 29), and we 
observed that they are spread over the entire structure of the monomer. We thus 
grouped the selected mutations based on the position of the mutated amino acids. It 
can be observed that some are located on protein surface areas, other on stretches 
involved in monomer-monomer interactions, or in regions located at the entrance 
of active site.  
M48L D124A A246V H339R 
N57M L138I K252P Y340F 
E60Q A144G A268G L349M 
A65S A149C I285L M351L 
S76A L168I N304D F356L 
A90G T169S Q306R 
I91V L172F V321I 
E99Q L194I E322Q 
V112I E198Q I324T 
I114A E203Q I334M 
E117Q Y228H D337S 
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Figure 29. Cartoon representation of the OxDC monomer (PDB: 1J58) showing the 
map of the residues target of the mutations identified by bioinformatic analyses and 
listed in Table 4. Mutated residues are shown as light blue sticks, while the Mn2+ ion is 
shown in violet.  
 
 
6.2.2 Library construction with the ISOR method and screening of the OxDC 
variants upon expression in E. coli 
 
The ISOR method is a molecular biology technique used to create libraries of 
mutants of a target protein by combining in a stochastic manner a selected number 
of mutations (Rockah-Shmuel et al., 2014). The overall protocol involves three 
steps, as summarized in figure 30: 
 
(i) DNA SHUFFLING: it consists in the random breaking of the 
cDNA of the target protein using DNaseI; 
(ii) ASSEMBLY PCR: it is a particular type of PCR in which all the 
oligonucleotides containing the selected mutations and 
annealing in overlapping regions are used concomitantly. It 
gives rise to products of different lengths containing random 
combinations of the selected mutations;  
(iii) NESTED PCR: it consists in the amplification of each of the 
different constructs obtained in the previous step to obtain 
enough amount of cDNA of each variant of the target protein for 
the subsequent cloning step. 
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Figure 30. Brief summary of ISOR technique. 
 
 
We first setup the Assembly PCR to obtain 2- to 4 mutations by preparing a suitable 
mixture of primers (equal molar concentration of each mutagenic primer, sense or 
antisense strand). We then performed the NESTED PCR to increase the yield of the 
assembled DNA, we purified the product, and we cloned them in a pET21(a) vector 
by using restriction enzymes. The cloning procedure was setup according to 
Rockah-Shmuel et al. 2014 (see Materials and Methods). 
As a final step, we verified the success of the cloning procedure by gel 
electrophoresis of the vector using the empty vector and the vector containing the 
wild-type OxDC gene as negative and positive control, respectively.  
We transformed the OxDC library into competent BL21 E. coli cells. We obtained 
several plates where each colony represents a putative variant. We then setup the 
screening procedure by performing a small-scale growth and induction of each 
bacterial colony in 96-well plates, followed by lysis of the culture of each well, and 
analysis of the soluble lysate.  
As read-out, we determined the oxalate decarboxylase specific activity of the 
bacterial lysate at pH 5.5 and 6.5, and we compared the obtained values with those 
of wild-type OxDC and of the untrasformed bacteria as positive and negative 
control, respectively. Technical details are given in Materials and Methods.  
In the first set of experiments, we screened enough colonies to cover most of the 
possible combinations of mutants (Rockah-Shmuel et al., 2014). Unfortunately, we 
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did not obtain any variant showing an improved activity at physiological pH. Thus, 
we decided to test the possible epistatic effect of the selected mutations and to 
combine all the selected changes in a single run, i.e. to use conditions in which a 
large number of mutations at a time is inserted in each DNA sequence. It should be 
mentioned that a similar approach would require the screening of a very high 
number of clones to cover the whole mutational space. Since our experimental 
setting did not allow to test thousands of colonies, in order to have a preliminary 
idea of the possible success of this procedure, we decided to limit our testing to 
approximately 1000 clones. 
  
The screening of the second set of mutants allowed to identify 31 clones showing 
an improved decarboxylase activity at pH 5.5 and 6.5 with respect to wild-type 
OxDC. We then performed a second run in which each positive clone was screened 
in triplicate at both pHs to exclude false positives possibly resulting from the 
intrinsic variability of the assay and/or of the screening procedure. The results are 
shown in Figure 31 and allowed us to select four clones showing improved activity 
at pH 5.5 and 6.5. Since the sequence of each clone was unknown, we named them 
based on their position in the screening plate as D7, G2, G10 and G11.  
Among the positive clones, we decided to proceed our study only with G2, because 
it was the only mutant showing a significant change of specific activity with respect 
to wild-type OxDC.  
 
 
Figure 31. Results of the second-run screening of OxDC mutants. The bars show the 
oxalate decarboxylase specific activity at pH 6.5 measured in the cellular lysate of bacteria 
expressing each variant. The screening procedure is described in the Materials and Methods 
section.  
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6.2.3 Analysis of the G2 clone 
 
Upon sequencing of the vector expressing the G2 clone we noticed that the variant 
is characterized by the combination of mutations reported in Table 6.  
 
Table 6. Mutations identified in the G2 clone of OxDC. 
 
N57M E99Q I180L 
E60Q L138I E198Q 
A65S A144G E203Q 
S76A A149C Y228H 
I91V T169S K252P 
 
The visual inspection of the mapped mutations (Figure 32) reveals that the mutated 
residues are only part of the cupin domain I. Some of them, such as Glu198 and 
Ala65, are located at the entrance of active site, while others, such as Tyr228 and 
Lys252, are involved in the interaction with cupin domain II, and others, such as 
Ala144, Iso180 and Glu203, are located on the protein surface. It has been 
demonstrated that cupin domain I is the catalytic site for OxDC, while cupin domain 
II plays a structural role (Just et al., 2007). Thus, we could speculate that mutations 
of residues belonging to the cupin domain II could have deleterious effects on 
OxDC folding, and thus strongly compromise protein fitness, while mutations of 
residues belonging to the cupin domain I could be better tolerated. This could 
explain why the mutations present on the G2 variant are only located in domain I. 
 
 
Figure 32. Cartoon representation of the OxDC monomer (PDB: 1J58) showing the 
map of the residues mutated the G2 mutant. Mutated residues are shown as light blue 
sticks, while the Mn2+ ion is shown in violet.  
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It should be mentioned that a screening based on the specific activity measured in 
the bacterial lysate does not allow to distinguish between variations caused by an 
altered intrinsic catalytic activity of a protein, variations due to an altered 
expression level, and variations resulting from a combination of both factors. Thus, 
in order to substantiate the improved features of the G2 variant, we performed a 
large scale expression and we purified the protein to homogeneity.  
We first investigated the pH-profile of the variant by determining the oxalate 
decarboxylase activity in the range of pH from 4.2 to 7.2. We did not notice any 
significant shift of the optimum pH with respect to wild-type OxDC (data not 
shown). However, when we analysed the thermostability at neutral pH by 
monitoring the loss of the CD signal at 222 nm with time, as reported in Figure 33, 
we found and improved stability. In fact, under the same experimental conditions, 
the mutant shows a Tm of 79°C, while wild-type OxDC shows a Tm of 39°C.  
 
 
 
Figure 33. Thermal stability of OxDC WT and G2 mutant. Change in the CD signal at 
222 nm at increasing temperature from 25° to 90°C (heating rate 1.5°C/min). All 
measurements were performed at 0.5 mg/ml enzyme concentration, in 16 mM Tris-HCl pH 
7.2, 140 mM NaCl (red line) or 52 mM sodium acetate pH 4.2, 140 mM NaCl (black line), 
at 25°C. The colour code is the following: red, wild-type OxDC; black, G2 mutant. 
 
 
Thus, we can conclude that the improved specific activity of the G2 variant is not 
due to an increase of intrinsic catalytic activity of the enzyme, but is probably the 
consequence of an improved expression yield of the protein caused by its increased 
thermodynamic stability.  
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At the moment it is difficult to define which of the mutations present on the G2 
mutant contributes to the gain of stability, or if the improvement results from the 
combination of more than one mutation. The second option is the more probable 
based on the location of mutations which are spread over the structure of domain I. 
It can be speculated that one or more than one mutation leads to a different 
orientation of some amino acids which play a key role in the maintenance of the 
OxDC three-dimensional structure, or in influencing the aggregation propensity of 
the protein, thus resulting in an improved intracellular stability that in turn leads to 
an higher expression level. Similar results have been obtained in 2016 by Mesa-
Torres et al., who used a consensus-based approach to produce a mutant form of 
alanine:glyoxylate aminotransferase showing an increased kinetic stability. 
Moreover, in 2018 Cirri et al., using consensus mutagenesis obtained a 
thermostable human excitatory amino acid transporter variant that shared up to 95% 
amino acid identity with the wild type transporters, but remained natively folded 
and functional for a long time under thermal stress conditions. 
 
Studies are under way to better define the biochemical features of the G2 variants, 
the role of each mutation, and the possible occurrence of epistatic effects.  
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CONCLUSIONS 
 
An optimum pH of OxDC in the neutral range is one of the more desirable features 
for the therapeutic use of the protein. In fact, notwithstanding its high activity at 
strongly acidic pH values, OxDC is considered as a new frontier in treatment of 
hyperoxaluria, where the enzyme should be active and stable at neutral pH (Grujic 
et al., 2009; Langman et al., 2016). Our study is the first aiming at improving the 
optimum pH of the enzyme through the use of protein engineering techniques. The 
strategy that we used is two-fold: 1) a rational approach, which did not give us any 
significant improvements of activity, and 2) an irrational approach based on the 
combination of a consensus-based approach and of the ISOR technique. Overall, 
the irrational approach was not able to give us an OxDC with improved activity at 
neutral pH. Nevertheless, we obtained a new enzyme showing an improved  
stability at neutral pH. The significance of this discovery is not only related to a 
better definition of the biochemical features of OxDC, but also to the selection of 
an enzyme with a remarkable resistance under conditions mimicking a 
physiological environment. This could represent a key property in the light of the 
application of the mutant as biological drug. In particular, we will exploit this 
property by encapsulating the mutant in RBCs and by comparing the half-life of the 
loaded protein with that of wild-type OxDC. 
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Background Information 
	
The propensity to aggregation is an inevitable issue for most proteins and protein 
aggregates formation is the basis of several misfolding diseases, including those 
displaying loss-of-function pathogenesis. Different types of aggregates can be 
formed and they can lead to different effects in cells and organisms. For example, 
in age-related neurodegenerative disorders like Alzheimer’s disease, a protein 
undergoes a conformational change favouring the formation of ordered oligomers 
and fibrillar aggregates that exert a toxic effect on a specific cell type (Oliva et al., 
2015; Roberts et al., 2014).  In other cases, like in diseases caused by protein 
deficits, pathogenic mutations can promote the aggregation of the protein involved 
causing the formation of amorphous aggregates that undergo degradation. The 
consequent reduction in the folding yield leads to a deficit of activity specific of the 
protein, as the CFTR chloride transporter in the case of cystic fibrosis (Walsh et al., 
2010; Pallas et al., 2006), or the sphingolipid catabolism in the case of Gaucher 
disease (Torok et al., 2002; Cuthbert et al., 1992). 
Although aggregation is often attributed to the population of intermediates exposing 
hydrophobic surfaces, the contribution of electrostatic forces has recently gained 
attention. The process of electrostatic aggregation is based on the attraction between 
complementary charged domains of a protein surface and it usually decreases at 
high ionic strength, due to screening effects (Sarkadi et al., 1992). Studies aimed at 
improving protein aggregation resistance have indicated that surface charge 
strongly influences protein stability and that the controlling factor is the spatial 
location of charges (Mistry et al., 2017: Wajnera et al., 2004; Wang et al., 2010). 
In fact, the main factor governing the aggregation extent is protein charge 
anisotropy, i.e. the asymmetric distribution of charged residues on the exterior of a 
particular protein.  
Human alanine:glyoxylate aminotransferase (AGT) as described in the Introduction 
section, is associated with Primary Hyperoxaluria Type I. The majority of disease-
causing mutations on the AGXT gene encoding AGT are missense mutations 
(Morris et al., 2009; Fink et al., 1998). Data obtained in prokaryotic and eukaryotic 
models as well as analyses on variants in the purified form, indicate that many 
mutations reduce the folding efficiency of AGT by promoting its aggregation 
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(Neves-Petersen et al., 2003; Majhi et al., 2006; Ugolini et al., 2001). In some case 
the aggregation is due to a low dimer stability, which allows the formation of 
monomers exposing hydrophobic surfaces and prone to self-association 
(Austerberrya et al., 2017). In other case however, an aggregation driven by 
electrostatic interactions between folded dimers showing an increased surface 
charge anisotropy has been reported (Neves-Petersen et al., 2003).  
AGT exists as two polymorphic variants named major (AGT-Ma, the most 
frequent) and minor (AGT-Mi, present in 20% of Caucasian population) (Lee et al., 
2001; Der et al., 2013). AGT-Mi shows an increased aggregation propensity and a 
reduced stability with respect to AGT-Ma, both in vitro and in the cell (Majhi et al., 
2006, Lee et al., 2016). This effect has been attributed to a reduced stability of the 
dimeric structure (Austerberrya et al., 2017; Lee et al., 2016; Perchiacca et al., 
2011). However, it cannot be excluded that either the P11L and/or the I340M 
substitutions typical of the minor allele could also influence the electrostatic surface 
of the protein. Moreover, it has been reported that several pathogenic mutations that 
lead to PH1 associated with the minor allele, play their effects by increasing the 
AGT aggregation propensity (Majhi et al., 2006; Ugolini et al., 2001; Lee et al., 
2016) and can functionally synergize with the minor allele polymorphism.  
So, we decided to combine computational and in vitro studies to investigate the 
aggregation process of AGT in the recombinant purified form. These findings, by 
increasing the knowledge of the biochemical properties of AGT and of the 
pathogenesis of PH1, constitute the base to design new strategies able to improve 
the stability of the protein as a possible premise for the development of innovative 
therapeutic approaches.  
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RESULTS AND DISCUSSION 
 
7.1 In silico analysis of the AGT surface 
 
Based on the known 3D structure of AGT-Ma in the holo-form (PDB: 3R9A), we 
evaluated the distribution of hydrophobic surfaces as well as the electrostatic map. 
As reported in Figure 34A and B, AGT-Ma shows only few hydrophobic patches 
on its surface, mainly located along the dimerization interface in line with the 
finding that mutations inducing AGT monomerization favour aggregative 
processes driven by hydrophobic attractions (Dindo et al., 2016). 
Moreover, the electrostatic map of AGT-Ma reveals an asymmetric distribution of 
negative and positive charges on the dimeric surface (Figure 34C). In particular, 
four main negative patches are present in one face of the dimer. 
 
 
 
Figure 34. Distribution of hydrophobic patches and electrostatic potential around 
AGT-Ma. (A) Hydrophobic patches of dimeric AGT shown as green areas on a gray 
background. (B) Representation of the hydrophobic patches around AGT on a 2D map. The 
red and blue lines indicate the equatorial and central meridian porjection axes, respectively. 
(C,D) Electrostatic potential contours shown as mesh (−0.5 (red) and +0.5 (blue) kT/e) 
around AGT obtained by using the pdb2pqr tool for structure preparation, propka 3.0 for 
the protonation state of the residues of AGT and the adaptive poisson-boltzmann solver 
(APBS) tool to generate the electrostatic potential map. Each tool was run on the Opal web 
service. The visualization of the potential electrostatic map was performed using the UCSF 
chimera 1.11 program setting 0.06 M KP, pH 7.4 as buffer at 37 °C 
 
On the other hand, as shown in Figure 34D, four main positive patches are present 
on the other side. So, we decided to compare the electrostatic map of AGT with 
those of other PLP-dependent aminotransferases belonging to the Fold type I family 
such as human cytosolic aspartate aminotransferase (PDB: 3WZF), human 
ornithine aminotransferase (PDB: 1OAT) and human tyrosine aminotransferase 
A B C D
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(PDB: 3DYD) as well as with proteins showing a sequence similarity ≥ 30% with 
AGT. All the latter proteins (except alanine:glyoxylate aminotransferase from 
Aedes aegypti that displays some positive patches), show an unvarying negative 
potential on their surface (data not shown) suggesting us that the peculiar 
distribution of surface charges in human AGT could promote its electrostatic self-
association. Following this view, pH and ionic strength could critically influence 
aggregation rate and/or extent. Moreover, mutations of surface residues could 
change the charge distribution and negatively or positively influence the self-
association process. 
 
7.2 Effect of pH and ionic strength on the aggregation propensity of AGT-Ma  
 
We evaluated the self-association propensity of AGT-Ma by dynamic light 
scattering (DLS) experiments performed at various pHs and ionic strengths. 
Preliminary analyses were carried out to guarantee that almost all the protein was 
present in the dimeric form. We monitored the increase in the mean count rate, a 
parameter that represents the average scattering intensity during the measurement 
and directly reports on aggregated species present in solution. To determine the 
aggregation rate, we have fitted the data on the time-dependent increase in count 
using the analytic equation proposed by Morris et al., 2008. This equation is related 
to the minimalistic/”Ockham’s razor” Finke-Watzky (F-W) two-step model, which 
has been used to analyse the aggregation data of a wide set of proteins (Watzky et 
al., 2008; Morris et al., 2008). In this model, a continuous nucleation step (A→B, 
rate constant k1) is followed by a fast, autocatalytic growth step (A + B → 2B, rate 
constant k2). AàB and A + Bà2B processes are composites of multiple 
elementary steps and therefore the resultant rate constants, k1 and k2, are 
experimental average values. In our experiments, we assumed that A is the dimeric 
form of AGT, B is the polymeric aggregation nucleus, k1 and k2 correspond to the 
average rate constants for nucleation and growth, respectively.  
It is well-known that a lot of proteins tend to have decreased solubility near the pI, 
often referred to as isoelectric precipitation, where the low net charge of the protein 
corresponds to the loss of repulsive forces. AGT has a predicted pI of 8.59. So, we 
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decided to perform the analyses at 37°C in 0.1 M potassium phosphate buffer (KP) 
in the pH range 5.5-8.0, to avoid protein unfolding due to strong acid or alkaline 
conditions. HoloAGT-Ma does not show any significant increase in count rate from 
pH 8 down to 6.5, while a slight aggregation propensity can be seen at pH 5.5 and 
6 (Figure 35A). At pH 5.5, the values of k1 and k2 were equal to 1.70 ± 0.02 ⋅ 10-2 
min-1 and 7.3 ± 0.5 ⋅ 10-4 min-1 µM-1, respectively. In contrast, apoAGT-Ma showed 
an increase in count rate along the whole pH range, with extent and rate of 
aggregation higher than the corresponding of holoAGT-Ma (Figure 35B). The 
values of k1 and k2 increase as the pH is lowered from 8 to 5.5, giving values of 
pkspec of 6.0 ± 0.1, and 6.18 ± 0.09, respectively (Figure 35C).  
 
Figure 35. Aggregation profiles of holoAGT-Ma (A) and apoAGT-Ma (B) and trend 
of the rate constants values of apoAGT-Ma (C) as a function of pH. (A) Time-
dependent changes of the total count rate (measured as kilocounts per second) of holoAGT-
Ma. (B) Time-dependent changes of the total count rate (measured as kilocounts per 
second) of apoAGT-Ma. (C) Plot of k1 (black circles) and k2 (blue circles) rate constants of 
apoAGT-Ma. Measurements were performed at 10 µm enzyme concentration, 0.1 M KP, 
37 °C. The color code for (A, B) is the following: blue, pH 5.5; black, pH 6.0; green, pH 
6.5; purple, pH 7.0; red, pH 7.5; and cyan, pH 8.0. 
 
Thus, the aggregation extent is higher at pHs where the protein net charge shows 
the highest values. It also be mentioned that the aggregation process leads to the 
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formation of aggregates of size spanning from 400 to 800 nm (data not shown), 
which confirms that aggregates are the main responsible for the scattering signal 
and that the count rate increase is a suitable parameter to follow the aggregation 
process, as already reported (Bemporad et al., 2009). However, the signal of the 
dimer is always visible in the whole pH range, thus indicating that the dimer still 
remains the more represented species in solution. 
 
By monitoring the aggregation process of apoAGT-Ma at pH 5.5 and 8 at various 
protein concentrations (Figure 36A and B) we found an increase in k1 and k2 values 
at increasing AGT concentrations under both conditions. When we studied the 
aggregation process of apoAGT-Ma at pH 5.5 varying KP concentration from 0.05 
to 1 M, we found that the aggregation rate decreases at increasing ionic strength of 
the buffer. In particular, aggregation is completely prevented at values equal or 
higher than 0.2 M, and occurs with k1 values of 3.1 ± 0.3 ⋅ 10-2 min-1 and 2.2 ± 0.2 
⋅ 10-2 min-1, and k2 values of 2.9 ± 0.3 ⋅ 10-3 min-1 µM-1 and 2.0 ± 0.2 ⋅ 10-3 min-1 
µM-1, at 0.05 M and 0.1 M, respectively (Figure 36C). These data indicate that the 
process is not mediated by hydrophobic attractions, which would have been 
enhanced by increased salt concentrations. Rather, it depends on electrostatic 
interactions, which are reduced or suppressed at high ionic strength due to screening 
effects. 
In order to investigate if aggregation was accompanied by an unfolding process, we 
registered the dichroic signal at 222 nm, indicative of the secondary structure 
content, of 10 µM apoAGT-Ma in KP 0.05 M pH 5.5, 37°C, i.e. under conditions 
in which a strong aggregation phenomenon is observed. Since we did not observe 
any loss of secondary structure with time during aggregation up to 300 minutes 
(Figure 36D), we concluded that the process is not dependent on a partial unfolding, 
but occurs starting from a native or native-like form of the protein. Furthermore, by 
exploiting the different behaviour of the protein in the apo- and holo-form, we 
found that aggregation is not reversible. In fact, the addition of 100 µM PLP to an 
aggregating mixture of 10 µM apoAGT-Ma at pH 5.5 in 0.05 M KP was able to 
stop but not to revert the self-association process.  
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Figure 36. Aggregation of apoAGT-Ma at different protein concentrations and ionic 
strengths. (A,B) Time dependence of total count rate (measured as kilocounts per second) 
of apoAGT-Ma at 2 µM (black), 10 µM (blue) and 20 µmM(green) concentration, in 0.1 M 
KP buffer, 37 °C at the indicated pH value. (C) Time-dependent changes of the total count 
rate (measured as kilocounts per second) of 10 µM apoAGT-Ma at 37 °C in KP buffer pH 
5.5 at 0.05 M (black), 0.1 M (red), 0.2 M (green), 0.5 M (blue), and 1 M (cyan). (D) Time-
dependent changes in the CD signal at 222 of apoAGT-Ma in 0.1 M KP, pH 5.5, 37 °C, 10 
µM enzyme concentration. 
 
Altogether, these data allow us to conclude that the aggregation of AGT-Ma is not 
an isoelectric precipitation phenomenon, because it is not influenced by the global 
net charge of the protein, and is not due to the formation of disulphide bonds. 
Rather, it depends on the electrostatic interaction between patches of opposite 
charge present on the native dimeric species as a consequence of the charge 
anisotropy of the protein surface. A similar aggregation mechanism has been 
already reported for β-Lactoglobulin, which shows a strong aggregation 
phenomenon at pH values below the pI (Majhi et al., 2006). 
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7.3 Effects of the P11L and I340M polymorphic mutations on the aggregation 
process 
 
We analysed the aggregation process of apo- and holoAGT-Mi as a function of pH 
by DLS under the same experimental conditions used for AGT-Ma and we have 
found that the aggregation rate increases at decreasing ionic strength, thus 
indicating that the process is mediated by electrostatic forces (data not shown). The 
trends of the k1 and k2 as a function of pH of holo- and apoAGT-Mi, reported in 
Figure 37, reveal that both species show an increased aggregation propensity at 
acidic pH with estimated values of pKspec of 5.8 ± 0.3 and 5.7 ± 0.1 for k1 and 6.4 ± 
0.1 and 6.2 ± 0.3 for k2 of apo and holoAGT-Mi, respectively. Moreover, the species 
populating during AGT-Mi aggregation were similar to those formed by AGT-Ma 
but characterized by a higher molecular weight (~1000 nm diameter). 
 
 
 
Figure 37. Trends of k1 and k2 of AGT-Mi, P11L, and I340M as a function of pH. The 
proteins either in the holo (A,B) or apo (C,D) form were incubated in 0.1 M KP at different 
pH values at 37 °C and the mean count rate in DLS was monitored. The values of k1 and 
k2 were obtained by fitting the data to Eq. 8 (see Materials and Methods). The color code 
is the following: AGT-Mi, blue; P11L, black; I340M, green. The values of AGT-Ma (red) 
are also shown for comparison. 
 120 
At both 5.5 and pH 8, the aggregation rate is proportional to protein concentration 
(data not shown) and no unfolding is dected during aggregation, as indicated by CD 
spectroscopy experiments (data not shown). By comparing the aggregation rate 
constants of holo- and apoAGT-Mi with those of the corresponding forms of AGT-
Ma we noticed that the minor allelic form shows an increased aggregation 
propensity. In fact, a visible aggregation event was present at pHs lower or equal to 
7 in holoAGT-Mi, while holoAGT-Ma only aggregates at pH 5.5. At the latter pH 
value, holoAGT-Mi showed k1 and k2 values about 2- and 10-fold higher, 
respectively, as compared with those of holoAGT-Ma. As for the apo-form, the 
values of k1 and k2 were from 1- to 2.5-fold and from 2- to 4-fold higher than those 
of apoAGT-Ma, respectively (Figure 37).  
Overall, these data allow to conclude that AGT-Mi is prone to an electrostatically-
driven process of self-association analogous to that already observed for AGT-Ma, 
but characterized by a higher aggregation rate. The latter effect seems to depend 
more on an increased autocatalytic growth rate than on an increased nucleation rate. 
This suggest that one or both of the two polymorphic mutations typical of the minor 
allele, P11L and I340M, could directly or indirectly change the surface of the 
protein and somehow influence the interaction between oppositely-charged patches 
during aggregates growth. 
In order to understand the structural determinants responsible for the increased 
aggregation propensity of AGT-Mi, we expressed, purified and characterized the 
two single mutants P11L and I340M. Their absorbance and CD spectra in the 
visible region were similar to the corresponding of AGT-Ma and AGT-Mi (data not 
shown). Moreover, the P11L and I340M mutations did not affect the KD(PLP) value 
of AGT as well as the kinetic parameters of the overall transamination reaction, 
except for a 30% reduction in kcat of the P11L variant (dat not shown).  
Finally, the two mutations did not alter the quaternary structure of the protein up to 
0.3 µM (the detection limit of SEC experiments). 
We thus investigated the aggregation behaviour of I340M and P11L single variants. 
HoloI340M displayed a visible increase in count rate only at pH 5.5 and 6. At pH 
5.5 the values of k1 and k2 were equal to 1.5 ± 0.4 ⋅ 10-2 min-1 and 6.0 ± 0.1 ⋅ 10-5 
min-1 µM-1, respectively. The value of k1 was similar while that of k2 was 12-fold 
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lower than the corresponding of holoAGT-Ma. Accordingly, apoI340M only 
aggregated at pH 5.5, with a k1 value similar to that of apoAGT-Ma but a k2 value 
14-fold lower than the corresponding of apoAGT-Ma (k1 = 3.20 ± 0.15 ⋅ 10-2 min-
1, k2 = 1.9  ± 0.1 ⋅ 10-4 min-1 µM-1) (Figure 37). Hence, the I340M mutation has a 
stabilizing effect on the AGT native structure.  
A completely different effect is exerted by the P11L mutation, as shown by the pH-
dependence of the k1 and k2 values of aggregation of the apo and holovariant, 
respectively (Figure 38).  
 
 
Figure 38. Aggregation profiles of apoAGT-Mi and apoP11L at different protein 
concentrations. Time dependence of total count rate (measured as kilocounts per second) 
of apoAGT-Mi (A,B) and apoP11L (C,D) at 2 µM (black), 10 µM (blue), and 20 µM (green 
dots) protein concentration, in 0.1 M KP buffer, 37 °C at pH 5.5 (panels A and C) or 8 
(panels B and D).  
 
 
An increase in count rate was detectable for both forms in the whole pH range. The 
aggregation increased at acidic pH with pKspec for k1 and k2 of 6.1 ± 0.2 and 6.4 ± 
0.2 respectively, for holoP11L, and 6.1 ± 0.4 and 6.9 ± 0.2, respectively, for 
apoP11L. These values agree quite well with those previously found for AGT-Ma 
and AGT-Mi. The aggregation rate increased at increasing protein concentration 
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(Figure 38C and D) and is not accompanied by loss of secondary structure, thus 
suggesting a molecular mechanism similar to that already proposed for AGT-Ma 
and AGT-Mi. The comparison between the aggregation kinetics of the P11L variant 
with those of AGT-Ma revealed that the mutation increases by approximately 1.5-
2 fold and by 2-4 fold the k1, and by approximately 9 and 4-fold the k2 of the holo- 
and apo-form, respectively. Nevertheless, the signal of the dimer disappeared after 
~20 minutes during the aggregation process of P11L. This indicates that a 
significant portion of the variant is present as aggregated species in agreement with 
the fact that the mixture displays a visible turbidity at the end of the analysis.  
Overall, by comparing the data obtained on AGT-Mi, P11L, and I340M, with those 
of AGT-Ma, we can conclude that while the I340M mutation exerts a stabilizing 
effect, the P11L mutation significantly increases the aggregation propensity of 
AGT. The hypothesis that the two polymorphic mutations could have opposite 
effects on AGT has been previously advanced. Mesa-Torres et al., 2014 have 
reported the mutation of Ile340 as one of the consensus amino acids substitutions 
that contribute to create a form of AGT endowed with a higher stability in solution 
and in cellular systems. On the other hand, the P11L mutation has been claimed as 
responsible for the increased sensitivity of AGT-Mi to chemical and thermal stress 
(Cellini et al., 2010). However, all these data have been interpreted by looking to 
the possible effects of the two substitutions on dimer stability. Our data indicate 
that they also play a role on the electrostatic aggregation of the protein. In particular, 
both mutations seem to mainly influence the autocatalytic growth of the aggregates. 
However, since k1 and k2 in the F-W model do not describe completely independent 
events, it cannot be excluded that the increase in k2 is influenced by the increase in 
k1, which would determine a more rapid accumulation of aggregating nuclei that in 
turn would promote aggregate growth for mass action (Cohen et al., 2012). 
Pro11 is located at the monomer-monomer interface. In silico analyses predict that 
its substitution by a leucine residue could increase the flexibility of the N-terminal 
arm of AGT, possibly promoting its dissociation from the neighbouring subunit. 
This is also confirmed by biochemical studies showing an increased susceptibility 
of AGT variants bearing the P11L mutation to proteolytic cleavage at the N-
terminus (Cellini et al., 2010; Montioli et al., 2015; Coultier-Mackie et al., 2008). 
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Based on these data and considerations, we compared the electrostatic map of AGT-
Ma with that of a truncated form of the protein deleted by the first 21 residues 
mimicking the possible detachment of the N-terminal arm (Figure 39). 
 
 
 
 
Figure 39. Electrostatic potential contours (−0.5 (red) and +0.5 (blue) kT/e) of full 
length AGT-Ma (A,B) and of a truncated form with residues 1–21 deleted (C,D). We 
have setted 0.06 M KP, pH 7.4 as buffer at 37 °C. Blue and red arrows indicate the 
differences between the electrostatic potential map of AGT-Ma and its truncated form. 
 
 
We found that negatively charged residues would be exposed upon detachment of 
the N-terminal arm of AGT, including Asp52, Glu59, Asp196, Glu274 and Glu281. 
It can be hypothesised that the increased flexibility of the N-terminal arm due to the 
P11L mutation could promote its transient dissociation from the neighbouring 
subunit, thus causing the exposure of negative areas. This in turn would increase 
the anisotropy of charge distribution on the AGT surface, thus creating more 
favourable conditions for the electrostatic interactions between dimers. An 
analogous mechanism has been already proposed to explain the behaviour of 
variants bearing mutations at Gly41 (Cellini et al., 2010). 
The comparison of the aggregation kinetics of each analysed species in the apo- and 
holo-form gives other important information. In the case of AGT-Ma and I340M, 
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we noticed that the holo-form displays a reduction of both k1 and k2 with respect to 
the apo-form, thus indicating that the binding of PLP influences both the nucleation 
and the autocatalytic growth step. However, it is difficult to draw definitive 
conclusions since the holo-forms do not aggregate in a wide range of pHs. On the 
other hand, in both AGT-Mi and P11L, bound PLP mainly influences the nucleation 
step. In fact, the k1 values of apoAGT-Mi are 7- to 15-fold higher than the 
corresponding of holoAGT-Mi in the range of pH 5.5-7.0, while the k2 values are 
of the same order of magnitude. Similarly, in the P11L variant the k1 values of the 
apo-form are from 4 to 7-fold higher than those of the holo-form, while the k2 values 
are of the same order of magnitude. It can be speculated that the stabilizing effect 
of PLP could be mediated by an overall conformational change induced by the 
cofactor that would probably disfavour the electrostatic interaction with 
neighbouring dimers, thus reducing the aggregation rate. Although the crystal 
structure of apoAGT has not been solved, its dichroic features in the near-UV 
region indicate that it has a tertiary structure slightly different from that of holoAGT 
(Oppici et al., 2012), as well as an higher flexibility of the polypeptide chain making 
it more susceptible to unfolding and proteolytic degradation (Cellini et al., 2012). 
It has been well documented that the PLP coenzyme is able to play a chaperone role 
for AGT, an effect mainly interpreted as being due to a quaternary structure 
stabilization (Dindo et al., 2012). Based on our data, we can suggest that PLP 
binding could also reduce the exposure of charged residues possibly involved in the 
aggregation process. In this regard, the finding that in the presence of the P11L 
substitution PLP binding mainly affects the nucleation step could be explained 
through an indirect effect of coenzyme binding on the loop 24-32 that is connected 
to the N-terminal arm on one side, and to the active site on the other side. A role of 
the coenzyme in inducing conformational 
changes of the bound apoenzyme has been already proved in other B6-enzymes 
(Giardina et al., 2011, Giardina et al., 2015), but only the resolution of the crystal 
structure of apoAGT will shed light on the structural bases of the stabilizing role. 
To investigate the consequences of the aggregation process for AGT functionality, 
as well as the effect of the two polymorphic mutations, we measured the residual 
catalytic activity of AGT-Ma, AGT-Mi, P11L and I340M upon 3 h incubation at 
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37°C in KP 0.1 M pH 5.5 (to favour aggregation), at a protein concentration of 10 
µM. We then performed the assays in KP 0.1 M pH 7.4 at 25°C in the presence of 
PLP at saturating substrates concentrations, to stop the aggregation process. Holo 
and apoAGT-Ma, holo and apoI340M and holoAGT-Mi showed residual catalytic 
activity >90%. On the other hand, apoAGT-Mi, holo P11L and apoP11L displayed 
a residual activity of 64%, 48%, and 26%, respectively. In analogy with DLS 
analyses, the residual activity increased at increasing pH and increasing ionic 
strength. Moreover, the residual activity of the holo-form is higher than that of the 
corresponding apo-form under similar experimental conditions (Figure 40).  
 
 
 
Figure 40. Residual catalytic activity of AGT-Mi and P11L upon incubation under 
different conditions of pH and ionic strength. Each species was incubated for 3 h at 
10 µM concentration, 37 °C under different conditions. The residual transaminase activity 
was measured by a standard enzymatic assay at 0.1 µM concentration as described in 
Materials and methods. Bars are colored as follows: red, 0.1 M KP, pH 5.5; green, 0.1 M 
KP, pH 8.0; blue, 0.1 M KP pH 7.0, and cyan, 1 M KP, pH 7.0. 
 
 
These data are in line with the aggregation mechanism, and confirm the 
destabilizing effect of the P11L mutation as well as the protective role of the PLP 
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coenzyme. Notably, the finding that the native-like aggregation process is 
associated with loss of protein functionality is not in contrast with CD spectroscopy 
analyses indicating no loss of secondary structure, because it is known that even 
small conformational changes far from the active site can reduce or abolish AGT 
catalytic activity (Oppici et al., 2012, Giardina et al., 2011). Thus, it can be 
hypothesized that the association of native-like dimers could negatively influence 
enzyme functionality leading to a loss of activity even in the absence of an 
unfolding process. A loss of activity has been already documented during the 
native-like aggregation of the acylphosphatase form Sulfolobus solfataricus 
(Bemporad and Chiti 2009). 
 
7.4 Modulation of AGT-Mi aggregation by common PH1-causing mutations 
 
Some of the most common mutations associated with PH1, including the F152I, 
G170R and I244T (Williams et al., 2009), induce conformational changes on AGT 
that synergize with those generated by the minor allele polymorphism reducing the 
overall efficiency of the folding pathway and causing the population of monomeric 
intermediates kept by mitochondria (Danpure 2006). PLP is able to shift the 
equilibrium toward the holo-form, by probably promoting the formation of the 
native dimer, in line with the responsiveness to B6 reported at cellular and/or 
clinical level (Fargue et al., 2013; Hoyer-Kuhn et al., 2014). Based on the 
significant influence of the polymorphic mutations on the aggregation propensity 
of AGT in the native form, we investigated if the F152I, G170R and I244T 
mutations could also play a role in this process when present on the background of 
the minor allele.  
We determined the aggregation rate of the F152I-Mi, G170R-Mi and I244T-Mi 
variants in the holo- and apo-form at three different pHs by DLS. As described 
above for the polymorphic AGT species, the aggregation propensity decreases at 
increasing pH (Figure 41A). The rate of the process increases at increasing protein 
concentration and low ionic strengths (data not shown).  
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Figure 41. Electrostatic map and time-dependent aggregation of the pathogenic 
variants F152I-Mi, G170R-Mi, and I244T-Mi in the holo and apo form. (A) Time-
dependent changes of the total count rate (measured as kilocounts per second) of the 
indicated species at 10 µM concentration in 0.1 M KP at pH 5.5 (blue), 7.0 (green), and 8.0 
(red). (B) Residual catalytic activity upon 3 h incubation under different conditions of pH 
and ionic strength. Each species was incubated for 3 h at 10 µm concentration, 37 °C under 
different conditions. The residual transaminase activity was measured by a standard 
enzymatic assay at 0.1 µM concentration as described in Materials and Methods. Bars are 
colored as follows: red, 0.1 M KP, pH 5.5; green, 0.1 M KP, pH 8.0; blue, 0.1 M KP pH 
7.0, and cyan, 1 M KP, pH 7.0.  
 
At each pH, the values of both k1 and k2 of the three variants are higher than the 
corresponding of AGT-Mi. In line with these results, we found that a significant 
reduction of catalytic activity occurs upon aggregation, with higher residual activity 
at increasing pH and ionic strength (Figure 41B). Thus, we can conclude that (i) at 
neutral and alkaline pH the variants undergo a native-like aggregation process 
driven by electrostatic forces, which accounts for a significant loss of functionality 
of the protein, in particular in the apo-form; (ii) at acidic pH, the holovariants show 
electrostatic aggregation in the native-like form, while the apovariants also undergo 
A B
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a time-dependent unfolding process, in line with their reduced stability already 
suggested by chemical or thermal unfolding studies (Mesa-Torres et al., 2014).  
A global analysis of the behaviour of the variants allows to hypothesize that the 
F152I, G170R and I244T mutations synergize with the minor allele polymorphisms 
not only by interfering with the folding pathway of AGT populating monomeric 
intermediates prone to hydrophobic aggregation, degradation, and mistargeting to 
mitochondria, but also by increasing the electrostatic aggregation propensity of the 
protein once folded. Both phenomena would concur to the strong functional deficit 
of AGT of cells expressing the three variants, and would explain why they are partly 
present in the insoluble fraction of the lysate (Oppici et al., 2015).  
It should be also pointed out that the F152I-Mi, G170R-Mi and I244T-Mi variants 
are found to be responsive to Vitamin B6 in a cellular model of PH1 and the 
responsiveness is confirmed by clinical data in the case of F152I-Mi and G170R-
Mi [49]. Previous reports ascribed the responsiveness to the ability of the coenzyme 
to promote AGT folding and dimerization (Dindo et al., 2016). Our analyses 
support an additional role of PLP in protecting the native protein from aggregation. 
In fact, the aggregation extent of each species in the apo-form is higher than that of 
the corresponding holo-form, an effect mainly driven by the increase in k2. It 
remains to be explained why the coenzyme in the pathogenic variants seems to 
mainly affect the aggregates growth rather than nucleus formation. In the absence 
of structural information, we can only speculate that this could be partly due to the 
different conformational changes induced by polymorphic and pathogenic 
mutations, and to their synergic action. 
 
We have gained important insights into how point alterations of a protein surface 
could impact its behavior and stability in solution. Most studies on the pathogenesis 
of protein deficits interpret the aggregation propensity of disease-causing variants 
as being due to the population of folding intermediates showing sticky hydrophobic 
patches (misfolding-based aggregation). Our results, along with those on other 
proteins of pharmacological interest (Roberts 2014, Austerberrya et al., 2017), 
highlight that a deep analysis of the electrostatic surface should be also carried out 
to provide insights into possible alterations of the surface charge anisotropy that 
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could promote electrostatic aggregation of a protein once folded (native-like 
aggregation). In particular, by combining the data reported here with those of 
previous reports (Cellini et al., 2009; Cellini et al., 2011; Mesa-Torres et al., 2013), 
we delineated a more comprehensive picture describing AGT aggregation. 
Figure 42 illustrates the minimal proposed model of AGT-Ma folding and 
highlights the differential influence of mutations from a quantitative and qualitative 
point of view. The protein is prone to aggregate both during the folding pathway, 
as a consequence of the population of monomeric intermediates exposing 
hydrophobic surfaces, and once folded, as a consequence of the exposure of 
oppositely charged surfaces. Polymorphic and pathogenic mutations can increase 
the propensity of the protein to misfolding-based hydrophobic aggregation and/or 
to native-like electrostatic aggregation. In addition, the coenzyme PLP plays a wide 
chaperone role for the protein because it not only favors the folding of intermediates 
in the apo form and the attainment of the dimeric structure but also stabilizes the 
protein once folded. 
 
 
Figure 42. Global scheme describing the influence of polymorphic and pathogenic 
mutations on the AGT aggregation propensity.  
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CONCLUSIONS 
 
Here we combined in silico and in vitro studies to analyse the aggregative behaviour 
of AGT and to shed light on the possible influence of polymorphic and pathogenic 
mutations. The results obtained indicate that: (i) the major allelic form of AGT 
shows a high surface charge anisotropy that makes it susceptible to an aggregation 
mediated by electrostatic forces; (ii) PLP binding strongly reduces the aggregation 
of the protein, thus suggesting that the coenzyme could have a more wide chaperone 
role than previously known (Cellini et al., 2010); (iii) the P11L mutation enhances 
the aggregation propensity of AGT, while the I340M mutation has a stabilizing 
effect; (iv) missense mutations associated with PH1 could play their effects by 
promoting electrostatic aggregation. 
We have gained important insights into how point alterations of a protein surface 
could impact its behaviour and stability in solution. Most studies on the 
pathogenesis of protein deficits interpret the aggregation propensity of disease-
causing variants as being due to the population of folding intermediates showing 
sticky hydrophobic patches (misfolding-based aggregation) (Camilloni et al., 
2016). Our results, along with those on other proteins of pharmacological interest 
(Roberts 2002), highlight that a deep analysis of the electrostatic surface should be 
also carried out to provide insights into possible alterations of the surface charge 
anisotropy that could promote electrostatic aggregation of a protein once folded 
(native-like aggregation). In particular, by combining the data reported here with 
those of previous reports (Cellini et al., 2009), we delineated a more comprehensive 
picture describing AGT aggregation. Fig. 14 illustrates the minimal proposed model 
of AGT-Ma folding and highlights the differential influence of mutations from a 
quantitative and qualitative point of view. The protein is prone to aggregate both 
during the folding pathway, as a consequence of the population of monomeric 
intermediates exposing hydrophobic surfaces, and once folded, as a consequence of 
the exposure of oppositely charged surfaces. Polymorphic and pathogenic 
mutations can increase the propensity of the protein to misfolding-based 
hydrophobic aggregation and/or to native-like electrostatic aggregation. In addition, 
the coenzyme PLP plays a wide chaperone role for the protein because it not only 
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favours the folding of intermediates in the apo-form and the attainment of the 
dimeric structure, but also stabilizes the protein once folded.  
These findings, by increasing the knowledge of the biochemical properties of AGT 
and of the pathogenesis of PH1, constitute the base to design new strategies able to 
improve the stability of the protein as a possible premise for the development of 
innovative therapeutic approaches. Recently, a strategy for the successful 
administration of recombinant purified AGT based on the conjugation with 
polymeric carriers has been setup. The knowledge of the influence of surface charge 
on protein stability will be pivotal for the future development of the conjugates as 
a biological drug. 
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During the last years, many efforts have been focused on the development of an 
effective treatment for Hyperoxaluria (Cowley et al., 2017; Grujic et al., 2009, 
Langman et al., 2014; Hoppe et al., 2006; Hoppe et al., 2011; Cellini et al., 2011; 
Monico et al., 2005; Hoyer-Kuhn et al., 2014; Oppici et al., 2015; Moya-Garzon et 
al. 2018; Lai et al., 2018). Some of them are currently in clinical testing and 
especially address PH1, which is the most severe form of disease. One of the main 
problem deriving from hyperoxaluria is systemic oxalosis, in which oxalate 
accumulates in plasma and deposit in many organs including skin, heart and eye. It 
is well known that oxalate-degrading enzymes are presented in bacteria, fungi and 
plants, but their direct administration in humans is not feasible. During my PhD, I 
focused my attention on the possibility of using oxalate decarboxylase (OxDC) 
from B. subtilis as a biological drug, once encapsulated inside red blood cells 
(RBCs) to prevent its immunogenicity. 
Altogether, the data obtained indicate that: 
 
1) OxDC and its mutated form OxDC-DSSN (i) display optimal activity at pH 
4.2 but retain a detectable residual activity at pH 7.2, the intracellular pH of 
RBCs, (ii) do not undergo major structural changes at neutral pH, (iii) are 
able to detoxify oxalate endogenously produced in eukaryotic cells. 
2) OxDC can be efficiently encapsulated in human and murine RBCs and does 
not loose catalytic activity during the encapsulation process. 
3) By using directed evolution approaches, we engineered a mutated form of 
OxDC more resistant to thermal stress and aggregation under physiological 
conditions as compared with wild-type OxDC.  
 
Overall these data provide the proof-of-principle for the feasibility of a therapy for 
Hyperoxaluria based on the administration of RBCs-loaded with an oxalate-
degrading enzyme. Future studies will be focused on the testing of the ability of 
wild-type and engineered OxDC to detoxify oxalate in a mouse model of PH1. 
 
In addition, I participated to a study focused on the effect of pathogenic and 
polymorphic mutations on the propensity to aggregation of AGT, the enzyme 
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mutated in PH1. The results obtained indicate that AGT is highly susceptible to an 
aggregation mediated by electrostatic forces and that the coenzyme PLP strongly 
reduces the self-association of the protein. The P11L and I340M polymorphic 
mutations play an opposite role on the aggregation propensity of AGT, while the 
most common missense mutations associated with PH1 promote the process. These 
findings improve the knowledge of the pathogenic mechanisms of PH1 and 
constitute the base to design innovative therapeutic approaches able to improve 
AGT stability. 
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ANNEX	I	
	
	
Summary of the results obtained and activities performed during the PhD 
course 
	
Publications 
 
During my PhD I have focused my research on the study of hyperoxaluria, a 
pathologic condition due to genetic and non-genetic causes that leads to the 
deposition of calcium oxalate stones in the urinary tract. Hyperoxaluria can be 
caused either by the increased amount of endogenous oxalate production (primary 
hyperoxaluria or PH) or by an increased intestinal oxalate absorption (secondary 
hyperoxaluria or SH). The most severe form of PH is primary hyperoxaluria type I, 
which is due to a mutations on the gene encoding alanine:glyoxylate 
aminotransferase (AGT). Current therapeutic approaches are poorly effective and 
the development of a new therapeutic strategy is highly desirable.  To afford this 
question, the main project during my PhD was the development of a new strategy 
based on the encapsulation of an oxalate-degrading enzyme, oxalate decarboxylase 
from B. subtilis (OxDC) inside red blood cells (RBCs) to metabolize plasmatic 
oxalate. This would in turn contributes to reducing urinary oxalate thus avoiding 
the precipitation of calcium oxalate in the kidneys. 
The first results of my study have been accepted to publication. They describe the 
characterization of wild-type OxDC and of a mutant form at neutral pH: 
 
1) C. Conter, E. Oppici, M. Dindo, L. Rossi, M. Magnani and B. Cellini, 
“Biochemical properties and oxalate-degrading activity of oxalate 
decarboxylase from Bacillus subtilis at neutral pH”, IUBMB Life, (2019) 
doi: 10.1002/iub.2027. 
 
In parallel with my main PhD project, I have been also involved in a second project 
related to PH1, focused on the study of the effect of polymorphic and pathogenic 
mutations on the electrostatic aggregation of AGT. The results obtained are 
reported in the following paper:  
 
2) M. Dindo, C. Conter and B. Cellini “Opposite effect of polymorphic 
mutations on the electrostatic aggregation of human alanine:glyoxylate 
aminotransferase: implications for the pathogenesis of primary 
hyperoxaluria type I”, FEBS J., (2017) doi: 10.111/febs.14269. 
 
Finally, I have participated to the writing of a review and a book chapter on the 
molecular bases of PH: 
  
3) M. Dindo*, C. Conter*, E. Oppici, V. Ceccarelli, L. Marinucci and B. 
Cellini, “Molecular basis of primary hyperoxaluria: clues to innovative 
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treatments”, Urolithiasis, (2018), doi: 10.1007/s00240-018-1089-z. *Co-
first authors. 
 
4) E. Oppici, M. Dindo, C. Conter, C.B. Voltattorni and B. Cellini “Folding 
defects leading to Primary Hyperoxaluria” Handbook of Experimental 
Pharmacology, (2017) doi: 10.1007/164_2017_59 
 
 
Meeting attendance  
 
1) 4 June - 6 June 2018 “Sensory Systems in Health Disease”, Verona (Italy). 
2) 28 May - 30 May 2018 “PROTEINE 2018”, Verona (Italy). 
3) 14 July -16 July 2017 “12th International Primary Hyperoxaluria 
Workshop” Tenerife (Spain) 
4) 30 March – 1 April 2016 “PROTEINE 2016”, Bologna (Italy) 
 
 
 
Short oral communications to national and international meetings 
 
1) C. Conter, “Electrostatic interactions drive native-like aggregation of 
human alanine:glyoxylate aminotransferase”, “Sensory Systems in Health 
Disease”, Verona (Italy) - June 4-6, 2018 (Selected from abstract). 
 
2) C. Conter, “Erythrocytes as carriers of oxalate decarboxylase: an 
innovative approach for the treatment of Hyperoxaluria”, 12th International 
Primary Hyperoxaluria Workshop”, Tenerife (Spain) – July 14-16, 2017 
(Selected from abstracts). 
 
 
Visiting experience 
 
1) September 4th 2017-December 17th. Visit to the University of Granada, 
dept. of Chimical Chemistry, under the supervision of Dr. Angel Luis Pey. 
During these three months I learned the Isothermal Tritation Calorimetry 
and Differential Scanning Calorimetry techniques, that I applied to study 
the denaturation and aggregation processes of oxalate decarboxylase 
(OxDC). 
 
2) March 20th – 24th 2017. Visit to the University of Urbino “Carlo Bo”, dept. 
of Biomolecular Science, under the supervision of Prof. Mauro Magnani 
and Prof. Luigia Rossi. During this week I have setup the encapsulation of 
OxDC in murine erythrocytes, an important prerequisite for the aim of my 
PhD project. 
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3) May 2nd – 6th 2016. Visit to the University of Urbino “Carlo Bo”, dept. of 
Biomolecular Science, under the supervision of Prof. Mauro Magnani and 
Prof. Luigia Rossi. During this week I learned the techniques of 
erythrocytes loading and, I have setup the encapsulation of OxDC in 
human erythrocytes, as the basis to proceed in my PhD project. 
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